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Summary	  
Significant	   improvement	   in	   the	   treatment	   of	   pediatric	   ALL	   has	   been	   achieved	   by	   multi-­‐drug	  
chemotherapy	  and	  risk-­‐adapted	  treatment	  that	  accomplished	  an	  overall	  survival	  rate	  over	  80%,	  but	  
children	  who	  relapse	  with	  ALL	  still	  account	  for	  the	  majority	  of	  cancer-­‐related	  deaths.	  Furthermore,	  
the	   development	   of	   targeted	   approaches	   is	   urgently	   needed,	   as	   currently	   used	   multi-­‐agent	  
chemotherapy	   is	   associated	   with	   relevant	   short	   and	   long-­‐term	   toxicity.	   Therefore,	   we	   used	   a	  
combined	   genetic	   and	   functional	   approach	   to	   seek	   vulnerable	   targets	   and	   novel	   potent	   agents	  
using	   a	   comprehensive	   xenograft	  model	   of	   drug	   resistant	   ALL	   subtypes,	   including	   a	   paradigm	   of	  
resistant	  disease,	  TCF3-­‐HLF-­‐positive	  ALL.	  	  
	  
As	  central	  coordinator	  of	  a	   large	   international	  consortium,	   I	  established	  xenografts	  of	  14	  cases	  of	  
the	   rare,	   but	   always	   fatal,	   TCF3-­‐HLF-­‐positive	   ALL.	   We	   obtained	   whole-­‐genome,	   -­‐exome	   and	   -­‐
transcriptome	   sequencing	   analysis	   of	   leukemia	   patient	   samples	   and	   corresponding	   xenografts.	  	  
Integrating	   clinical	   and	   genomic	   information	   from	   patients	   with	   the	   data	   generated	   using	   the	  
leukemia	   xenograft	  model,	  we	   identified	   specific	   pattern	  of	  mutation,	   gene	  expression,	   and	  drug	  
response	  profiles	  of	   resistant	  TCF3-­‐HLF-­‐positive	  ALL	   in	  comparison	   to	   treatment-­‐responsive	  TCF3-­‐
PBX1-­‐positive	  ALL.	  We	  show	  that	  the	  leukemia	  xenografts	  closely	  resemble	  the	  human	  disease	  and	  
recapitulated	  the	  multiclonal	  hierarchies	  that	  are	  observed	  in	  patients.	  The	  TCF3-­‐HLF	  translocation	  
is	  associated	  with	  recurrent	  intragenic	  deletions	  of	  the	  lymphoid	  transcription	  factor	  gene	  PAX5	  or	  
somatic	  mutations	  in	  the	  non-­‐translocated	  allele	  of	  TCF3	  (acting	  upstream	  of	  PAX5),	  indicating	  that	  
this	  initiating	  event	  must	  occur	  in	  a	  stage	  of	  lymphoid	  development	  characterized	  by	  reduced	  levels	  
of	  PAX5.	  The	   transcriptional	   signature	  presents	  with	  a	  prevalence	  of	   stem	  cell,	  mesenchymal	  and	  
myeloid	   features,	   consistent	   with	   reprogramming	   towards	   a	   hybrid,	   more	   drug-­‐resistant	  
hematopoietic	  state	  by	  TCF3-­‐HLF	  ALL.	  
	  
We	   developed	   a	   unique	   drug-­‐profiling	   platform	   based	   on	   automated	   image	   analysis	   of	   patient	  
samples.	   We	   selected	   therapeutic	   agents	   that	   are	   in	   clinical	   use	   or	   in	   clinical	   development	   to	  
constitute	  a	  customized	  library	  of	  98	  compounds	  and	  investigated	  the	  potential	  of	  this	  approach	  on	  
a	  set	  of	  61	  ALL	  patients.	  Distinct	  drug	  activity	  profiles	  were	  detected	  for	  defined	  genetic	  subtypes,	  
including	  TCF3-­‐HLF-­‐translocated	  and	  MLL-­‐rearranged	   leukemia.	  This	  approach	  also	   identified	  new	  
subgroups	  based	  on	  particular	   sensitivity	   to	   specific	   classes	  of	  new	  agents.	   	  TCF3-­‐HLF	   cases	  were	  
extremely	  sensitive	  to	  the	  BCL-­‐2	  inhibitor	  venetoclax	  (ABT-­‐199),	  revealing	  dependence	  on	  BCL-­‐2	  for	  
survival.	  Furthermore,	  other	  subgroups	  of	  ALL	  were	  also	  very	  sensitive	  to	  this	  agent,	  including	  MLL-­‐
rearranged	  ALL	  and	  a	  subset	  of	  T-­‐ALL	  cases,	  which	  represent	  subgroups	  with	  unmet	  medical	  needs.	  
The	   drug-­‐profiling	   data	   accurately	   predicts	   strong	   in	   vivo	   activity	   of	   venetoclax	   in	   leukemia	  
xenografts,	  which	  identifies	  BCL-­‐2	  as	  a	  rationale	  for	  targeted	  therapeutic	  intervention	  and	  provides	  
proof	  of	  concept	  for	  its	  use	  as	  an	  additional	  tool	  for	  precision	  medicine.	  	  
	  
Using	   a	   proteomic	   approach	   in	   this	   xenograft	  model,	  we	   identified	   the	   glycophosphatidylinositol	  
anchored	  surface	  protein	  Vanin-­‐2	  (VNN2,	  GPI-­‐80),	  a	  marker	  of	  fetal	  hematopoietic	  stem	  cells,	  to	  be	  
exclusively	  detectable	   at	   the	   cell	   surface	  of	   patients	  with	  more	   resistant	  disease	   and	  high	   risk	  of	  
relapse.	  Based	  on	  our	  retrospective	  analysis	  in	  the	  context	  of	  a	  large	  multinational	  clinical	  trial,	  the	  
detection	  of	  VNN2	  by	  flow	  cytometry	  at	  diagnosis	  identifies	  a	  new	  subgroup	  of	  patients	  at	  risk	  for	  
relapse.	  Remarkably,	  VNN2	  was	  detected	  in	  all	  TCF3-­‐HLF-­‐positive	  ALL	  cases	  tested,	  providing	  a	  new	  
strategy	   to	   improve	   the	   detection	   of	   this	   subgroup	   of	   patients,	   currently	   difficult	   to	   identify.	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Interference	  with	  VNN2,	  using	  a	  specific	  monoclonal	  antibody,	  resulted	  in	  delayed	  homing	  of	  ALL	  to	  
the	  bone	  marrow	  and	  spleen	  in	  the	  xenograft	  model,	  suggesting	  that	  VNN2	  contributes	  directly	  to	  
the	  leukemia	  pathogenesis.	  	  
	  
In	   conclusion,	   with	  my	   PhD	   Thesis	   I	   contributed	   to	   the	   development	   of	   a	   translational	   research	  
platform	   that	   integrates	   clinical	   and	  genomic	   information	  with	   functional	  drug	  activity	  data,	  with	  
the	   aim	   to	   detect	   actionable	   features	   in	   leukemia,	   in	   particular	  with	   regard	   to	  TCF3-­‐HLF-­‐positive	  
ALL,	  in	  a	  more	  personalized	  manner.	  Moreover,	  we	  discovered	  that	  VNN2/GPI80,	  a	  marker	  of	  fetal	  
hematopoietic	   stem	   cells,	   can	   be	   used	   to	   identify	   patients	   with	   a	   more	   aggressive	   form	   of	   the	  
disease	  (including	  patients	  with	  fatal	  TCF3-­‐HLF-­‐positive	  ALL)	  and	  these	  findings	  constitute	  the	  basis	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Zusammenfassung	  
Durch	  die	  Entwicklung	  der	  Kombinationstherapie	  mit	  verschiedenen	  Chemotherapeutika	  und	  einer	  
risiko-­‐adaptierten	   Behandlung	   für	   Patienten	   mit	   pädiatrischer	   ALL	   konnte	   eine	   signifikante	  
Verbesserung	   der	  Überlebensrate	   auf	   über	   80%	   erreicht	  werden.	   Dennoch	   zählen	   refraktäre	   ALL	  
immer	  noch	  zu	  den	  häufigsten	  krebs-­‐assoziierten	  Todesfällen	   im	  Kindesalter.	  Des	  Weiteren	   ist	  die	  
aktuelle	   Kombinationstherapie	   mit	   schwerwiegender	   Kurz-­‐	   und	   Langzeittoxizität	   verbunden,	   so	  
dass	   die	   Entwicklung	   von	   zielgerichteten	   Therapien	   von	   hoher	   Relevanz	   ist.	   Anhand	   der	   hoch	  
resistenten	  TCF3-­‐HLF-­‐positiven	  ALL	  sollten	  in	  dieser	  Arbeit	  durch	  Kombination	  von	  genetischen	  und	  
funktionalen	   Studien	   im	   Xenotransplantationsmodel	   neue	   wirkungsvolle	   und	   nutzbare	  
Therapiemöglichkeiten	  identifiziert	  werden.	  
	  
Als	   zentrale	   Koordinatorin	   eines	   grossen	   internationalen	   Konsortiums	   habe	   ich	   in	   dieser	   Arbeit	  
Xenotransplantate	   von	   14	   Fällen	   der	   seltenen	   aber	   hoch	   riskanten	   TCF3-­‐HLF	   ALL	   etabliert.	   Es	  
wurden	   Genom-­‐,	   Exom-­‐	   und	   Transkriptomsequenzierungen	   der	   korrespondierenden	  
Patientenproben	   und	   Xenotransplantate	   durchgeführt.	   Die	   Integration	   der	   klinischen	   und	  
genomischen	   Informationen	  der	  Patientenproben	  und	  der	  Xenotransplantate	   sowie	  der	  Vergleich	  
der	   resistenten	   TCF3-­‐HLF-­‐positive	   ALL	   mit	   der	   therapierbaren	   TCF3-­‐PBX1-­‐positiven	   ALL	   ergaben	  
spezifische	  Muster	   für	  Mutationen,	   Genexpressionen	   und	  Wirkungsprofile	   für	  Medikamente.	  Wir	  
konnten	  zeigen,	  dass	  leukämische	  Xenotransplantate	  eine	  hohe	  Übereinstimmung	  mit	  der	  initialen	  
Krankheit	   zeigten	   und	   die	   multiklonalen	   Hierarchien,	   die	   in	   Patienten	   beobachtet	   wurden,	  
rekapituliert	   wurden.	   Interessanterweise	   war	   die	   TCF3-­‐HLF	   Translokation	   mit	   einer	  
wiederkehrenden	   Deletion	   des	   lymphoiden	   Transkriptionsfaktors	   PAX5	   oder	   mit	   somatischen	  
Mutationen	  in	  dem	  nicht-­‐translozierten	  TCF3-­‐Allel	  (agiert	  oberhalb	  von	  PAX5)	  assoziiert.	  Dies	  führte	  
zu	  dem	  Modell,	  dass	  das	  Leukämie-­‐initiierende	  Ereignis	  in	  einem	  spezifischen	  Kontext	  während	  der	  
lymphoiden	   Differenzierung	   entstehen	   muss,	   welcher	   durch	   die	   reduzierte	   Dosis	   von	   PAX5	  
bevorzugt	  wird.	  Die	  transkriptionelle	  Signatur	  dieser	  Zellen	  zeigte	  eine	  Anreicherung	  für	  Stammzell-­‐
,	  mesenchymale	  und	  myeloide	  Faktoren,	  was	  mit	  der	  TCF3-­‐HLF	   induzierten	  Reprogrammierung	  zu	  
einem	  hybriden,	  therapie-­‐resistenteren	  hämatopoietischen	  Status	  übereinstimmt.	  
	  
In	  unserem	  Labor	  haben	  wir	  eine	  einzigartige	  Plattform	  zur	  Bestimmung	  von	  Wirkungsprofilen	  von	  
Medikamenten	  entwickelt,	  die	  auf	  einer	  automatischen	  Bildanalyse	  des	  Patientenmaterials	  basiert.	  
Für	   eine	   Gruppe	   von	   61	   ALL	   Patienten	   wurden	   98	   Medikamente,	   die	   bereits	   in	   der	   klinischen	  
Entwicklung	   oder	   Gebrauch	   sind,	   auf	   deren	   therapeutisches	   Potenzial	   getestet.	   	   Für	   bestimmte	  
genetische	  Subklassen,	  wie	  der	  TCF3-­‐HLF-­‐translozierten	  oder	  der	  MLL-­‐rearrangierten	  ALL,	  konnten	  
spezifische	  Wirkungsprofile	   von	  Medikamenten	   beschrieben	   werden.	   Des	  Weiteren	   identifizierte	  
diese	   Studie	   auch	   neue	   Subgruppen,	   basierend	   auf	   ihrer	   spezifischen	   Sensitivität	   für	   bestimmte	  
Medikamentenklassen.	  TCF3-­‐HLF	  Patientenproben	  waren	  zum	  Beispiel	  besonders	  sensitiv	  auf	  den	  
BCL-­‐2	   Inhibitor	  Venetoclax	   (ABT-­‐199),	  was	  eine	  Abhängigkeit	  der	  ALL	  Zellen	  von	  BCL-­‐2	  annehmen	  
lässt.	   Aber	   auch	   andere	   ALL-­‐Subtypen,	   wie	   die	   MLL-­‐rearrangierten	   ALL	   und	   ein	   Anteil	   der	  
getesteten	  T-­‐ALL	  zeigten	  eine	  hohe	  Sensitivität	  für	  diesen	  Inhibitor.	  Interessanterweise	  konnten	  die	  
Daten	   der	   Wirkungsprofile	   für	   eine	   akkurate	   Vorhersage	   der	   Aktivität	   von	   Venetoclax	   in	   vivo	  
genutzt	  werden.	  Mit	  dieser	   automatisierten	  Analyseplattform	  konnte	  BCL-­‐2	   als	   ein	  neues	   Ziel	   für	  
die	  gerichtete	  therapeutische	  Intervention	  identifiziert	  werden	  und	  beweist	  die	  Nutzbarkeit	  unserer	  
experimentellen	  Wirkungsprofile	  als	  ein	  weiteres	  Instrument	  für	  die	  personalisierte	  Medizin.	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Des	   Weiteren	   wurde	   durch	   proteomische	   Analysen	   der	   Xenotransplantate	   das	  
Glycophosphatidylinositol	   verankerte	  Oberflächenprotein	   Vanin-­‐2	   (VNN2,	  GPI-­‐80),	   ein	  Marker	   für	  
fötale	   hämatopoietische	   Stammzellen,	   ausschliesslich	   auf	   der	   Oberfläche	   von	   Patienten	   mit	  
erhöhter	   Resistenz	   und	   hohem	   Risiko	   eines	   Rezidivs	   identifiziert.	   Eine	   retrospektive	   Analyse	   im	  
Kontext	   einer	   grossen	  multinationalen	   klinischen	   Studie	   zeigte,	   dass	   die	   Präsenz	   von	   VNN2	   zum	  
Zeitpunkt	  der	  Diagnose	  eine	  neue	  Subgruppe	  von	  Patienten	  mit	  erhöhtem	  Rezidivrisiko	  klassifiziert.	  
Bemerkenswert	  ist,	  dass	  VNN2	  in	  allen	  TCF3-­‐HLF-­‐positiven	  ALL	  Patienten	  detektiert	  werden	  konnte	  
und	   somit	   eine	   weitere	   Strategie	   zur	   Identifizierung	   von	   Subklassen	   darstellt,	   die	   im	   normalen	  
Arbeitsablauf	   eventuell	   nicht	   erkannt	   werden	   würden.	   Die	   Blockierung	   von	   VNN2	   mittels	   eines	  
spezifischen	   monoklonalen	   Antikörpers	   ergab	   eine	   Verzögerung	   des	   “homings”	   der	   ALL	   im	  
Knochenmark	   und	   der	   Milz	   im	   Xenotransplantat,	   was	   eine	   direkte	   Mitwirkung	   von	   VNN2	   in	   die	  
leukämische	  Pathogenese	  nahe	  legt.	  	  
	  
Zusammengefasst	   ist	   meine	   Doktorarbeit	   ein	   wichtiger	   Beitrag	   zur	   Entwicklung	   einer	  
translationalen	  Forschungsplattform,	  die	  klinische	  und	  genomische	  Informationen	  mit	  funktionalen	  
Wirkungsprofilen	  von	  Medikamenten	  integriert,	  um	  personalisierte	  und	  nutzbare	  Eigenschaften	  in	  
Leukämien,	  im	  Besonderen	  der	  fatalen	  TCF3-­‐HLF-­‐positiven	  ALL,	  zu	  identifizieren.	  Wir	  identifizierten	  
den	   fötalen	   hämatopoetischen	   Stammzellmarker	   VNN2/GPI80	   als	   Charakteristikum	   für	   refraktäre	  
Leukämien	   und	   legen	   damit	   die	   Basis	   für	   weitere	   funktionale	   und	   klinische	   Untersuchungen	   zur	  
Verbesserung	  der	  Chemotherapie	  von	  ALL.	  	  
	  
	   	  
	  
	   7	  
Table	  of	  Contents	  
1	   Introduction	  ...............................................................................................................	  10	  
1.1	   	  Adult	  and	  Pediatric	  cancers:	  differences	  and	  similarities	  .................................................	  10	  
1.2	   Leukemia	  .........................................................................................................................	  12	  
1.3	   Childhood	  acute	  lymphoblastic	  leukemia	  (ALL)	  .................................................................	  13	  
1.3.1	   Epidemiology	  ....................................................................................................................	  13	  
1.3.3	   Symptoms	  .........................................................................................................................	  13	  
1.3.4	   Diagnosis	  ...........................................................................................................................	  13	  
a)	  Morphology	  ...............................................................................................................................	  13	  
b)	  Immunophenotype	  ....................................................................................................................	  13	  
c)	  Genetic	  features	  ........................................................................................................................	  14	  
1.4	   Prognostic	  factors	  in	  acute	  lymphoblastic	  leukemia	  .........................................................	  15	  
1.4.1	   Cytogenetic	  abnormalities	  ................................................................................................	  15	  
1.4.2	   Clinical	  response	  (Minimal	  residual	  disease	  assessment)	  ................................................	  16	  
1.5	   Clinical	  treatment	  of	  ALL	  pediatric	  patients	  ......................................................................	  18	  
1.5.1	   Phases	  of	  the	  treatment	  ...................................................................................................	  18	  
1.5.2	   Stem	  cell	  transplantation	  and	  intrathecal	  chemotherapy	  ................................................	  18	  
1.6	   Key	  mechanisms	  driving	  leukemogenesis	  during	  B-­‐cell	  development	  ...............................	  19	  
1.6.1	   Illegitimate	  RAG	  recombination	  activity	  contribute	  to	  genome	  instability	  ......................	  19	  
1.6.2	   Mutations	  in	  transcription	  factors	  involved	  in	  B-­‐cell	  development	  .................................	  20	  
a)	  TCF3	  ...........................................................................................................................................	  20	  
b)	  PAX5	  ..........................................................................................................................................	  20	  
1.7	  	   Model	  of	  leukemogenesis	  ................................................................................................	  22	  
1.7.1	   Recurrent	  genetic	  alterations	  ...........................................................................................	  22	  
1.7.2	   Integration	  of	  the	  genomic	  and	  cytogenetic	  data	  to	  improve	  risk	  stratification	  criteria	  .	  24	  
1.8	  	   TCF3-­‐HLF	  and	  TCF3-­‐PBX1	  -­‐positive	  ALL	  model	  ..................................................................	  24	  
1.8.1	   TCF3-­‐HLF-­‐positive	  ALL	  ......................................................................................................	  25	  
1.8.2	   TCF3-­‐PBX1-­‐positive	  ALL	  ....................................................................................................	  25	  
1.9	  	   Utility	  of	  Patient	  Derived	  Xenograft	  (PDX)	  mouse	  models	  in	  B-­‐cell	  precursor	  ALL	  ............	  26	  
1.10	  	   Integration	  of	  functional	  and	  genomics	  approaches	  to	  develop	  personalized	  cancer	  
therapies	  ...................................................................................................................................	  27	  
1.10.1	   Next-­‐generation	  sequencing	  methods	  ...........................................................................	  27	  
1.10.2	   In	  vitro	  drug	  screening	  using	  primary	  patient	  cells	  ........................................................	  27	  
1.10.3	   In	  vitro	  high-­‐throughput	  drug	  screening	  in	  co-­‐culture	  with	  bone	  marrow	  stromal	  cells28	  
1.10.4	   Multi-­‐parametric	  approach	  to	  analyze	  in	  vitro	  drug	  response	  .......................................	  28	  
1.11	   BCL-­‐2	  .............................................................................................................................	  29	  
1.11.1	   Apoptosis	  ........................................................................................................................	  29	  
	  
	   8	  
1.11.2	   Importance	  of	  BCL2	  in	  ALL	  ..............................................................................................	  29	  
1.11.3	   Venetoclax	  (ABT-­‐199)	  BCL-­‐2	  specific	  inhibitor	  ...............................................................	  29	  
1.12	   Cell	  Surface	  proteins	  as	  biomarkers	  in	  ALL	  .....................................................................	  30	  
1.12.1	   VNN2	  (GPI-­‐80)	  ................................................................................................................	  30	  
2	   Subject	  of	  investigation	  and	  my	  contributions	  ............................................................	  32	  
3	   Results	  .......................................................................................................................	  33	  
Manuscript	  1	  .............................................................................................................................	  33	  
Genomics	  and	  drug	  profiling	  of	  fatal	  TCF3-­‐HLF-­‐positive	  acute	  lymphoblastic	  leukemia	  identifies	  
recurrent	  mutation	  patterns	  and	  novel	  therapeutic	  options	  ........................................................	  33	  
Manuscript	  2	  .............................................................................................................................	  34	  
Drug	  response	  profiling	  to	  identify	  selective	  pharmacological	  activity	  in	  drug	  resistant	  ALL	  ..........	  34	  
Manuscript	  3	  .............................................................................................................................	  35	  
Vanin-­‐2	  (GPI-­‐80)	  identifies	  aggressive	  subtypes	  of	  childhood	  acute	  lymphoblastic	  leukemia	  .........	  35	  
VNN2	  Prospective	  analysis	  proposal	  ..........................................................................................	  36	  
Proposal	  for	  prospective	  evaluation	  of	  VNN2	  as	  prognostic	  marker	  for	  BCP-­‐ALL	  ...........................	  36	  
4	   Discussion	  ..................................................................................................................	  37	  
4.1	   Rationale	  ..........................................................................................................................	  37	  
4.1.1	   Genomic	  characterization	  is	  not	  sufficient	  for	  the	  development	  of	  targeted	  
therapies	  ......................................................................................................................................	  37	  
4.1.2	   Integration	  of	  genomic	  profiling	  and	  functional	  investigations	  based	  on	  the	  leukemia	  
xenograft	  system	  ...........................................................................................................................	  38	  
4.2	   Patient	  derived	  xenograft	  (PDX)	  .......................................................................................	  39	  
4.2.1	   PDXs	  used	  to	  model	  relevant	  subtypes	  of	  ALL	  .................................................................	  39	  
4.2.2	   Resemblance	  of	  the	  clonal	  composition	  of	  Patient	  Derived	  Xenograft	  (PDX)	  to	  the	  original	  
sample	  40	  
4.2.3	   Genomic	  characterization	  of	  TCF3-­‐translocated	  ALL	  PDX	  models	  ....................................	  41	  
4.2.4	   Identification	  of	  leukemia-­‐associated	  markers	  using	  the	  PDX	  model	  ..............................	  41	  
4.3	   Contribution	  of	  the	  genomic	  study	  of	  TCF3-­‐HLF-­‐positive	  ALL	  to	  our	  understanding	  of	  
leukemogenesis	  .........................................................................................................................	  42	  
4.4	   Development	  of	  a	  large	  scale	  drug-­‐screening	  platform	  for	  primary	  ALL	  samples	  ...............	  43	  
4.4.1	   Co-­‐culture	  of	  primary	  leukemia	  cells	  on	  mesenchymal	  stromal	  cells	  ..............................	  43	  
4.4.2	   Survival	  and	  proliferation	  .................................................................................................	  43	  
4.4.3	   Correlation	  of	  in	  vivo	  and	  in	  vitro	  drug	  activity	  in	  our	  models	  .........................................	  44	  
4.5	   Proof	  of	  concept	  data	  to	  support	  the	  use	  of	  in	  vitro	  drug	  profiling	  in	  translational	  research45	  
4.6	   	  Impact	  of	  our	  models	  on	  translational	  research	  ...............................................................	  47	  
5	   References	  .................................................................................................................	  48	  
	  
	   9	  
Acknowledgements	  ..........................................................................................................	  53	  
Curriculum	  vitae	  ...............................................................................................................	  55	  
Manuscripts	  and	  	  VNN2	  prospective	  analysis	  proposal………........……………..………………………………...56	  
	   	   Introduction	   	  
10	  
1	   Introduction	  
1.1	   	   Adult	  and	  Pediatric	  cancers:	  differences	  and	  similarities	  
Cancer	  is	  a	  term	  used	  to	  describe	  diseases	  in	  which	  atypical	  cells	  proliferate	  without	  control,	  invade	  
surrounding	  normal	  tissues	  and	  eventually	  spread	  to	  other	  parts	  of	  the	  body	  through	  the	  blood	  and	  
lymph	  systems.	  There	  are	  more	  than	  100	  different	  types	  of	  cancer	  and	  they	  are	  classified	  by	  the	  type	  
of	   tissue	   in	   which	   the	   cancer	   originates	   and	   by	   the	   location	   in	   the	   body	   where	   the	   cancer	   first	  
developed.	  
Cancers	  figure	  among	  the	  leading	  causes	  of	  morbidity	  and	  mortality	  worldwide,	  with	  approximately	  
14	  million	  new	  cases	  and	  8.2	  million	  cancer	  related	  deaths	  per	  year	  (Ref.	  World	  Cancer	  Report	  2014	  
related	   to	   2012).	   The	   relative	   incidence	   of	   cancer	   types	   changes	   remarkably	   across	   different	   age	  
groups	   (Figure	   1)	   (1).	   Children	   (0-­‐14	   years)	   develop	   primarily	   hematological	   malignancies,	  
neuroectodermal	   tumors	   and	   sarcomas.	   Carcinoma	   occurs	   mainly	   in	   adults.	   Distinct	   spectrum	   of	  
cancers	  between	  adults	  and	  children	  is	  due	  to	  the	  different	  type	  of	  tissue	  that	  undergoes	  substantial	  
expansion.	   For	   example,	   the	   B-­‐cell	   repertoire	   develops	   mainly	   during	   the	   age	   0-­‐14	   years	   and	   is	  
associated	   with	   high	   proliferation	   of	   B-­‐cell	   precursors.	   This	   event	   increases	   the	   possibility	   of	   the	  
emergence	  and	  enrichment	  of	  genetic	  aberrations.	  
The	  development	  of	   cancer	  derives	   from	  the	  accumulation	  of	  genetic	  and	  epigenetic	  alterations	   in	  
normal	  cells	  that	  provide	  a	  selective	  growth	  advantage.	  This	  process	  of	  mutations	  followed	  by	  clonal	  
expansion	  leads	  to	  the	  formation	  of	  cancer.	  Notably,	  different	  tumor	  types	  display	  heterogeneity	  in	  
the	  number	  of	  mutations,	  ranging	  from	  ~200	  non-­‐synonymous	  mutations	  per	  tumor	  to	  2	  (2)	  (Figure	  
2)	  Melanoma	  and	  lung	  tumors	  are	  among	  the	  tumors	  with	  the	  highest	  number	  of	  mutations	  due	  to	  
the	   effect	   of	   mutagens	   (UV	   light	   and	   smoke)	   in	   the	   pathogenesis.	   While	   pediatric	   tumors	   and	  
leukemia	   harbor	   only	   few	   point	   mutations	   (9.6	   in	   average	   per	   tumor).	   The	   lower	   number	   of	  
mutations	   in	  pediatric	   tumor	   can	  be	  explained	  by	   the	   fact	   that	  pediatric	   cancers	  occur	   in	  non–self	  
renewing	  tissues	  or,	  in	  case	  of	  leukemia,	  from	  precursor	  cells	  that	  have	  not	  renewed	  themselves	  as	  
often	   as	   in	   adults.	   It	   has	   been	   shown	   that,	   at	   least	   for	   some	   tumors,	   the	   number	   of	   mutations	  
depends	  by	   the	   age	   and	   the	   cell	   division	  number	   (3).	  Additionally,	   the	  explosion	   in	   the	   amount	  of	  
genomic	  data	  published	   in	   the	   last	   two	  decades	   shed	   light	  on	   the	  heterogeneity	   in	   the	  mutational	  
landscape	  across	  different	  patients	  highlighting	  the	  need	  of	  patient	  specific	  therapies.	  	  	  
Although	   origin	   and	   genomic	   background	   of	   the	   cancers	   are	   heterogeneous,	   they	   share	   widely	  
described	  common	  biological	  features,	  such	  as:	   	  a	  sustaining	  proliferative	  signaling,	  evading	  growth	  
suppressors,	   resisting	   cell	   death,	   enabling	   replicative	   immortality,	   inducing	   angiogenesis,	   and	  
activating	   invasion	   and	  metastasis	   (Figure	   3)	   (4).	   These	   pathways	   are	   indeed	   targets	   of	   clinical	   or	  
experimental	  anti-­‐cancer	  drugs.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  1.	  The	  relative	  incidence	  of	  cancer	  types	  changes	  across	  different	  age	  groups.	  Acute	  lymphoblastic	  leukemia	  is	  the	  
most	  common	  disease	  in	  children.	  Relative	  proportions	  are	  for	  European	  populations	  covered	  by	  cancer	  registries.	  Data	  are	  
derived	  from	  a	  total	  of	  53’717	  cases	  for	  age	  0–14	  years,	  82’042	  cases	  for	  age	  15–29	  years,	  and	  5’950’220	  cases	  for	  age	  >30	  
years.	  Adapted	  from	  (1).	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Figure	  2.	  Different	  tumor	  types	  display	  heterogeneity	  in	  the	  number	  of	  mutations.	  (A)	  Tumors	  in	  children	  (left)	  and	  adults	  
(right).	   Numbers	   in	   parentheses	   indicate	   the	   median	   number	   of	   non-­‐synonymous	   mutations	   per	   tumor	   detected	   by	  
genome-­‐wide	  sequencing	  studies.	  (B)	  The	  median	  number	  of	  non-­‐synonymous	  somatic	  mutations	  per	  human	  tumor.	  Error	  
bars	  indicate	  the	  25th	  and	  75th	  quartiles.	  MSI,	  microsatellite	  instability;	  SCLC,	  small	  cell	  lung	  cancers;	  NSCLC,	  non–small	  cell	  
lung	  cancers;	  ESCC,	  esophageal	  squamous	  cell	  carcinomas;	  MSS,	  microsatellite	  stable;	  EAC,	  esophageal	  adenocarcinomas.	  
Adapted	  from	  (2).	  
	  	  	  	  	  	  	  	   	  
Figure	  3.	  Cancers	  share	  widely	  described	  common	  biological	  features.	  The	  hallmarks	  of	  cancer	  and	  importance	  of	  tumor-­‐
associated	  microenvironment	  is	  summarized	  in	  the	  scheme.	  Adapted	  from	  (4).	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1.2	   Leukemia	  
Leukemia	   literally	   means	   “white	   blood”	   (λευκός	   αίμα,	   leukos	   aima)	   and	   is	   a	   cancer	   of	   the	   blood	  
characterized	  by	  an	  abnormal	  increase	  of	  white	  blood	  cells.	  	  
Leukemias	  are	  usually	  divided	  into	  two	  major	  groups,	  acute	  and	  chronic	  leukemia.	  Acute	  leukemia	  is	  
associated	  with	  a	  quick	  increase	  of	  immature	  white	  cells	  and	  may	  lead	  to	  death	  within	  a	  few	  weeks	  
or	   months	   if	   not	   treated,	   while	   chronic	   leukemia	   progresses	   slowly,	   and	   is	   characterized	   by	   the	  
abnormal	  proliferation	  of	  more	  mature	  white	  cells.	  Further	  classification	  depends	  on	  the	   lineage	  of	  
the	   cell	   affected,	   distinguishing	   between	   myeloid	   and	   lymphoblastic	   leukemia:	   acute	   myeloid	  
leukemia	   (AML),	   acute	   lymphoblastic	   leukemia	   (ALL),	   chronic	  myeloid	   leukemia	   (CML)	   and	   chronic	  
lymphoblastic	   leukemia	  (CLL).	  While	  adults	  can	  get	  all	  types	  of	   leukemia,	  children	  typically	  show	  an	  
acute	  form	  of	  the	  disease.	  The	  present	  doctoral	  thesis	  focuses	  on	  pediatric	  BCP-­‐ALL	  (B-­‐cell	  precursor	  
acute	  lymphoblastic	  leukemia),	  which	  results	  from	  the	  clonal	  expansion	  of	  B-­‐lymphoid	  cells	  arrested	  
at	  an	  early	  stage	  of	  differentiation	  (Figure	  4).	  
	  
	  
	  	  	  	  	  	  	  	   	  
Figure	  4.	  B-­‐cell	  precursor	  ALL	  results	  from	  the	  developmental	  block	  and	  clonal	  expansion	  of	  committed	  B-­‐cell	  precursor	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1.3	   Childhood	  acute	  lymphoblastic	  leukemia	  (ALL)	  
1.3.1	   Epidemiology	  
ALL	  is	  the	  most	  common	  cancer	  in	  children,	  representing	  about	  30%	  of	  all	  childhood	  cancers	  and	  its	  
diagnosis	  peak	  between	  the	  ages	  of	  2	  and	  5	  years.	  In	  Europe,	  ALL	  accounts	  for	  80%	  of	  leukemia	  cases	  
among	  children	  aged	  0–14	  years,	  with	  an	  annual	  incidence	  of	  3-­‐4	  children	  per	  100,000	  individuals	  (6).	  
In	  Switzerland,	  approximately	  45	  to	  55	  children	  per	  year	  are	  newly	  diagnosed	  with	  ALL	  (7).	  Around	  
80%	  of	  the	  cases	  belong	  to	  the	  B-­‐cell	  precursor	  subtype,	  and	  the	  remaining	  20%	  are	  T-­‐ALL	  cases.	  
1.3.2	   Etiology	  
Evidences	   indicated	   an	   association	   with	   disorders	   due	   to	   congenital	   genetic	   instability	   (i.e.,	   Down	  
syndrome,	   ataxia	   telangiectasia),	   prenatal	   exposure	   to	   X-­‐rays,	   ionizing	   radiation	   and	  
chemotherapeutic	  agents.	  Recent	  genome-­‐wide	  studies	  reported	  associations	  between	  a	  higher	  risk	  
for	   ALL	   and	   the	   presence	   of	   specific	   allelic	   variants	   (single	   nucleotide	   polymorphism	   in	   DNA	  
sequence)	  of	  genes	  involved	  in	  the	  transcriptional	  regulation	  and	  differentiation	  of	  B-­‐cell	  progenitors	  
(IKZF1,	  ARID5B,	  CEBPE	  and	  CDKN2A)	  (8-­‐10).	  Further	  studies	  have	  been	  conducted	  to	  investigate	  the	  
role	   of	   infection,	   exposure	   to	   electromagnetic	   field	   and	   fetal	   growth,	   however	   very	   few	   of	   these	  
findings	  are	  based	  on	  reproducible	  data	  or	  have	  a	  sufficient	  statistical	  power	  (11).	  	  
1.3.3	   Symptoms	  	  
The	  common	  symptoms	  include	  fever,	  fatigue,	  bone	  or	  joint	  pain,	  bleeding	  and	  recurrent	  infections.	  
These	   symptoms	   correlate	  with	   the	  uncontrolled	   growth	  of	   the	  malignant	   cell	   population	   invading	  
the	   bone	   marrow,	   lymphoid	   organs,	   and	   extra-­‐medullary	   (outside	   of	   the	   bone	   marrow)	   sites.	  
Deregulated	   hematopoiesis	   leads	   to	   insufficient	   numbers	   of	   red,	   white	   mature	   blood	   cells	   and	  
platelets	   and,	   indeed,	   common	   clinical	   features	   are	   anemia,	   neutropenia,	   thrombocytopenia,	  
lymphadenopathy,	  splenomegaly	  and	  hepatosplenomegaly.	  
1.3.4	   Diagnosis	  
Accurate	  diagnosis	  and	  classification	  are	  important	  for	  the	  successful	  treatment	  and	  biologic	  study	  of	  
childhood	  acute	   leukemia.	  Disease	  subtypes,	   that	  are	  clinically	  and	  biologically	  relevant,	  are	  mainly	  
classified	   based	   on	   patient	   clinical	   response,	   immunophenotype	   and	   genetic	   abnormalities	   of	   the	  
disease.	  	  Bone	  marrow	  aspirates	  of	  the	  patient	  undergo	  multiple	  analyses:	  
a)	  Morphology	  
The	  morphologic	  diagnosis	  of	  leukemia	  requires	  examination	  of	  the	  bone	  marrow	  and	  is	  based	  on	  the	  
microscopic	   features	   of	   the	   leukemia	   cells,	   analyzed	   by	   Wright-­‐Giemsa-­‐stained	   smears.	   ALL	   are	  
classified	   according	   to	   the	   French-­‐American-­‐British	   (FAB)	   system.	   Analysis	   of	   the	   morphology	   still	  
represents	   the	   fastest	   method	   to	   clinically	   diagnosis	   leukemia,	   and	   an	   experienced	   analyst	   can	  
immediately	  distinguish	  between	  ALL	  or	  AML.	  However,	  the	  recent	  WHO	  International	  panel	  on	  ALL	  
recommends	   the	   abandonment	   of	   the	   FAB	   classification,	   since	   it	   lacks	   independent	   clinical	   or	  
prognostic	   significance,	   and	   suggests	   instead	   the	   use	   of	   the	   immunophenotypic	   classification	  
described	  in	  the	  next	  section.	  	  
b)	  Immunophenotype	  
The	   diagnosis	   and	   treatment	   of	   ALL	   are	   depended	   on	   the	   tumor	   cells	   lineage	   and	   stage	   of	  
maturation.	  Immunophenotypic	  analysis	  is,	  therefore,	  an	  essential	  part	  of	  the	  diagnostic	  phase,	  as	  it	  
establishes	   the	   leukemic	   cell	   lineage	   and	   determines	   the	   stage	   of	   differentiation.	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Immunophenotyping	   divides	   ALL	   into	   two	   broad,	   but	   clinically	   and	   biologically	   meaningful,	  
categories:	   B-­‐cell	   ALL	   (B-­‐ALL)	   and	   T-­‐cell	   ALL	   (T-­‐ALL).	   A	   panel	   of	   antibodies	   is	   used	   to	   define	   the	  
diagnosis	  of	  ALL	  by	  flow	  cytometry.	  This	  process	  includes	  markers	  that	  are	  highly	  lineage	  specific	  (for	  
example,	  CD19	  marks	  the	  B-­‐lineage	  and	  CD7	  the	  T-­‐lineage).	  Additional	  markers	  are	  used	  for	  subtype	  
classification	  (Table	  1).	  	  
	  
	  
Table	  1.	  Markers	  used	  for	  lineage	  assignment	  and	  subtype	  classification	  at	  diagnosis.	  Lineage	  markers	  according	  to	  WHO	  
2008	  criteria	  (12).	  Subtype	  classification	  markers	  according	  to	  AIEOP-­‐BFM	  ALL	   Immunophenotyping	  Consensus	  Guidelines	  
(13),	  which	  is	  based	  on	  the	  European	  Group	  for	  the	  Immunological	  Characterization	  of	  Leukemia	  (EGIL)	  guidelines	  (14)	  .	  
	  
c)	  Genetic	  features	  
ALL	   displays	   significant	   heterogeneity	   at	   genetic	   level.	   The	   genetic	   characteristics	   define	   disease	  
subsets	   with	   distinct	   biologic	   behavior	   and	   prognostic	   implications.	   They	   are	   used	   in	   the	   risk	  
stratification	   in	   most	   modern	   treatment	   protocols.	   Genetic	   abnormalities,	   such	   as	   chromosomal	  
translocations,	   changes	   in	   ploidy,	   amplification	   and	   deletions	   in	   recurrent	   affected	   genes,	   are	  
analyzed	  by	   chromosomal	  analysis,	  RT-­‐PCR,	   fluorescence	   in	   situ	  hybridization	  and	  MLPA	   (Multiplex	  
Ligation-­‐dependent	   Probe	   Amplification),	   a	   multiplex	   PCR	  method	   that	   can	   detect	   abnormal	   copy	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1.4	   Prognostic	  factors	  in	  acute	  lymphoblastic	  leukemia	  	  
	  
The	  prognosis	  of	  childhood	  ALL	  has	   improved	  dramatically	  over	  the	   last	   five	  decades,	  as	  a	  result	  of	  
therapy	   adaptation	   based	   on	   the	   risk	   for	   relapse	   and	   continual	   reconfiguration	   of	   existing	  
chemotherapeutic	   drugs.	   Treatment	   protocols	   stratify	   patients	   based	   on	   multiple	   factors	   such	   as	  
genetics,	  immunophenotype,	  patient	  age,	  white	  blood	  count	  and	  treatment	  response	  (Table	  2).	  	  
	  	  	  	  	  	  	  	  	  
	  
Table	  2.	  Factors	  used	  for	  risk	  stratification	  in	  childhood	  ALL.	  Adapted	  from	  (15)	  	  
	  
1.4.1	   Cytogenetic	  abnormalities	  
Currently,	   75%	  of	   childhood	  B-­‐Cell	   Precursor	   (BCP)	  ALL	  patients	   are	   classified	  according	   to	  defined	  
cytogenetic	   subgroups	   associated	  with	   clinical	   outcome	   (Figure	   5	   and	   Table	   3	   for	   a	   complete	   list,	  
updated	  in	  January	  2015).	  
A	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  B	  
	  
Figure	  5.	  Cytogenetic	  alterations	  have	  strong	  implications	  on	  survival.	  A)	  B-­‐cell	  precursor	  (BCP)	  ALL	  cytogenetic	  subtypes.	  
Frequency	  of	  each	  subtype	  among	  BCP-­‐ALL	  cases	  is	  shown.	  In	  red	  are	  the	  subtypes	  associated	  with	  poor	  prognosis	  and	  in	  
green	  those	  with	  favourable	  outcome.	  Adapted	  from	  (16).	  B)	  Event	  free	  survival	  probability	  at	  12	  years	  of	  some	  cytogenetic	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Table	   3.	   Cytogenetic	   subtypes	   of	   B-­‐cell	   precursor	   ALL	   that	   are	   associated	   with	   clinical	   outcome.	   *Historically	   poor	  
outcome,	  prognosis	  improved	  with	  addition	  of	  imatinib	  and/or	  dasatinib	  to	  intensive	  chemotherapy.	  Adapted	  from	  (18)	  .	  
	  
1.4.2	   Clinical	  response	  (Minimal	  residual	  disease	  assessment)	  
Evaluation	  of	  treatment	  response	   is	  the	  most	  powerful	  predictor	  for	  the	  risk	  of	  disease	  recurrence.	  
Precise	  time	  points	  over	  the	  treatment	  and	  residual	   leukemia	  thresholds	  have	  been	  established	  for	  
the	  monitoring	  of	  the	  minimal	  residual	  disease	  (MRD).	  The	  predictive	  value	  of	  this	  strategy	  has	  been	  
confirmed	  independently	  by	  several	  studies	  (Figure	  6)	  (19-­‐21).	  MRD	  can	  be	  assessed	  by	  quantitative	  
RT-­‐PCR	   and	   flow	   cytometry.	   RT-­‐PCR	   detects	   leukemia	   specific	   immunoglobulin	   (Ig)	   and	   T-­‐cell	  
receptor	   (TCR)	   gene	   rearrangement	   or	   fusion	   transcripts.	   Immunophenotyping	   by	   flow	   cytometry	  
discriminates	   lymphoblasts,	   since	   they	   typically	   show	   an	   aberrant	   pattern	   of	   expression	   of	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Figure	  6.	  Minimal	  residual	  disease	  assessment	  by	  PCR	  is	  the	  most	  powerful	  predictor	  for	  the	  risk	  of	  disease	  recurrence.	  
A)	   Scheme	   of	   the	   time	   points	   over	   the	   patient	   treatment	   phases,	   adapted	   from	   AIEOP-­‐BFM	   ALL	   2009.	   Patients	   are	  
considered	  MRD	  standard	  risk	  (SR)	  if	  MRD	  is	  already	  negative	  at	  day	  33	  (with	  a	  sensitivity	  of	  at	   least	  10
−4
);	  MRD	  high	  risk	  
(HR)	  if	  10
−3
	  or	  more	  at	  day	  78;	  others	  are	  classified	  as	  intermediate	  risk	  (IR).	  Patients	  that	  are	  still	  positive	  at	  day	  154	  are	  
classified	  as	  Very	  High	  Risk	   (VHR).	  B)	   Event-­‐free	   survival	   according	   to	  PCR-­‐MRD	  classification.	   Large	  prospective	   study	  of	  
3’184	  BCP-­‐ALL	  patients.	  42%	  were	  MRD-­‐SR,	  52%	  MRD-­‐IR,	  and	  6%	  MRD-­‐HR;	  they	  had	  a	  significantly	  different	  outcome	  with	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1.5	   Clinical	  treatment	  of	  ALL	  pediatric	  patients	  
1.5.1	   Phases	  of	  the	  treatment	  
Swiss	   patients	  with	   ALL	   are	   treated	   uniformly	   according	   to	   the	   international	   AIEOP-­‐BFM-­‐ALL-­‐2009	  
treatment	   protocol	   (NCT01117441).	   The	   treatment	   includes	   three	   phases	   (Figure	   7	   and	   Table	   4):	  
induction	   of	   remission,	   intensification/consolidation	   and	   maintenance.	   Importantly,	   differences	   in	  
the	  treatment	  regimens	  are	  applied	  according	  to	  risk	  group,	  aiming	  to	  obtain	  an	  effective	  treatment	  
with	  low	  toxicity.	  	  
1)	   The	   induction	   of	   remission	   phase	   aims	   to	   eradicate	   the	   initial	   leukemia	   burden.	   Treatment	  
regimen	  consists	  of	  a	  3-­‐drugs	  (vincristine,	  steroids	  and	  asparaginase)	  or	  of	  a	  more	  intense	  4-­‐drug	  mix	  
(i.e.,	  adding	  anthracycline).	  Patients	  with	  BCR-­‐ABL1	  positive	  disease	  benefit	  from	  the	  early	  treatment	  
with	  tyrosine	  kinase	  inhibitors.	  
2)	  The	  intensification/consolidation	  treatment	  phase	  has	  the	  goal	  to	  eliminate	  drug	  resistant	  residual	  
leukemic	   cells	   and	   therefore	   reduce	   the	   risk	   of	   relapse.	   Administered	   drugs	   during	   this	   phase	   can	  
vary	  based	  on	  the	  risk	  stratification.	  	  
3)	  The	  purpose	  of	  the	  maintenance	  phase	  is	  to	  preserve	  remission	  and	  contrast	  relapse.	  	  
	  
	  	  	  	   	  
Figure	   7.	   Scheme	   of	   the	   phases	   included	   in	   the	   treatment	   protocol	   for	   ALL.	   Combinations	   of	   different	   drugs	   are	  
administered	   over	   the	   different	   treatment	   phases.	   Additional	   drugs	   for	   high	   risk	   cases	   are	   indicated	   in	   orange.	   Scheme	  
adapted	  from	  AIEOP-­‐BFM	  ALL	  2009.	  Abbreviations:	  Prednisolone	  (PDN),	  Vincristine	  (VCR),	  Daunorubicin	  (DNR),	  Asparginase	  
(ASP),	   Methotrexate	   (MTX),	   Cyclophosphamide	   (CPM),	   Cytarabine	   (ARA-­‐C),	   Mercaptopurine	   (6-­‐MP),	   Dexamethasone	  
(DEXA),	  Vindesine	  (VDS),	  Ifosfamide	  (IFO),	  Etoposide	  (VP-­‐16),	  Thioguanine	  (TG),	  Leucovorin	  (LEU).	  	  
	  
1.5.2	   Stem	  cell	  transplantation	  and	  intrathecal	  chemotherapy	  
Allogeneic	   hematopoietic	   stem	   cell	   transplantation	   counts	   as	   the	  most	   intensive	   treatment	   and	   is	  
considered	   an	   option	   for	   resistant	   cases.	   Intrathecal	   chemotherapy	   with	   methotrexate,	  
hydrocortisone	  and	  cytarabine	   is	  administered	  to	  ALL	  cases	  with	  an	   increased	  risk	  of	  relapse	   in	  the	  
central	  nervous	  system,	  such	  as	  cases	  with:	  high	  risk	  genetic	  features,	  T-­‐cell	  immunophenotype,	  large	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Table	  4.	  Classification	  of	  the	  most	  common	  drugs	  used	  for	  ALL	  based	  on	  the	  mechanism	  of	  action.	  
	  
	  
1.6	   Key	  mechanisms	  driving	  leukemogenesis	  during	  B-­‐cell	  development	  	  
B-­‐cell	   development	   is	   a	   multistep	   process,	   in	   which	   hematopoietic	   stem	   cells	   (HSCs)	   differentiate	  
sequentially	  into	  common	  lymphoid	  precursors	  (CLP),	  B-­‐cell	  precursors	  and	  finally	  become	  mature	  B-­‐
cells	  expressing	  the	  B-­‐cell	  receptor	  (Figure	  8).	  Normal	  differentiation	  requires	  the	  coordination	  of	  the	  
intrinsic	  cell	  differentiation	  program,	  appropriate	  recombination	  of	  the	  immunoglobulin	  forming	  the	  
B-­‐cell	  receptor	  and	  interactions	  with	  microenvironment.	  	  
Here	  I	  describe	  two	  mechanisms	  contributing	  to	  leukemogenesis	  during	  B-­‐cell	  development:	  	  
1) Illegitimate	  RAG	  recombination	  activity	  	  
2) Mutations	  in	  transcription	  factors	  involved	  in	  B-­‐cell	  development.	  	  
These	  mechanisms	  are	  important	  for	  understanding	  the	  findings	  present	  in	  Manuscript	  1.	  
1.6.1	   Illegitimate	  RAG	  recombination	  activity	  contribute	  to	  genome	  instability	  	  
In	  pro-­‐B	  cell	  and	  pre-­‐B	  cell	  precursors	   the	  genetic	  elements	   that	  encode	   the	  antigen	  specific	  B-­‐cell	  
receptors	   (BCR	   or	   immunoglobulin)	   are	   assembled	   by	   V(D)J	   rearrangement	   (Figure	   9).	   Their	  
rearrangement	   is	   primarily	   mediated	   by	   the	   RAG	   endonucleases,	   RAG1	   and	   RAG2.	   RAG	   enzymes	  
recognize	   recombination	   signal	   sequence	   (RSS)	   motifs	   consisting	   of	   a	   highly	   conserved	   heptamer	  
(CACAGTG)	   and	   a	   less	   conserved	  nonamer	   (ACAAAAACC)	   sequence	   separated	  by	   a	   12-­‐bp	  or	   23-­‐bp	  
sequence-­‐independent	   space.	   RAG	   endonucleases	   bind	   DNA	   at	   RSS	   motifs	   and	   cleave	   DNA.	  
Processing	   of	   these	   ends	   often	   involves	   the	   addition	   of	   Non-­‐Template	   Sequence	   (NTS)	   at	   the	  
breakpoint	  by	  Terminal	  Deoxynucleotidyl	  Transferase	   (TdT).	   It	  has	  been	  reports	   that	   in	   some	  cases	  
RAG	   and	   TdT	   recombination	   can	   induce	   illegitimate	   recombination	   at	   genetic	   sites	   outside	   of	   the	  
V(D)J	  regions.	  (23).	  Heptamers	  or	  nonamers	  outside	  the	  context	  of	  a	  conserved	  RSS	  and	  deaminated	  
methyl	  CpGs	  elements	  have	  also	  been	  associated	  with	  mechanisms	  of	  RAG	  activity	   contributing	   to	  
genome	  instability	  and	  the	  development	  of	  lymphoid	  malignancies.	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1.6.2	   Mutations	  in	  transcription	  factors	  involved	  in	  B-­‐cell	  development	  	  
B-­‐cell	  differentiation	  relies	  on	  the	  activation	  of	  multiple	  transcription	  factors	  (RUNX1,	  ERG,	   IKAROS,	  
TCF3,	  EBF1	  and	  PAX5)	  at	   specific	   times	  during	  development	   (Figure	  8	  and	  9)	   (24).	  Genomic	  studies	  
have	  shown	  that	  mutations	  in	  these	  transcriptional	  regulators	  are	  highly	  enriched	  in	  ALL	  suggesting	  
their	  important	  role	  in	  leukemogenesis.	  More	  information	  on	  TCF3	  and	  PAX5	  transcription	  factors	  are	  
reported	  below	  because	  they	  are	  relevant	  for	  Manuscript	  1.	  	  
a)	  TCF3	  
TCF3	  (transcription	  factor	  3)	  or	  also	  called	  E2A	  (immunoglobulin	  enhancer-­‐binding	  factors	  E12/E47),	  
is	  a	  transcription	  factor	  essential	  for	  B-­‐cell	  development	  (25).	  TCF3	  proteins	  (isoforms	  E12	  and	  E47)	  
derive	   from	   alternative	   splicing	   and	   contain	   the	   helix-­‐loop-­‐helix	   (HLH)	   DNA	   binding	   domain.	   E	  
proteins	   activate	   transcription	   by	   binding	   to	   regulatory	   E-­‐box	   sequences	   on	   target	   genes	   as	  
homodimers	  or	  heterodimers.	   	  The	  E12	  and	  E47	  differ	  by	  20%	   in	   their	  amino	  acid	  sequence	  of	   the	  
HLH	  domain,	  however	  differences	  in	  their	  function	  have	  not	  been	  shown.	  	  
E2A	   is	   upregulated	   at	   the	   common	   lymphoid	   progenitor	   (CLP)	   stage	   of	   development	   and	   remains	  
high	   in	   pro-­‐B,	   pre-­‐B	   and	   immature	   B	   cells	   in	   the	   bone	   marrow	   (26)	   (Figure	   13).	   TCF3	   drives	   the	  
expression	   of	   a	   number	   of	   B-­‐cell	   specific	   genes	   essential	   for	   B-­‐cell	   development	   including	   Pax5,	  
Foxo1,	   Ebf1,	   Rag1,	   Rag2,	   Lgll1,	   Vpreb1	   and	   Cd79a.	   Moreover,	   E2A	   represses	   myeloid/erythroid-­‐
lineage-­‐specifying	  genes,	  such	  as	  Gata1,	  Csf1r	  and	  Epor.	  
Lymphoid	  defects	  in	  Tcfe2a-­‐/-­‐	  mice	  are	  already	  apparent	  at	  the	  CLP	  stage	  of	  the	  development	  and	  a	  
major	   development	   block	   occurs	   at	   the	   pre-­‐B	   cell	   and	   pro-­‐B	   cell	   stages	   (27-­‐29).	   E2A-­‐deficient	  
lymphoid	  cell	  lines	  have	  the	  capacity	  for	  multi	  lineage	  differentiation	  (30,	  31).	  
TCF3	   is	   implicated	   in	   several	   different	   types	   of	   hematological	   malignancies.	   In	   pediatric	   B-­‐cell	  
precursor	  ALL,	  TCF3	  is	  rearranged	  with	  PBX1	  or	  HLF	  genes	  to	  form	  TCF3-­‐PBX1	  and	  TCF3-­‐HLF	  chimeric	  
transcription	  factors,	  while	  recurrent	  mutations	  in	  TCF3	  are	  found	  in	  Burkitt’s	  lymphoma	  (32).	  
b)	  PAX5	  
The	   PAX5	   gene	   belongs	   to	   the	   paired	   box	   (PAX)	   gene	   family	   of	   transcription	   factors.	   	   PAX5	   is	  
expressed	   in	   constant	   level	   from	   the	  pro-­‐B	   cell	   stage	  onwards	  until	   it	   is	  down	   regulated	   in	  plasma	  
cells	  (Figure	  13)	  (33).	  PAX5	  binds	  to	  thousands	  of	  promoter	  regions	  and	  induces	  activation	  of	  genes	  
important	  for	  the	  B-­‐cell	  development,	  like	  co-­‐receptors	  Cd21	  and	  Cd19,	  MB-­‐1/Cd79a,	  and	  repression	  
of	  alternative	  gene	  expression	  program,	   i.e.	  PAX5-­‐repressed	  genes	  are	  Mcsfr,	  Notch1	   and	  Flt3	   (34-­‐
36).	  In	  absence	  of	  Pax5,	  B-­‐cell	  development	  is	  arrested	  at	  the	  pro-­‐B	  cell	  stage	  of	  differentiation	  (37),	  
and	  Pax5-­‐/-­‐	  pre-­‐B	  cells	  have	  extraordinary	  developmental	  plasticity	  showing	  hematopoietic	  stem	  cell	  
features	  such	  as	  multi-­‐potency	  and	  self-­‐renewing	  capacity	  (38).	  	  
PAX5	   is	   the	  most	   frequently	  mutated	   gene,	   which	   is	   affected	   in	   over	   one-­‐third	   of	   B-­‐ALL	   cases	   by	  
deletions,	  sequence	  mutations	  or	  translocations.	  Most	  of	  the	  PAX5	  aberrations	  are	  hemizygous	  and	  
somatically	  acquired.	  These	  mutations	  lead	  to	  reduced	  expression	  level	  of	  PAX5	  (haploinsufficiency),	  
but	   still	   allow	   the	   expression	   of	   PAX5	   target	   genes,	   like	  CD19,	   RAG1	   and	  RAG2.	   Recent	   studies	   in	  
Pax5
-­‐/+	  mice	  have	  showed	  that	  haploinsuffiency	  of	  PAX5	  favors	  the	  acquisition	  of	  secondary	  genetic	  
changes	   and	   therefore	   the	   leukemogenesis.	  PAX5	  deletions	   occur	   in	   about	   13%	   of	   BCP-­‐ALL	   cases,	  
however,	   the	   frequency	   increases	   when	   ALL	   subgroups	   are	   considered.	   For	   example,	   27%	   of	   TEL-­‐
AML1-­‐positive	  ALL	  (39),	  28%	  of	  high	  risk	  for	  relapse	  ALL	  (40),	  51%	  of	  BCR–ABL1-­‐positive	  ALL	  (41)	  have	  
PAX5	  deletions.	  It	  has	  been	  shown	  that	  PAX5	  alterations	  are	  not	  associated	  with	  poor	  outcome,	  but	  
rather	  seems	  to	  be	  a	  secondary	  important	  event,	  since	  it	  is	  frequently	  associated	  with	  other	  lesions.	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Figure	  8.	  Overview	  of	  the	  normal	  function	  of	  the	  B-­‐lineage	  transcription	  factors	  affected	  in	  B-­‐cell	  precursor	  ALL.	  RUNX1	  is	  
required	   for	   the	   emergence	   of	   primitive	   HSC,	   ERG	   for	   definitive	   HSC	  maintenance,	   IKZF1	   for	   the	   formation	   of	   Common	  
Lymphoid	  Progenitors	  (CLPs),	  TCF3	  and	  EBF1	  for	  the	  generation	  of	  pro-­‐B	  cells,	  PAX5	  to	  generate	  functional	  pre-­‐B	  cells	  and	  
maintain	  B-­‐cell	  identity.	  (24)	  
	  
.	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1.7	  	   Model	  of	  leukemogenesis	  
In	   most	   of	   the	   ALL	   cases	   chromosome	   translocations	   are	   often	   early	   or	   initiating	   events	   in	  
leukemogenesis.	  A	  prenatal	  origin	  of	   the	   translocation	   in	  pediatric	  ALL	  has	  been	  demonstrated	   for	  
MLL-­‐AF4	  (43)	  and	  TEL-­‐AML1	  (44).	  Chromosomal	  rearrangements	  disrupt	  genes	  that	  regulate	  normal	  
hematopoiesis	  or	  activate	  tyrosine	  kinases.	  	  Although	  these	  genetic	  changes	  are	  necessary	  to	  support	  
the	  leukemic	  transformation,	  experimental	  models	  have	  showed	  that	  they	  are	  usually	  not	  sufficient	  
to	   cause	   the	  disease,	   but	   additional	   structural	   alterations	   and/or	   sequence	  mutations	   are	   needed.	  
Such	  cooperative	  lesions	  lead	  to	  the	  block	  of	  differentiation,	  aberrant	  proliferation	  and	  resistance	  to	  
programmed	  cell	  death	  (Figure	  10	  and	  Table	  4)	  (45).	  
	  
Figure	   10.	   Molecular	   pathogenesis	   of	   ALL	   implicates	   the	   cooperation	   of	   initiating	   lesions	   and	   additional	   genetic	  
alteration.	  Initiating	  lesions,	  usually	  translocations,	  are	  associated	  with	  additional	  aberrations	  affecting	  genes	  implicated	  in	  
the	  lymphoid	  development	  (IKZF1,	  RUNX1,	  TCF3,	  EBF1,	  PAX5,	  VPREB1	  and	  RAG1/RAG2),	  control	  of	  survival	  and	  proliferation	  
(ABL1,	   NRAS/KRAS,	   JAK2,	   IL7R,	   CRLF2),	   transcriptional	   regulators	   (TBL1XR1,	   CREBBP,	   BTG1)	   and	   tumor	   suppressor	   genes	  
(RB1,	  CDKN2A,	  CDKN2B	  and	  TP53).	  Adapted	  from	  (45).	  
	  
1.7.1	   Recurrent	  genetic	  alterations	  	  
Increasing	   numbers	   of	   genome-­‐wide	   studies	   (40,	   46-­‐51)	   have	   identified	   recurrent	   mutations	   in	  
pathways	   that	   govern	   B-­‐cell	   development,	   cell	   cycle,	   in	   signaling	   pathways,	   epigenetic	   regulators	  
(Figure	  11	  and	  Table	  5).	  A	  comparison	  of	  diagnostic	  and	  relapse	  ALL	  cases	  revealed	  clonal	  diversity	  
comparable	   between	   the	   two	   disease	   states,	   although	   for	   half	   of	   the	   patients	   usually	   one	   minor	  
clone	  from	  diagnosis	  survives,	  acquires	  additional	  mutations	  and	  becomes	  the	  relapse	  clone	  founder.	  
Relapse-­‐specific	  mutations	  have	  been	  found,	  such	  as	  NT5C2	  (52),	  TP53	  (53),	  NRAS	  (46,	  54),	  IKZF1	  and	  
CREBBP	   (55).	   Mutations	   in	   these	   genes	   were	   never	   present	   in	   the	   falling	   clones	   after	   treatment,	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Table	  5.	  Recurrent	  genetic	  alterations	  identified	  in	  pediatric	  B-­‐cell	  precursor	  ALL.	  Adapted	  from	  (18).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  11.	  Recurrent	  mutated	  pathways	   in	  B-­‐cell	  precursor	  ALL	  at	  diagnosis	  and	  relapse.	  Recurrent	  lesions	  are	  found	  in	  
RAS	  pathway,	  JAK-­‐STAT	  signaling,	  transcriptional	  regulation	  of	   lymphoid	  development,	  nucleoside	  metabolism,	  epigenetic	  
modification	   and	   cell	   cycle	   regulation.	   Abbreviations:	   Single	   Nucleotide	   Variation	   (SNV),	   Copy-­‐Number	   Variations	   (CNV),	  
Structural	  Variations	  (SV).	  Adapted	  from	  (46).	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1.7.2	   Integration	  of	  the	  genomic	  and	  cytogenetic	  data	  to	  improve	  risk	  stratification	  criteria	  
Multiple	   genetic	   alterations	   are	   required	   in	   the	   pathogenesis	   of	   B-­‐ALL,	   therefore	   development	   of	  
new	   genetic	   biomarkers	   that	   consider	   constellations	   of	   genetic	   lesions,	   rather	   than	   single	   gene	  
mutation	   or	   translocation,	   are	   needed	   (56).	   Specific	   patterns	   of	   lesions	   are	   associated	   with	   poor	  
outcome,	   for	   example,	   IKFZ1	   deletions	   in	   BCR-­‐ABL1-­‐positive	   and	   BCR-­‐ABL1-­‐negative	   ALL	   (57).	  
Recently	  Moorman	  et	  al.	  have	  defined	  new	  criteria	  of	  risk	  stratification	  combining	  cytogenetic	  data	  
with	   the	   copy	   number	   variation	   profile	   of	   each	  patient.	   Based	  on	   this	   integrated	   approach	   clinical	  
response	  could	  be	  predicted	  and	  a	   large	  subset	  of	  children	  suitable	   for	   treatment	  deintensification	  
could	  be	  identified	  (58).	  	  
	  
1.8	  	   TCF3-­‐HLF	  and	  TCF3-­‐PBX1	  -­‐positive	  ALL	  model	  	  
This	   thesis	   focuses	  on	  TCF3-­‐HLF	  and	  TCF3-­‐PBX1-­‐positive	  ALL	  subtypes	  both	  of	  which	  are	  associated	  
with	   the	   translocation	   of	  TCF3,	   but	   have	   opposite	   clinical	   outcomes	   (Figure	   12).	  TCF3-­‐HLF-­‐positive	  
ALL	   is	  rare	  (~1%	  of	  BCP-­‐ALL	  cases)	  and	  currently	  not	  curable,	  while	  TCF3-­‐PBX1-­‐positive	  ALL	   is	  more	  
frequent	   (10%	   of	   BCP-­‐ALL)	   and	   associated	   with	   good	   outcomes	   (the	   median	   five-­‐year	   event-­‐free	  
survival	  rate	  rich	  78-­‐85%).	  	  
	  	  	  	  	  	  	  
	  
Figure	  12.	  Transactivation	  domain	  of	  TCF3	   is	   rearranged	   in	  TCF3-­‐HLF	   and	  TCF3-­‐PBX1-­‐positive	  ALL	   subtypes	   resulting	   in	  
disease	  with	  opposite	  outcomes.	  Both	  translocations	  involved	  the	  same	  N-­‐terminal	  portion	  containing	  the	  transactivation	  
domains	  of	  TCF3.	  Abbreviations:	  TCF3,	  transcription	  factor	  3;	  PBX1,	  pre-­‐B-­‐cell	  leukemia	  transcription	  factor	  1;	  HLH,	  hepatic	  
leukemia	  factor;	  AD,	  activation	  domain;	  bHLH,	  basic	  helix-­‐loop-­‐helix;	  PAR,	  prolin/acidic	  amino	  acid	  rich	  domain;	  bZIP,	  basic	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1.8.1	   TCF3-­‐HLF-­‐positive	  ALL	  
The	  TCF3-­‐HLF	  fusion	  protein	  is	  resulted	  from	  t(17;19)(q22;p13)	  translocation	  in	  which	  the	  N-­‐terminal	  
transactivation	  domains	  of	  TCF3	  are	   joined	  to	  the	  basic	   leucine	  zipper	  dimerization	  domain	  of	  HLF.	  
TCF3	  is	  involved	  in	  the	  B-­‐cell	  development	  and	  HLF	  is	  a	  member	  of	  the	  proline	  and	  acidic	  amino	  acid-­‐
rich	  basic	  leucine	  zipper	  (PAR	  bZip)	  transcription	  factor	  family.	  HLF	  is	  expressed	  in	  the	  liver,	  but	  not	  in	  
the	  hematopoietic	  system.	  	  
Two	  types	  of	  genomic	  rearrangements	  underlie	  the	  fusion	  of	  TCF3	  with	  HLF.	  In	  type	  I	  rearrangement,	  
a	   cryptic	   exon	   occurs	   between	  TCF3	   exon	   16	   and	  HLF	   exon	   4.	   This	   cryptic	   exon	   insertion	   includes	  
intronic	  portions	  of	  both	  TCF3	  and	  HLF	  genes.	  Type	  II	  rearrangement	  results	  from	  the	  fusion	  of	  TCF3	  
exon	   15	   spliced	   to	  HLF	   exon	   4.	   Non-­‐template	   nucleotides	   are	   included	   at	   the	   break	   point	   in	   both	  
types	  to	  maintain	  the	  proper	  HLF	  reading	  frame	  (60).	  No	  difference	  in	  the	  DNA-­‐binding,	  but	  a	  slight	  
difference	  in	  transcriptional	  transactivation	  activity	  were	  found	  in	  a	  comparison	  of	  type	  I	  and	  type	  II	  
TCF3-­‐HLF	   fusion	   proteins	   (61).	   However,	   no	   clear	   correlation	   of	   either	   type	   with	   outcome	   was	  
detected.	  	  
An	  early	   study	  has	   shown	   the	   importance	  of	   TCF3-­‐HLF	  protein	   for	   the	   survival	   of	  human	   leukemia	  
cells.	   Overexpression	   of	   a	   dominant	   negative	   form	   of	   TCF3-­‐HLF,	   which	   lacks	   the	   transactivation	  
domain	   of	   TCF3	   and	   has	   a	   defective	  HLF	   basic	   domain,	   leads	   to	   apoptosis	   of	   leukemia	   cells	   (62).	  
However,	  attempts	  to	  generate	  a	  transgenic	  mouse	  model	  of	   this	  disease	  failed.	  Overexpression	  of	  
human	  TCF3-­‐HLF	  under	  the	  control	  of	  the	  Eμ	  enhancer	  with	  the	  SV40	  promoter	  did	  not	  recapitulate	  
the	  abnormal	  proliferation	  of	  precursor	  B-­‐cells	  (63).	  In	  this	  model,	  a	  TCF3-­‐HLF	  fusion	  protein	  could	  be	  
expressed	  by	  mature	  B-­‐cells	  indicating	  that	  B-­‐cells	  were	  not	  blocked	  in	  the	  development.	  Only	  half	  of	  
the	   mice	   developed	   leukemia	   and	   in	   90%	   of	   the	   cases	   was	   T-­‐ALL.	   Another	   model	   used	   the	   Ig	  
enhancer	  with	   its	   corresponding	   Ig	   promoter	   to	   express	  TCF3-­‐HLF	   (64),	   but	   also	   in	   this	  model	   the	  
human	  disease	  has	  not	  been	  recapitulated.	  These	  data	  suggest	  that	  additional	  mutations	  or	  a	  specific	  
cell	  of	  origin	  may	  be	  required.	  	  
1.8.2	   TCF3-­‐PBX1-­‐positive	  ALL	  
The	   TCF3-­‐PBX1	   fusion	   protein	   derives	   from	   the	   t(1;19)(q23;p13)	   translocation.	   The	   N-­‐terminal	  
portion	   of	   TCF3	   (19p13,	   exons	   1-­‐16)	   including	   the	   transactivation	   domains	   is	   joined	   with	   the	   C-­‐
terminal	  Hox	  homeodomain	  of	  PBX1	  (1q23,	  exons	  4-­‐9)	  (65).	  PBX1	  belongs	  to	  homeobox	  gene	  family,	  
which	  are	  classical	  master	  regulators	  of	  developmental	  programs.	  PBX1	   is	  normally	  not	  express	  in	  B	  
or	  T	  lymphocytes.	  	  
Targets	   of	   TCF3-­‐PBX1	   have	   been	   recently	   identified	   by	   chromatin	   immunoprecipitation	   (ChIP)	   in	   a	  
human	  TCF3-­‐PBX1-­‐positive	  ALL	  cell	  line	  (697)	  and	  a	  primary	  TCF3-­‐PBX1-­‐positive	  ALL	  sample.	  ChIPseq	  
data	   revealed	   that	  TCF3-­‐PBX1	  binds	   to	  promoter	   regions	  of	  genes	   that	  encode	  key	  components	  of	  
the	  pre-­‐BCR,	   including	   IGLL1,	  VPREB1	  and	  pre-­‐BCR	  downstream	  signaling	  molecules	   (BLK,	  LCK,	  SYK,	  
ZAP70,	   PIK3CD).	   TCF3-­‐PBX1	   induces	   the	   overexpression	   of	   BCL6	   through	   pre-­‐B	   signaling.	   The	  BCL6	  
proto-­‐oncogene	  represents	  an	  essential	  prosurvival	  factor	  at	  the	  pre-­‐BCR	  checkpoint	  during	  early	  B-­‐
cell	  development.	  BCL6	  reinforces	  the	  pre-­‐BCR	  signaling	  activation	  by	  the	  transcriptional	  activation	  of	  
multiple	   pre-­‐BCR	   related	   proteins	   (IGLL1,	   VPREB1,	   BLK,	   SYK,	   PIK3D)	   and	   by	   the	   transcriptional	  
repression	  of	  the	  inhibitory	  phosphatase	  PTPRO	  (66).	  	  
In	   in	   vitro	   experiments	   TCF3-­‐PBX1	   fusion	   protein	   seems	   capable	   to	   transform	   both	   lymphoid	   and	  
fibroblast	   cell	   lines	   (67).	   However	   attempts	   to	   assess	   the	   oncogenic	   potential	   of	   E2A-­‐Pbx1	  
translocation	  in	  primary	  murine	  B-­‐lineage	  cells	  have	  not	  yielded	  successful	  mouse	  models	  (68),	  likely	  
secondary	  genetic	  events	  are	  required	  for	  leukemic	  transformation.	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1.9	  	   Utility	  of	  Patient	  Derived	  Xenograft	  (PDX)	  mouse	  models	   in	  B-­‐cell	  precursor	  
ALL	  	  
In	  research	  the	  use	  of	  model	  systems	  is	  indispensable	  for	  studying	  biological	  phenomena	  underlying	  
malignant	   cell	   transformation	   and	   cancer	   progression.	   Despite	   cell	   lines	   have	   been	   preferred	   as	  
model	   system	   since	   they	   are	   inexpensive	   and	   easy	   to	   handle,	   their	   use	   implicates	   two	   major	  
limitations:	  cell	  lines	  cannot	  be	  established	  from	  all	  patients	  and	  are	  not	  representative	  of	  the	  clonal	  
heterogeneity	  of	  the	  tumor.	  In	  the	  field	  of	  ALL	  genetic	  engineered	  mouse	  models	  mimicking	  known	  
genetic	   aberration	   are	   not	   always	   able	   to	   recapitulate	   the	   human	   disease,	   like	   TCF3-­‐HLF	   (63,	   64),	  
MLL-­‐AF4	   (69),	   TEL-­‐AML1	   (70),	   BCR-­‐ABL1	   (71)–positive	   ALL.	   Moreover,	   mouse	   model	   cannot	   be	  
generated	  for	  ALL	  subtypes	  with	  unknown	  aberrations.	  Especially	  in	  the	  context	  of	  scientific	  research	  
focus	  on	  the	  development	  of	  personalized	  medicine,	  alternative	  systems	  that	  allow	  to	  model	  patient	  
specific	  features	  are	  needed.	  	  	  
In	  the	  last	  decade,	  PDXs	  have	  been	  established	  for	  several	  subtypes	  of	  leukemia	  with	  known	  (72-­‐74)	  
and	  unknown	  genetic	  (51,	  75)	  aberrations.	  Primary	  patient	  material	  is	  transplanted	  by	  intravenous	  or	  
intraosseal	  into	  immunodeficient	  mouse	  strains.	  Animals	  develop	  leukemia,	  which	  exhibits	  biological	  
features	  and	  dissemination	  pattern	  similar	  to	  the	  one	  observed	  in	  humans.	  Leukemia	  cells	  circulate	  in	  
the	  blood	  flow	  and	  accumulate	  mainly	  in	  the	  bone	  marrow	  and	  spleen.	  More	  than	  hundreds	  millions	  
of	  cells	  can	  be	  usually	  harvested	  from	  the	  spleen	  of	  the	  mice	  even	  after	  transplanting	  only	  1	  million	  
of	   patients	   cells.	   	   	   It	   has	   been	   shown	   that	   the	   leukemia	   samples	   after	   amplification	   in	   NSG	  mice	  
(NOD.Cg-­‐PrkdcscidIl2rgtm1Wjl/SzJ)	   generally	   reproduced	   the	   immunophenotype	   and	   drug	   sensitivity	  
profile	   -­‐although	   few	   clinical	   drugs	   were	   tested-­‐	   of	   original	   human	   tumor	   (75,	   76).	   However	   the	  
influence	   of	   mouse	   microenvironment	   on	   the	   disease	   evolution	   in	   this	   system	   is	   still	   matter	   of	  
investigation	  and	  it	  depends	  not	  only	  on	  the	  recipient	  (more	  or	  less	  permissive	  mouse	  strain)	  but	  also	  
on	   the	   intrinsic	  properties	  of	   transplanted	   cells.	   It	  was	   shown	   that	   clonal	   composition	  of	   leukemia	  
samples	  was	  to	  some	  extend	  altered	  after	  xenotransplantation	  (72,	  73,	  75,	  77).	  This	  concerned	  rather	  
quantitative	  than	  qualitative	  relationships	  between	  individual	  sub-­‐clones	  and	  in	  majority	  of	  the	  cases	  
clones	   present	   after	   xenotransplantation	   could	   be	   backtracked	   to	   diagnostic	   sample.	   Due	   to	   the	  
possible	   variability	   associated	   with	   PDXs,	   their	   genetic	   characterization	   is	   required.	   Overall	   PDX	  
models	  are	  very	  useful	  for	  representing	  the	  patient	  leukemias	  with	  known	  and	  unknown	  aberrations	  
and	   the	   tumor	   multi-­‐clonal	   composition.	   They	   also	   constitute	   a	   theoretically	   unlimited	   source	   of	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1.10	  	   Integration	  of	   functional	  and	  genomics	  approaches	  to	  develop	  personalized	  
cancer	  therapies	  
Integration	   of	   functional	   and	   genomic	   screening	   strategies	   aims	   to	   identify	   genetic	   biomarkers	  
predictive	   of	   patient	   response	   to	   specific	   drugs	   and	   to	   develop	   effective	   and	   less	   toxic	   targeted	  
therapies.	   Progresses	   in	   the	   next	   generation	   sequencing	   technics	   allowed	   to	   discover	   underlying	  
biological	  pathways	   that	  drive	   leukemogenesis.	   Leukemia	   specific	   targets	  have	  been	   identified,	  but	  
therapeutic	  options	  targeting	  these	  lesions	  are	  still	  rare.	  The	  only	  successful	  example	  in	  the	  field	  of	  
leukemia	   is	   the	  clinical	  use	  of	   tyrosine	  kinases	   inhibitors	   (TKIs),	  which	  selectively	  target	  the	  protein	  
product	  of	  the	  BCR-­‐ABL1	  translocation.	  The	  development	  of	  tyrosine	  kinase	  inhibitors	  (TKIs),	  such	  as	  
imatinib,	   consistently	   improved	   the	   outcome	   of	   chronic	   myelogenous	   leukemia	   (CML)	   (78)	   and	  
pediatric	  BCR-­‐ABL1-­‐positive	  ALL	  (79).	  Therefore,	  development	  of	  new	  targeted	  therapies	  to	  extend	  to	  
other	  subtypes	  of	  ALL,	  it	  remains	  the	  next	  challenge.	  	  
1.10.1	   Next-­‐generation	  sequencing	  methods	  	  
Next	  generation	  sequencing	  (NGS)	  methods	  enable	  the	  sequencing	  of	  millions	  of	  fragments	  of	  DNA	  
from	  a	  single	  sample	  at	  the	  same	  time.	  This	  unprecedented	  throughput,	  scalability	  and	  speed,	  have	  
led	   to	   previously	   unimaginable	   scientific	   achievements	   and	   novel	   biological	   applications.	   Different	  
NGS	   techniques	   have	   diverse	   capability	   and	   sensitivity	   in	   detecting	   mutations	   and	   structural	  
variations:	  
-­‐Targeted	  sequencing	  provides	  sensitive	  and	  deep	  coverage	  of	  targeted	  sites,	  but	  only	  a	  set	  of	  genes	  
or	  hotspot	  of	  mutations	  are	  studied.	  	  	  
-­‐Exome	  sequencing	  detects	  mutations	  present	  at	   subclonal	   level	   in	  all	  protein-­‐coding	   region	  of	   the	  
genome.	  
-­‐Transcriptome	   sequencing	   is	   the	   most	   informative	   approach,	   which	   allows	   the	   identification	   of	  
chromosomal	   rearrangements,	   mutations,	   expression	   of	   the	   mutations,	   gene-­‐expression	   profiling,	  
new	  transcripts	  and	  gene	  isoforms.	  	  
-­‐WGS	   entails	   the	   sequencing	   of	   the	   whole	   genome	   of	   a	   sample,	   but	   with	   less	   sensitivity	   respect	  
exome	   sequencing	   due	   to	   the	   large	   size	   of	   the	   human	   genome	   and	   variation	   in	   the	   sequencing	  
coverage	  along	  the	  genome	  (18).	  
1.10.2	   In	  vitro	  drug	  screening	  using	  primary	  patient	  cells	  	  
Preclinical	   in	   vitro	   drug	   screenings	   are	   essential	   to	   validate	   genomic	   biomarkers,	   explore	   the	  
molecular	  basis	  of	  drug	  activity	  and	  identify	  novel	  effective	  compounds.	  	  
In	  the	  last	  few	  years	  in	  vitro	  drug	  screening	  platforms	  using	  patient	  cells	  have	  been	  developed.	  Tyner	  
et	   al.	   (80)	   assessed	   the	   sensitivity	   to	   66	   small	  molecule	   kinase	   inhibitors	   of	   151	   leukemia	   patient	  
samples.	   Promising	   data	   have	   showed	   that	   in	   vitro	   drug	   sensitivity	   could	   predict	   clinical	   drug	  
response,	  as	  well	  as	  pathway	  dependence.	  For	  example,	  based	  on	  in	  vitro	  drug	  profile	  data,	  kinases	  
targeting	  ABL1	   and	   related	   pathways	  were	   predicted	   as	   the	   best	   targets	   for	   targeted	   therapy	   in	   a	  
BCR-­‐ABL1-­‐positive	   ALL	   case.	   Pemovska	   et	   al.	   (81)	   have	   performed	   drug	   screening	   of	   primary	   AML	  
patient	  cells.	   In	   the	   library	  were	   included	  187	  drugs	  targeting	  pathways	  affected	   in	  cancer	   like,	  cell	  
cycle,	  apoptosis,	  signaling	  and	  epigenetic	  regulators.	  The	  compounds	  included	  were	  already	  used	  in	  
the	   clinic	   or	   in	   late	   phase	   of	   the	   clinical	   trials.	   Although	   each	   individual	   sample	   showed	   a	   drug	  
selective-­‐response	  profile,	  similar	  drug	  sensitivity	  patterns	  were	  observed	  across	  the	  samples.	  Also	  in	  
this	   study	   correlation	   between	   in	   vitro	   drug	   response	   and	   clinical	   response	   was	   shown	   for	   few	  
samples	  and	  they	  could	  identify	  associations	  between	  gene	  mutated	  and	  response	  to	  drug	  targeting	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the	  affected	  gene	   (i.e.,	   samples	  with	  FLT3	  mutation	  were	   sensitive	   to	   TKIs	   as	   expected).	  However,	  
beyond	   few	   examples	   of	   drug	   sensitivity	   and	   gene	   mutation	   associations,	   the	   majority	   of	   drug	  
sensitivity	  or	  resistant	  profile	  could	  not	  be	  directly	  attributed	  to	  obvious	  genetic	  alterations.	  
1.10.3	   In	  vitro	  high-­‐throughput	  drug	  screening	  in	  co-­‐culture	  with	  bone	  marrow	  stromal	  cells	  
Hartwell	  et	  al.	  (82)	  have	  recently	  performed	  a	  high-­‐throughput	  drug	  screening	  system	  that	  includes	  
the	   supportive	   interactions	  of	   the	   leukemia	   stem	  cells	  with	   the	  microenvironment.	   Leukemia	   stem	  
cells	  were	  generated	  by	  retroviral	  transduction	  of	  MLL-­‐AF9	  (frequent	  translocation	  in	  AML)	  in	  murine	  
granulocyte-­‐monocyte	   progenitors	   and	   the	   transduced	   cells	   were	   amplified	   in	   BALB6	  mice.	   These	  
leukemia	  stem	  cells	  were	  co-­‐culture	  with	  a	  murine	  stromal	  cell	   line	   (OP9)	  and	  sensitivity	   to	  14’718	  
compounds	  was	  tested.	  Co-­‐culture	  system	  enabled	  to	  assess	  drug	  response	   in	  a	  more	  physiological	  
context,	  indeed	  the	  bone	  marrow	  niche	  supports	  survival	  and	  have	  a	  chemoprotective	  effect	  in	  AML	  
(83).	   Similar	   findings	   have	   been	   shown	   for	   ALL.	   Indeed,	   direct	   contact	   or	   secreted	   cytokine	   and	  
growth	  factor	  provided	  by	  the	  cells	  of	  the	  tumor	  niche	  support	  the	  survival	  (84-­‐86)	  and	  protect	  also	  
primary	  ALL	  cells	  from	  chemotherapy	  (87,	  88).	  Therefore	  in	  this	  thesis	  (Manuscript	  1	  and	  2)	  ALL	  drug	  
response	   profiles	   were	   performed	   in	   co-­‐culture	   on	   human	   bone	   marrow	   derived	   human	  
mesenchymal	  stromal	  cells	  (MSC).	  	  
1.10.4	   Multi-­‐parametric	  approach	  to	  analyze	  in	  vitro	  drug	  response	  	  
When	   assessing	   the	   sensitivity	   of	   in	   vitro	   cultures	   to	   drugs,	   dose	   response	   curves	   are	   used	   to	  
evaluate	   the	   efficacy	   and	   the	   potency	   of	   the	   drug.	   Commonly,	   only	   the	   IC50	   value	   is	   calculated	   to	  
represent	  the	  drug	  response,	  but	  additional	  parameters	  can	  be	  used	  to	  describe	  dose	  repose	  curves	  
(Figure	  13),	  such	  us	  EC50,	  AUC,	  EC90,	  Emax.	  A	  recent	  study	  (89)	  has	  suggested	  that	  the	  most	  informative	  
parameter	   varied	   with	   drug	   and	   dose	   range.	   And	   more	   attention	   should	   be	   given	   to	   Emax	  
(concentration	  with	  maximal	  response	  effect),	  because	  high	  level	  of	  Emax	  could	  reflect	  that	  the	  drug	  is	  
not	  effective	  or	  the	  tumor	  tested	  contains	  resistant	  subclones.	  Therefore,	  a	  more	  accurate	  evaluation	  
of	   dose	   response	   curves	   can	   lead	   to	   a	   better	   understanding	   of	   experimental	   drugs’	   potency	   and	  
efficacy,	  which	  in	  turn	  can	  lead	  to	  more	  precise	  assessment	  of	  anticancer	  agents	  in	  vitro.	  	  
	  
	  
Figure	   13.	   Graph	   showing	   a	   representative	   drug	  
response	   curve	   described	   by	   multi-­‐parameters.	   EC50,	  
drug	  dose	  that	  induces	  a	  response	  halfway	  between	  the	  
baseline	   and	   maximum	   effect.	   IC50,	   drug	   dose	   that	  
induces	   inhibition	   in	   50%	  of	   the	   cells.	   AUC,	   Area	   under	  
the	   curve,	   EC90,	   concentration	  of	   a	  drug,	  which	   induces	  
90%	   of	   the	   response	   between	   the	   baseline	   and	  
maximum	   effect,	   Emax,	   concentration	   that	   induces	  
maximal	  response.	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1.11	   BCL-­‐2	  
1.11.1	   Apoptosis	  
In	  physiological	   conditions	  apoptosis	   is	  a	   regulated	  process	   important	   for	   the	   removal	  of	  aged	  and	  
damaged	  cells.	  In	  cancer	  cells	  block	  of	  the	  apoptosis	  determine	  their	  abnormal	  proliferation.	  	  
Apoptosis	   occurs	   through	   two	   pathways:	   i)	   The	   intrinsic	   pathway	   is	   caused	   by	   chemotherapeutic	  
agents,	   irradiation	   or	   growth	   factor	   withdrawal.	   BCL-­‐2	   family	   proteins	   and	   other	   modulators	   of	  
apoptosis	   are	   activated	   and	   lead	   to	   mitochondrial	   outer	   membrane	   permeabilization	   (MOMP).	  
MOMP	   causes	   the	   release	   of	   cytochrome	   c	   and	   multiple	   pro-­‐apoptotic	   molecules	   leading	   to	   the	  
activation	  of	  caspases.	  ii)	  The	  extrinsic	  pathway	  is	  activated	  by	  death	  ligands	  (FASL	  or	  TRAIL)	  or	  tumor	  
necrosis	   factor-­‐α	   (TNFα).	   These	   ligands	   engage	   their	   cognate	   receptors	   to	   trigger	   the	   formation	  of	  
death-­‐inducing	   signaling	   complex	   (DISC).	  DISC	   recruitment	   leads	   to	   the	   activation	  of	   caspases.	   The	  
caspase	   cascade	   is	   responsible	   for	   the	   structural	   and	   biochemical	   cellular	   changes	   associated	  with	  
apoptosis.	  
1.11.2	   Importance	  of	  BCL2	  in	  ALL	  
BCL2	  (B	  cell	  lymphoma	  2)	  is	  the	  first	  identified	  apoptotic	  regulator,	  originally	  cloned	  in	  1984	  from	  the	  
breakpoint	   of	   a	   t(14;18)	   translocation	   present	   in	   human	  B-­‐cell	   follicular	   lymphoma	   (90).	   Following	  
studies	  have	  identified	  other	  proteins	  with	  sequence	  similarities	  to	  BCL2.	  They	  were	  classified	  based	  
on	  their	  pro-­‐apoptotic	  or	  pro-­‐survival	  role.	  Anti-­‐apoptotic	  proteins	  (BCL-­‐2,	  BCL-­‐XL,	  BCL-­‐w,	  MCL-­‐1,	  and	  
BFL-­‐1)	  share	  4	  BCL2	  homology	  (BH)	  domains.	  Pro-­‐apoptotic	  proteins	  are:	  BAX,	  BAK	  and	  BOK,	  contain	  
3	  BH	  domains,	  and	  BIM,	  BID,	  BAD,	  NOXA	  and	  PUMA	  with	  only	  1	  BH	  domain,	  in	  particular	  the	  BH3,	  are	  
called	   BH3-­‐only	   proteins.	   BH3-­‐only	   proteins	   can	   directly	   activate	   BAK	   and	   BAX	   or	   displace	   their	  
interacting	  anti-­‐apopototic	  proteins.	  Oligomerizazion	  of	  BAX	  and	  BAK	  leads	  to	  the	  formation	  of	  pores	  
in	  the	  mitochondrial	  membrane,	  which	  results	  in	  MOMP	  (91).	  	  
High	  BCL-­‐2	  levels	  have	  been	  detected	  in	  many	  human	  lymphoid	  malignancies:	  follicular	  lymphomas,	  
due	   to	   the	   (14;18)	   translocation	   involving	   the	   BCL2	   gene	   (90);	   diffuse	   large	   B-­‐cell	   lymphomas,	  
because	  of	  the	  (14;18)	  translocation	  and	  also	  the	  BCL2	  gene	  amplification	  (92);	  chronic	  lymphocytic	  
leukemias,	   as	   a	   result	   of	   epigenetics	  mechanisms	   (93)	   or	   post-­‐transcriptional	   regulation	   (94).	   	   The	  
importance	  of	  BCL-­‐2	  is	  also	  emerging	  in	  pediatric	  ALL.	  High	  level	  of	  BCL-­‐2	  became	  recently	  a	  hallmark	  
of	   immature	  subtypes	  of	  T-­‐ALL	  (95).	  Further	  studies	   in	  B-­‐ALL	  have	  showed	  high	   levels	  of	  BCL-­‐2	  (96)	  
and	  its	  importance	  in	  the	  control	  of	  glucocorticoid-­‐induced	  apoptosis	  (97).	  	  
1.11.3	   Venetoclax	  (ABT-­‐199)	  BCL-­‐2	  specific	  inhibitor	  	  
Venetoclax	  (ABT-­‐199)	  is	  a	  BH3-­‐mimetic	  agent	  that	  binds	  the	  hydrophobic	  BH3-­‐binding	  groove	  of	  BCL-­‐
2	   and	   prevents	   the	   binding	   of	   pro-­‐apoptotic	   family	  members.	   Venetoclax	   is	   the	   first	   BH3-­‐mimetic	  
small	  molecule	   inhibitor	  specific	   for	  BCL-­‐2	   (98).	   In	  contrast	   to	  the	  broader	  BH3	  mimetic	  Navitoclax,	  
which	  binds	  BCL-­‐2	   and	  BCL-­‐XL	   and	  exhibits	  on	   target	   thrombocytopenia,	   venetoclax	   spares	  human	  
platelets.	   Currently,	   venetoclax	   is	   in	   advanced	   phases	   of	   clinical	   trials	   for	   CLL,	   NHL,	   CML,	   AML,	  
lymphomas	  (99).	  	  
Based	  on	  previous	  studies,	  sensitivity	  to	  venetoclax	  could	  not	  always	  be	  associated	  with	  high	  levels	  of	  
BCL-­‐2.	  It	  has	  been	  shown	  that	  high	  BCL-­‐2	  expression	  correlates	  with	  sensitivity	  to	  venetoclax	  in	  NHL	  
cell	  lines	  and	  T	  cell	  lines	  (95,	  98),	  but	  in	  a	  later	  study	  the	  ratio	  BCL-­‐2:BCL-­‐XL	  was	  suggested	  predictive	  
of	  the	  response	  to	  venetoclax	  in	  T	  ALL	  (100).	  Mechanisms	  of	  resistance	  to	  venetoclax	  are	  not	  yet	  well	  
described.	   In	   one	   study,	   it	   has	   been	   shown	   that	   the	   overexpression	   of	   MCL-­‐1	   compensates	   and	  
maintains	   cell	   survival	   when	   BCL-­‐2	   is	   inhibited	   by	   venetoclax	   in	   primary	   ALL	   samples	   (96)
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1.12	   Cell	  Surface	  proteins	  as	  biomarkers	  in	  ALL	  
Biomarkers	   are	   important	   for	   disease	   detection,	   diagnosis	   and	   could	   be	   used	   for	   prognostic	   and	  
therapeutic	   purposes.	   Novel	   biomarkers	   are	   needed	   in	   the	   field	   of	   ALL	   for	   the	   early	   detection	   of	  
patients	   that	   are	   not	   sensitive	   to	   current	   treatments.	   As	   described	   in	   Manuscript	   3,	   we	   have	  
identified	  VNN2	  (GPI-­‐80)	  as	  a	  promising	  biomarker	  of	  resistant	  ALL	  cases.	  
1.12.1	   VNN2	  (GPI-­‐80)	  	   	  
GPI-­‐80,	   gycosylphospatidyl	   inositol-­‐80,	   or	   also	   called	   VNN2,	   is	   a	   member	   of	   the	   Vanin	   or	  
pantetheinase	  gene	  family.	  Vanin	  genes	  share	  high	  degree	  of	  homology	  and	  comprise	  VNN1,	  VNN2,	  
and	  VNN3	   in	  humans,	  while	   in	  mouse	  only	  Vanin-­‐1	  and	  Vanin-­‐3	  have	  been	   identified.	  For	  all	  Vanin	  
proteins	   pantetheinease	   activity	   (hydrolysis	   of	   pantetheine	   into	  pantothenic	   acid	   (Vitamin	  B5)	   and	  
cysteamine)	  was	  detected	  in	  vitro.	  	  
VNN1/Vanin-­‐1	   is	  a	  GPI-­‐linked	  membrane-­‐associated	  ectoenzyme	  responsible	  of	   the	  pantetheinease	  
activity	  in	  mice.	  	  The	  mouse	  Vanin-­‐1	  functions	  are	  the	  best	  documented,	  since	  Vanin-­‐1-­‐deficient	  mice	  
have	   been	   characterized	   in	   physiological	   and	   pathophysiological	   conditions.	   In	   physiological	  
conditions,	   it	   has	  been	   showed	   that	   vanin-­‐1	   is	   expressed	  by	  perivascular	   thymus	   stromal	   cells	   and	  
contributes	  to	  the	  homing	  of	  hematopoietic	  precursor	  cells	  to	  the	  thymus	  in	  mouse	  (101).	  Studies	  on	  
several	   mouse	   models	   of	   chronic	   inflammatory	   diseases	   have	   suggested	   that	   VNN1	   promotes	  
inflammation	  during	  an	  infection	  (102-­‐104).	  	  
Two	  independent	  groups	  have	  identified	  VNN2.	  Galland	  et	  al.	  in	  the	  ‘98	  (105)	  discovered	  two	  human	  
cDNAs	  homologous	   to	  mouse	   vanin-­‐1	   gene,	   therefore	   called	  VNN1	  and	  VNN2.	  And	  one	   year	   later,	  
Suzuki	   et	   al.	   (106)	   identified	   a	   protein	   recognized	   by	   the	  monoclonal	   antibody,	   3H9	   clone,	   which	  
modulated	   adhesion	   and	   transmigration	   of	   activated	   human	   neutrophils.	   This	   protein	   was	   named	  
GPI-­‐80	   (80-­‐kDa	   protein	   with	   GPI-­‐anchor).	   VNN2	   is	   widely	   expressed	   by	   different	   tissues,	   such	   as	  
blood,	   colon,	   spleen,	   placenta,	   kidney,	   liver	   and	   lung	   (107),	   and	   in	   neutrophils	   VNN2	   expression	  
increases	   during	   differentiation	   and	  maturation	   (108).	   In	   contrast	   to	   vanin-­‐1/VNN1,	   VNN2	  mouse	  
models	  have	  not	  been	  established,	  but	  evidences	   in	  human	  neutrophils	  have	  suggested	   that	  VNN2	  
supports	   the	  adhesion	  and	   invasion	  processes	   (Figure	  14).	  VNN2	   is	   localized	  on	  plasma	  membrane	  
and	   in	   secretory	   vesicles	   of	   neutrophils	   (109).	   Stimulation	   of	   the	   neutrophils	   with	   chemotactic	  
peptides	   (110)	   and	   TNF-­‐a	   (111)	   induces	   mobilization	   of	   the	   secretory	   vesicles	   determining	   an	  
increased	  expression	  of	  VNN2	  of	  the	  surface	  membrane	  and	  the	  release	  of	  VNN2	  from	  the	  secretory	  
vesicles	   as	   soluble	   form.	  Membrane	   VNN2	   associates	  with	   the	   adhesion	  molecule	  Mac-­‐1	   (integrin	  
complex	   that	   consists	   of	   ITGAM	   and	   ITGB2	   dimer),	   and	   modulates	   Mac-­‐1	   functionality.	   When	  
chemotaxis	  occurs	  VNN2	  protein	  shifts	   from	  the	  plasma	  membrane	  to	  the	  podia	  of	  the	  neutrophils	  
together	  with	  ITGB2,	  which	  is	  increased	  by	  VNN2.	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Figure	   14.	   VNN2	   (GPI-­‐80)	   cooperates	   with	   Mac-­‐1	   complex	   during	   the	   extravasation	   of	   human	   neutrophils.	   GPI-­‐80	   is	  
present	   on	   the	   cellular	  membrane	   associated	   with	  Mac-­‐1	   complex,	   and	   as	   soluble	   form	   (GPI-­‐80	   without	   GPI-­‐anchor)	   is	  
stored	   in	  secretory	  vesicles.	  Once	  activated	  by	  stimulators,	  neutrophils	  adhere	  to	  endothelial	  cells	  via	  Mac-­‐1	  and	  migrate	  
into	  the	  interstitial	  space.	  During	  adhesion	  to	  endothelial	  cells,	  some	  of	  the	  GPI-­‐80	  molecules	  move	  to	  the	  pseudopodia	  of	  
the	  neutrophils.	   	  Functions	  of	  the	   intracellular	  stores	  and	  of	  the	  soluble	  form	  of	  GPI-­‐80	  are	  not	  clear.	  Black	  ellipses	  show	  
GPI-­‐80,	  and	  striped	  ellipses	  show	  dimers	  of	  Mac-­‐1	  (ITGAM/ITGB2	  dimer).	  Adapted	  from	  (112).	  
A	  recent	  study	  has	  demonstrated	  that	  VNN2	  is	  functionally	  required	  for	  the	  self-­‐renewal	  of	  fetal	  liver	  
HSC.	   (113)	   Knockdown	  of	  VNN2	  or	   ITGAM	  was	   sufficient	   to	   block	   hematopoietic	   stem	  progenitors	  
cells	   (HSPC)	  expansion	   in	  culture	  and	  mouse.	  Since	  VNN2	  does	  not	  have	  an	   intracellular	  domain	  to	  
convey	  a	   signal	   from	  the	  niche,	   the	  cooperation	  with	  Mac-­‐1	   integrin	   complex	  may	  be	  essential	   for	  
self-­‐renewal.	  	  
Evidences	   in	  pathological	   conditions	  have	  also	   suggested	  VNN2	  as	   indicator	  of	   acute	   inflammatory	  
phase	   with	   neutrophil	   activation	   in	   arthritis	   and	   myocardial	   infarction.	   Indeed,	   soluble	   VNN2	  
molecules	  have	  been	  detected	  in	  synovial	  fluids	  of	  rheumatoid	  arthritis	  patients	  (110),	  and	  in	  serum	  
of	  the	  patients	  with	  isolated	  atherosclerotic	  coronary	  artery	  disease	  (114).	  Furthermore,	  in	  one	  study	  
high	  levels	  of	  membrane	  and	  soluble	  VNN2	  proteins	  have	  been	  associated	  with	  late	  stage	  of	  human	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2	   Subject	  of	  investigation	  and	  my	  contributions	  
Genomic	   profiling	   has	   revolutionized	   our	   understanding	   of	   the	   genetic	   basis	   of	   ALL	   by	   identifying	  
recurrent	  genomic	  lesions	  important	  for	  leukemogenesis.	  However	  the	  translation	  of	  this	  knowledge	  
for	  the	  development	  of	  targeted	  therapeutic	  options	  and	  for	  the	  improvement	  of	  risk	  stratification	  a	  
diagnosis	  remains	  very	  limited.	  	  
	  
To	  complement	  the	  genomic	  knowledge	  the	  major	  aims	  of	  my	  PhD	  thesis	  were	  to	  	  
1) Develop	  an	  integrated	  platform	  for	  functional	  and	  genomic	  evaluation	  of	  patients	  with	  drug	  
resistant	  acute	  lymphoblastic	  leukemia	  (ALL)	  
2) Establish	  a	  xenograft	  model	  of	  the	  disease	  progression	  for	  clinical	  relevant	  subtypes	  of	  ALL,	  
including	  TCF3-­‐HLF	  and	  TCF3-­‐PBX1	  -­‐positive	  ALL	  	  
3) Generate	   the	   drug	   response	   profile	  TCF3-­‐HLF	   and	  TCF3-­‐PBX1	   -­‐positive	  ALL	   in	   our	   platform	  
and	  evaluate	  promising	  compounds	  in	  our	  preclinical	  in	  vivo	  mouse	  model	  
4) Investigate	  the	  clinical	   relevance	  of	  VNN2	  protein	  as	   independent	  marker	  of	  poor	  outcome	  
and	  the	  role	  of	  VNN2	  in	  the	  biology	  of	  leukemia	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TCF3-­‐HLF	  fusion	  gene-­‐positive	  acute	  lymphoblastic	  leukemia	  (ALL)	  is	  currently	  not	  curable.	  We	  used	  
an	   integrated	  approach	   to	   reveal	  distinct	  mutation,	  gene	  expression,	  and	  drug	   response	  profiles	   in	  
TCF3-­‐HLF-­‐positive	   ALL	   and	   treatment-­‐responsive	  TCF3-­‐PBX1-­‐positive	   ALL.	   In	  TCF3-­‐HLF-­‐positive	   ALL,	  
recurrent	  intragenic	  deletions	  of	  the	  lymphoid	  transcription	  factor	  gene	  PAX5	  or	  somatic	  mutations	  
in	   the	   non-­‐translocated	   allele	   of	   TCF3	   (acting	   upstream	   of	   PAX5)	   were	   common	   and	   frequently	  
observed	  in	  conjunction	  with	  RAS	  pathway	  aberrations.	  Despite	  a	  probable	  lymphoid-­‐committed	  cell	  
of	  origin,	  the	  TCF3-­‐HLF-­‐positive	  ALL	  transcriptome	  was	  enriched	  for	  stem	  cell	  and	  myeloid	  features,	  
consistent	  with	   reprogramming	   towards	   a	   hybrid,	  more	   drug-­‐resistant	   hematopoietic	   state.	   These	  
genomic	   profiles	   were	   maintained	   in	   matched	   patient-­‐derived	   xenografts.	   TCF3-­‐HLF-­‐positive	   ALL	  
revealed	   a	   distinct	   drug-­‐response	   profile	   with	   resistance	   to	   some	   agents	   commonly	   used	   for	   its	  
treatment,	   but	   sensitivity	   towards	   glucocorticoids	   and	   agents	   in	   clinical	   development.	   Striking	   on-­‐
target	   sensitivity	   was	   achieved	   with	   the	   BCL2-­‐specific	   inhibitor	   venetoclax	   (ABT-­‐199)	   indicating	  
relevant	   BCL2-­‐dependency.	   Our	   integrated	   approach	   thus	   has	   revealed	   new	   options	   for	   the	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Abstract	  
Novel	  strategies	  are	  needed	  to	  identify	  vulnerable	  targets	   in	   individual	  patients	  with	  chemotherapy	  
resistant	   acute	   lymphoblastic	   leukemia	   (ALL).	   Here	   we	   describe	   a	   high-­‐throughput	   drug	   response	  
profiling	   platform	   based	   on	   automated	   image	   analysis	   of	   primary	   ALL	   cells	   co-­‐cultured	   with	  
mesenchymal	  stroma	  cells	  (MSC)	  and	  provide	  a	  bioinformatics	  toolkit	  for	  flexible	  data	  processing	  and	  
analysis.	  Screening	  a	  60-­‐compound	  library	  of	  clinically	  relevant	  new	  agents	  for	  activity	  in	  61	  primary	  
ALL	   samples	   enriched	   for	   resistant	   cases,	   we	   identified	   consistent	   drug	   sensitivity	   and	   resistance	  
patterns	   in	  genetically	  defined	   subgroups	   such	  as	  MLL-­‐AF4	   positive	  ALL	  or	   refractory	   relapsed	  ALL.	  
Striking	  activity	  was	  detected	  for	   the	  BCL2-­‐specific	  BH3-­‐mimetic	  venetoclax	   (ABT-­‐199)	   in	  a	  relevant	  
proportion	  of	  BCP-­‐ALL,	   in	  MLL-­‐AF4	  positive	  ALL	  and	   in	  a	  smaller	  subset	  of	  T-­‐ALL,	  providing	  a	  direct	  
approach	  to	   identify	  BCL2	  dependent	  ALL	  subsets.	  Higher	  sensitivity	   to	  venetoclax	  on	  this	  platform	  
predicted	  antileukemic	  activity	  in	  xenografts	  in	  vivo.	  Matrix	  combination	  testing	  identified	  recurrent	  
synergistic	   activity	   of	   venetoclax	   with	   the	   BRD4	   inhibitor	   JQ1	   providing	   a	   new	   rationale	   for	  
experimental	   therapy.	   Integration	  of	   drug	   activity	   profiling	  with	  other	   diagnostic	   testing	   should	  be	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The	   glycophosphatidylinositol	   anchored	   surface	   protein	   Vanin-­‐2	   (VNN2,	   GPI-­‐80),	   which	   has	   been	  
implicated	   in	   leukocyte	  adherence	  and	  migration,	   identifies	  human	   fetal	   liver	  hematopoietic	   stem/	  
progenitor	   cells	   (HSPCs)	  with	   self-­‐renewal	   ability	   and	   is	   required	   for	   their	   hematopoietic	   function.	  
Comparing	   the	   cell	   surface	   glycoproteome	   of	   19	   acute	   lymphoblastic	   leukemia	   (ALL)	   samples,	   we	  
identified	  VNN2	  as	  a	  unique	  feature	   in	  patients	  with	  a	  very	  high	  risk	  of	  relapse	  by	  minimal	  residual	  
disease.	   In	   a	   retrospective	   analysis	   of	   663	   patients	   on	   the	   ALL-­‐BFM-­‐2000	   treatment	   protocol	   high	  
VNN2	  transcript	   levels	  were	  associated	  with	  decreased	  event	   free	  survival.	  We	  show	  in	  a	  subset	  of	  
this	   cohort	   that	   VNN2	   detection	   by	   flow	   cytometry	   may	   serve	   as	   a	   prognostic	   marker	   instead.	  
Furthermore	  all	  of	  12	  TCF3-­‐HLF-­‐positive	  ALL,	  which	  defines	  a	  currently	   incurable	  ALL	  subtype,	  were	  
strongly	   surface	   VNN2,	   providing	   a	   simple	   procedure	   to	   preselect	   samples	   for	   specific	   diagnostic	  
testing.	  VNN2	  expression	  was	  not	  associated	  with	  other	  cytogenetic	  and	  copy	  number	  abnormality.	  	  
Antibody	   interference	   with	   VNN2	   resulted	   in	   delayed	   homing	   of	   ALL	   to	   the	   bone	   marrow	   of	  
immunodeficient	   mice,	   suggesting	   a	   potential	   role	   of	   VNN2	   in	   leukemia	   trafficking.	   Thus	   surface	  
VNN2	  expression	  identifies	  TCF3-­‐HLF3-­‐positive	  ALL	  as	  well	  as	  subset	  of	  ALL	  with	  unfavorable	  biology	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VNN2	  Prospective	  analysis	  proposal	  	  
Proposal	  for	  prospective	  evaluation	  of	  VNN2	  as	  prognostic	  marker	  for	  BCP-­‐ALL	  
	  
Major	   relevant	   findings	   and	   standard	   operating	   procedure	   (SOP)	   for	   the	   staining	   and	   analysis	   of	  
VNN2	   at	   diagnosis	   are	   described	   in	   this	   proposal.	   Currently	   the	   children’s	   hospital	   of	   Zürich	  
(Switzerland),	   Padova	   (Italy),	   Monza	   (Italy),	   Berlin	   (Germany),	   Wien	   (Austria)	   are	   performing	   the	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  detailed	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  attached	  document	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4	   Discussion	  
4.1	   Rationale	  	  
Although	   cure	   rates	   for	   childhood	   acute	   lymphoblastic	   leukemia	   (ALL)	   are	   approaching	   85%,	   the	  
development	  of	  new-­‐targeted	  treatments	  is	  essential	  for	  relapsed	  cases	  and	  for	  reducing	  toxicity	  of	  
the	   standard	   chemotherapy	   regimens	   currently	   employed.	   Integration	   of	   advanced	   biomedical	  
technologies,	  such	  as	  next	  generation	  genome	  sequencing	  and	  high-­‐throughput	  drug	  screening,	  aim	  
to	   identify	  both	  genetic	  biomarkers	   that	   can	  predict	   treatment	   response	  as	  well	   as	   targets	   for	   the	  
development	   of	   individualized	   treatment.	   This	   dissertation	   describes	   an	   unprecedented	   combined	  
genetic	  and	  functional	  study	  focus	  on	  clinically	  relevant	  subtypes	  of	  ALL.	  	  
4.1.1	   Genomic	   characterization	   is	   not	   sufficient	   for	   the	   development	   of	   targeted	  
therapies	  
Different	   subtypes	   of	   ALL	   can	   be	   defined	   based	   on	   recurring	   chromosomal	   abnormalities,	   such	   as	  
aneuploidy	   (hyperdiploid	   and	   hypodiploid)	   and	   chromosomal	   rearrangements	   (TEL-­‐AML1,	   TCF3-­‐
PBX1,	   TCF3-­‐HLF,	   BCR-­‐ABL1,	  MLL-­‐AF4,	   CRLF2-­‐rearrangement).	   Importantly,	   an	   increasing	   number	   of	  
these	   subgroups	   are	   currently	   being	   investigated	   using	   next	   generation	   sequencing	   techniques.	  
These	   revealed	   that	   constellations	   of	   characteristic	   genetic	   alterations,	   which	   perturb	   essential	  
cellular	   pathways,	   are	   found	   in	   addition	   to	   the	   defining	   chromosomal	   alterations.	   For	   example,	  
constellations	  including	  alterations	  in	  receptor	  tyrosine	  kinases,	  RAS	  pathway	  mutations	  or	  germline	  
TP53	  mutations	  were	  discovered	   in	  distinct	  cytogenetic	  subgroups	  with	  hypodiploid	  ALL	   (48).	  Most	  
recently,	   it	   has	   been	  described	   that	   the	  BCR-­‐ABL1-­‐like	  ALL	   subtype	   (50),	  which	   is	   characterized	   by	  
gene	   expression	   signatures	   that	   resemble	  BCR-­‐ABL1-­‐positive	   ALL,	   has	   different	   kinases	   involved	   in	  
the	  rearrangements	  such	  us	  ABL1,	  ABL2,	  CRLF2,	  JAK2,	  PDGFRB.	  60%	  of	  the	  BCR-­‐ABL1-­‐like	  patients	  do	  
not	  respond	  to	  standard	  treatments	  (116),	  but	  preliminary	  data	  from	  in	  vitro	  experiments	  and	  clinical	  
trials	  (117,	  118)	  recently	  suggested	  that	  this	  subtype	  might	  be	  sensitive	  to	  tyrosine	  kinases	  inhibitors	  
(TKI).	  Therefore,	   introduction	  of	  TKI	   for	   the	   treatment	  of	  BCR-­‐ABL1-­‐like	  positive	  ALL	   seems	   to	  be	  a	  
promising	   therapeutic	   option.	   However,	   it	   is	   not	   obvious	  whether	   the	   TK	   rearrangements	   are	   the	  
main	   cause	  of	   the	   treatment	   resistance.	   Indeed,	   further	   lesions	  were	  detected	   in	   IKZF1,	   PAX5	   and	  
genes	  of	  Ras	  pathway.	   Likely	   specific	   constellations	  of	   genomic	   lesions	   result	   in	  a	   resistant	  disease	  
phenotype.	  The	  challenge	  will	  be	  to	  design	  clinical	  trials	  for	  BCR-­‐ABL1-­‐like	  ALL	  cases	  to	  address	  two	  
different	   questions:	   i)	   does	   the	   implementation	   of	   TKI	   in	   the	   current	   treatment	   benefit	   resistant	  
patients	  and	  ii)	  can	  TKI	  be	  used	  to	  deescalate	  treatment	  intensity	  for	  patients	  with	  good	  risk	  profiles.	  
Here,	   a	   combination	   of	   novel	   genomic	   technologies	   and	   current	   functional	   stratification	   schemes	  
based	   on	   response	   to	   chemotherapy	   in	   patients	   will	   be	   required	   for	   stratification	   of	   future	  
treatments.	   Thus,	   also	   in	   this	   prototypic	   situation	   for	   a	   targeted	   intervention	   in	   ALL,	   integrated	  
genomic	   and	   functional	   approaches	  will	   be	   needed.	   These	   considerations	   indicate	   that	   due	   to	   the	  
genetic	   heterogeneity	   and	   the	   complexity	   of	   the	   cellular	   network	   intrinsic	   in	  ALL	   biology,	   genomic	  
characterization	  alone	  is	  not	  sufficient	  for	  the	  clinical	  development	  of	  targeted	  therapies.	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4.1.2	   Integration	  of	   genomic	  profiling	   and	   functional	   investigations	  based	  on	   the	   leukemia	  
xenograft	  system	  
Aiming	   to	   complement	   the	   knowledge	  derived	   from	  genomic	   studies,	  we	  have	  used	   an	   integrated	  
approach	  that	  combines	  genomic	  characterization	  and	  functional	  validation	  of	  resistant	  subtypes	  of	  
ALL	  (Figure	  15).	  The	  integrated	  study	  showed	  in	  this	  thesis	  (Manuscript	  1	  and	  2)	  is	  comprised	  of:	  
1)	  Generation	  of	  Patient	  Derived	  Xenografts	  (PDXs)	  of	  clinically	  relevant	  subtypes	  of	  ALL	  to	  model	  the	  
disease.	  	  
2)	  Integration	  of	  the	  genomic	  analysis	  of	  patient	  and	  matched	  PDX	  samples	  obtained	  at	  diagnosis	  and	  
after	  treatment	  to	  define	  the	  molecular	  features	  of	  resistant	  disease.	  	  
3)	  High	   throughput	   in	   vitro	   drug	   screening	   of	   primary	  ALL	   in	   co-­‐culture	  with	   human	  bone	  marrow	  
stromal	  cells	  for	  the	  identification	  of	  active	  compounds	  and	  informative	  drug	  response	  profiles.	  
4)	   Preclinical	   in	   vivo	   validation	   of	   promising	   compounds	   as	   single	   agents	   and	   in	   combination	  with	  
drugs	  currently	  used	  in	  treatment	  protocols.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	   15.	   Scheme	   of	   the	   integrated	   strategy	   described	   in	   this	   thesis.	   Patient	   samples	   bank,	   clinical	   trial,	   xenograft:	  
primary	  patient	  samples	  classified	  based	  on	  clinical	  criteria	  (genetic	  features	  and	  treatment	  response)	  were	  transplanted	  in	  
immunodeficient	  mice	  (NSG)	  to	  generate	  PDXs	  from	  diagnostic	  and	  relapse	  samples.	  Genomic	  and	  transcriptomic	  analysis	  
of	  primary	  patient	  samples	  and	  matched	  PDXs	  provides	  opportunities	   to	  characterize	  the	  genetic	  background	  of	  relevant	  
subsets	   of	   ALL	   and	   evaluate	   the	   conservation	   of	   the	   genomic	   and	   transcriptomic	   features	   in	   the	  matched	   PDX.	   Disease	  
modeling:	  PDXs	  were	  used	  to	  amplify	  the	  patient	  material	  and	  model	  the	  individual	  genomic	  features	  at	  diagnosis	  and	  after	  
treatment.	  Validation	   target:	   PDXs	  were	  used	   for	   in	   vivo	   and	   in	   vitro	   experiments	   allowing	   the	   validation	  of	   targets	   and	  
identification	  of	  promising	  compounds.	  Translation	  to	  the	  clinic:	  data	  derived	  from	  the	  functional	  genomic	  characterization	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4.2	   Patient	  derived	  xenograft	  (PDX)	  
4.2.1	   PDXs	  used	  to	  model	  relevant	  subtypes	  of	  ALL	  	  
As	  part	  of	  the	  European	  AEIOP-­‐BFM-­‐ALL	  and	  IntReALL	  study	  groups	  we	  had	  access	  to	  large	  banks	  of	  
primary	   diagnostic	   and	   relapse	   samples	  with	   clearly	   defined	   clinical	   backgrounds.	   Importantly,	   we	  
included	  samples	  associated	  with	  good	  and	  poor	  outcomes	  based	  on	  genetic	  features	  and	  response	  
to	   treatment,	  which	   are	   two	   important	   risk	   factors	   used	   in	   the	   clinic	   (Figure	   16).	   From	   2010	   until	  
now,	  our	  laboratory	  established	  PDXs	  for	  more	  than	  200	  cases.	  Among	  the	  resistant	  subtypes	  of	  ALL	  
we	  included	  samples	  associated	  with	  defined	  genetic	  subgroups	  –	  like	  TCF3-­‐HLF,	  BCR-­‐ABL1,	  MLL-­‐AF4,	  
BCR-­‐ABL1-­‐like	   –	   as	   well	   as	   cases	   with	   unknown	   genetic	   features	   that	   are	   refractory	   to	   induction	  
treatment	  or	  have	  high	   risk	  of	   relapse.	  When	  possible,	   paired	  diagnosis	   and	   relapse	   samples	  were	  
included.	   Furthermore,	   we	   included	   ALL	   subtypes	   associated	   with	   good	   prognosis,	   such	   as	   TCF3-­‐
PBX1,	   TEL-­‐AML1,	   hyperdiploid	   –	   each	   associated	  with	   a	   specific	   cytogenetic	   subgroup	   –	   and	   other	  
cases	  that	  respond	  well	  to	  treatment	  for	  which	  cytogenetic	  features	  are	  unknown.	  To	  investigate	  the	  
potential	   relevance	  of	  our	   integrated	  model	   shown	   in	   Figure	  15,	  we	  decided	   to	   focus	  on	   subtypes	  
with	  defined	  cytogenetic	  features	  in	  this	  thesis	  (Manuscript	  1).	  In	  particular,	  we	  compared	  TCF3-­‐HLF	  
and	   TCF3-­‐PBX1-­‐positive	   ALL	   because	   although	   they	   both	   rearranged	   the	   same	   portion	   of	   the	  
transcription	   factor	   TCF3	   in	   the	   chimeric	   fusion	   protein,	   they	   have	   completely	   opposite	   clinical	  
outcomes.	  TCF3-­‐HLF-­‐positive	  ALL	  is	  a	  fatal	  subtype,	  while	  TCF3-­‐PBX1-­‐positive	  ALL	  is	  associated	  with	  a	  
good	  outcome.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	   16.	   Clinically	   relevant	   ALL	   subtypes	   included	   in	   the	   PDX	   cohort.	   Genetic	   lesions	   and	   response	   to	   treatment	   are	  
important	   criteria	   for	   risk	   stratification.	   75%	   of	   the	   samples	   can	   be	   classified	   based	   on	   cytogenetic	   features	   that	   are	  
associated	  with	  good	  or	  poor	  prognosis.	  25%	  of	  the	  remaining	  patients	  are	  classified	  mainly	  based	  response	  to	  treatment.	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4.2.2	   Resemblance	   of	   the	   clonal	   composition	   of	   Patient	   Derived	   Xenograft	   (PDX)	   to	   the	  
original	  sample	  
Several	   studies	   have	   investigated	   the	   effect	   of	   passaging	   primary	   patient	   cells	   in	   the	   xenogenic	  
environment	   (51,	  72-­‐75,	  77)	  of	   immunodeficient	  mice	  on	   the	  clonal	  composition	  of	   the	  samples.	  A	  
study	  (73)	  focused	  on	  BCR-­‐ABL1-­‐positive	  ALL	  has	  shown	  that	  the	  clonal	  evolution	  process	  in	  the	  PDX	  
model	   can	   occur	   according	   different	   behaviors	   even	   within	   samples	   belonging	   to	   the	   same	  
cytogenetic	  subgroup.	  In	  half	  of	  the	  cases,	  the	  major	  clones	  at	  diagnosis	  were	  conserved	  in	  the	  PDXs	  
(defined	  as	  concordant	  PDXs),	  while	  in	  the	  other	  half	  of	  patients,	  minor	  subclones	  of	  the	  diagnostic	  
samples	  were	   amplified	   in	   the	   xenograft	   (defined	   as	   discordant	   PDXs).	   The	  different	   PDX	  behavior	  
was	  clearly	  associated	  with	  the	  additional	  cooperative	  lesions	  of	  the	  diagnostic	  samples.	  Those	  with	  
CDKN2A/2B	  and	  PAX5	  deletions	  (recurrent	  affected	  genes	  ALL)	  displayed	  a	  concordant	  behavior.	  This	  
group	  was	   also	   associated	   with	   a	   poor	   clinical	   outcome	   and	   a	   rapid	   kinetics	   of	   engraftment.	   This	  
study	  suggests	  that	  genetically	  distinct	  subclones	  have	  different	  repopulation	  capacity	  in	  the	  mouse,	  
which	  might	  have	  clinical	  relevance.	  
Our	  laboratory	  (75)	  has	  established	  PDX	  models	  of	  samples	  not	  associated	  with	  specific	  cytogenetic	  
subgroups,	  but	  clinically	  classified	  based	  on	  treatment	  response.	  Compared	  with	  the	  previous	  study,	  
clonal	   evolution	   was	   investigated	   by	   cytogenetic,	   FISH	   and	   Ig/TCR	   rearrangements,	   in	   addition	   to	  
CNA	   analysis.	   Overall,	   the	   xenograft	   samples	   were	   highly	   correlated	   with	   the	   original	   diagnostic	  
samples,	   including	   conservation	   of	   the	   clonal	   complexity	   as	   well.	   The	   clonal	   composition	   of	   PDXs	  
derived	  from	  chemo-­‐resistant	  patients	  remained	  stable	  on	  serial	  passages	  in	  mice	  and	  was	  associated	  
with	   shorter	   kinetics	   of	   engraftment.	   In	   contrast,	   PDXs	   of	   sensitive	   cases	   had	   longer	   engraftment	  
kinetics,	   which	   became	   comparable	   to	   the	   engraftment	   kinetics	   of	   resistant	   cases	   only	   at	   the	  
secondary	   passages	   and	   interestingly,	   few	   new	   clones	   were	   detected	   in	   the	   secondary	  
transplantations.	   This	   evidence	   suggests	   that	   sensitive	   cases	   may	   undergo	   a	   stronger	   selective	  
pressure,	  while	  the	  genetic	  features	  of	  resistant	  cases	  favor	  the	  tumor	  propagation	  in	  the	  unfriendly	  
microenvironment	   of	   the	  mice	   or	   enables	   the	   leukemia	   to	   propagate	   in	   a	   less	  microenvironment-­‐
dependent	  manner.	  
Furthermore	  a	   study	   (51)	   in	   T-­‐ALL	  has	   characterized	  paired	  diagnosis	   and	   relapse	  patient	   samples,	  
and	  PDXs	  derived	  from	  the	  transplantation	  of	  the	  diagnostic	  samples.	  Multiple	  techniques	  were	  used,	  
like	  genome-­‐wide	  DNA	  array,	   cytogenetic,	   FISH,	  quantitative	  genomic	  PCR	   for	   specific	  backtracking	  
abnormalities	   and	  microarray	   analysis.	  Notably,	   the	   PDXs	   resembled	   relapse	   samples	  more	   closely	  
than	   diagnostic	   samples,	   suggesting	   that	   PDXs	   can	  model	   the	   process	   of	   relapse	   in	   patients.	   PDXs	  
often	  contained	  additional	  genetic	  lesions	  in	  oncogene	  and	  tumor	  suppressor	  genes	  like,	  PTEN,	  MYC,	  
CDKN2A	  and	  NOTCH1	  that	  are	  also	  found	  in	  relapsed	  cases.	  	  
This	  data	  suggests	   that	   it	   is	   important	   to	  understand	  the	  extent	   to	  which	   the	  clonal	  architecture	   is	  
affected	  in	  PDXs	  and	  to	  assess	  stability	  upon	  multiple	  passages	  in	  mice	  in	  order	  to	  validate	  the	  basis	  
of	  this	  experimental	  model.	  Here	  we	  provide	  one	  of	  the	  first	   in-­‐depth	  analyses	  performed	  by	  using	  
next	  generation	  sequencing	  approaches	  of	  a	  PDX	  model	  focusing	  on	  TCF3-­‐translocated	  ALL.	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4.2.3	   Genomic	  characterization	  of	  TCF3-­‐translocated	  ALL	  PDX	  models	  
Genomic	  analysis	  of	  our	  PDX	  models	  of	  TCF3-­‐HLF	  and	  TCF3-­‐PBX1	  -­‐positive	  ALL	  showed	  a	  high	  degree	  
of	   resemblance	   between	   patient	   samples	   and	   matched	   PDXs.	   Both	   translocations	   remained	  
conserved	  in	  all	  PDXs.	  Moreover,	  we	  could	  identify	  lesions	  affecting	  genes	  recurrently	  mutated	  in	  ALL	  
that	  remained	  generally	  stable	  in	  the	  PDXs.	  Compared	  to	  TCF3-­‐PBX1-­‐positive	  ALL	  in	  which	  only	  1	  to	  4	  
mutations	  were	  detected	  per	  patient,	   in	  the	  resistant	  TCF3-­‐HLF	   -­‐positive	  ALL	  we	  identified	  a	  higher	  
number	  of	  lesions	  and	  recurrent	  alterations	  of	  PAX5	  and	  TCF3	  genes.	  This	  evidence	  suggests	  that	  the	  
translocation	  is	  the	  initiating	  event	  for	  both	  ALL	  subtypes,	  while	  the	  additional	   lesions	  cooperate	  in	  
the	  leukemogenesis	  process	  and	  possibly	  in	  the	  disease	  progression.	  	  
Recently,	  the	  clinical	  relevance	  of	  combined	  specific	  patterns	  of	  cooperative	  lesions	  with	  cytogenetic	  
features	   (73)	   has	   been	   demonstrated.	   Indeed,	   a	   higher	   complexity	   in	   the	   mutational	   pattern	   is	  
associated	  with	  poor	  risk	  in	  ALL,	  as	  also	  shown	  by	  our	  data.	  	  
Interestingly,	  the	  SNVs	  identified	  in	  the	  chemo-­‐sensitive	  TCF3-­‐PBX1-­‐positive	  ALL	  subtype	  tend	  to	  be	  
more	  stable	  in	  the	  PDX	  models	  than	  those	  in	  TCF3-­‐HLF-­‐positive	  ALL.	  This,	  in	  a	  sense,	  may	  contradict	  
the	   idea	   of	   a	   need	   for	   additional	   selection	   to	   establish	   sensitive	   cases	   in	   xenografts.	   Differences	  
between	  ALL	  subtypes	  may	  exist,	  and	  additional	  epigenetic	  adaptation	  may	  occur	  which	  has	  not	  been	  
investigated	  in	  this	  thesis.	  Moreover	  we	  uncovered	  clonal	  volatility	  of	  certain	  SNVs.	  A	  few	  mutations	  
that	  were	  present	  in	  a	  fraction	  of	  cells	  of	  the	  tumor	  at	  diagnosis	  were	  not	  detected	  in	  PDXs,	  including	  
GNB1	   and	   DDX3X,	   suggesting	   that	   these	   are	   either	   non-­‐essential	   mutations	   or	   may	   cause	   drug	  
sensitivity.	   In	  our	  model,	  Ras	  mutations	  were	  generally	  subclonal,	  almost	  exclusively	  present	   in	  the	  
TCF3-­‐HLF-­‐positive	  samples	  and	  with	  variable	  persistence	  over	  disease	  progression.	  In	  one	  patient	  we	  
could	   detect	   SNVs	   in	  NRAS,	   KRAS,	   and	   FLT3	  at	   diagnosis,	   but	   only	   the	   clones	  with	  KRAS	  and	   FLT3	  
mutations	  were	  maintained.	  In	  another	  case	  we	  could	  identify	  a	  switch	  of	  the	  mutation	  from	  NRAS	  at	  
diagnosis	  to	  KRAS	  in	  the	  PDXs.	  	  This	  data	  fits	  to	  observations	  in	  the	  clinic,	  in	  which	  RAS	  mutations	  are	  
associated	  with	  more	  resistant	  ALL	  and	  paired	  sample	  analysis	  identified	  gains,	  losses	  and	  switches	  of	  
RAS	   mutations	   (46,	   54).	   In	   our	   model,	   mutations	   in	   RAS	   patway	   likely	   contribute	   to	   the	   more	  
aggressive	  phenotype	  of	  TCF3-­‐HLF-­‐positive	  ALL	  and	  to	  the	  leukemia	  progression,	  but	  are	  not	  critical	  
for	  the	  leukemia	  initiation	  and	  survival.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Analysis	  of	  the	  transcriptome	  revealed	  that	  the	  signatures	  between	  patients	  and	  PDXs	  were	  strongly	  
conserved.	  Therefore,	  the	  translocation	  has	  a	  strong	  impact	  in	  defining	  the	  cellular	  reprogramming.	  
The	  high	  degree	  of	  resemblance	  between	  patient	  and	  PDXs	  of	  TCF3-­‐translocated	  ALL	  allows	  us	  to	  use	  
this	  model	  in	  further	  experiments	  in	  order	  to	  study	  its	  biology.	  For	  example,	  in	  our	  laboratory	  TCF3-­‐
HLF	  PDXs	  are	  used	  to	  decipher	  the	  transcriptional	  target	  of	  the	  translocation.	  	  
4.2.4	   Identification	  of	  leukemia-­‐associated	  markers	  using	  the	  PDX	  model	  
To	   identify	   new	   markers	   that	   are	   associated	   with	   resistant	   disease	   we	   took	   advantage	   of	   the	  
xenograft	  system	  to	  perform	  a	  comprehensive	  proteomic	  analysis	  of	  the	  cell	  surface	  of	  ALL	  (76).	  Our	  
group	  has	  shown	  that	  the	  immunophenotype	  of	  xenografts	  resembles	  closely	  the	  immunophenotype	  
of	   corresponding	   patients	   at	   diagnosis.	   Here	   I	   have	   used	   this	   dataset	   to	   identify	  markers	   that	   are	  
preferentially	  detected	  on	  the	  surface	  of	  highly	  resistant	  disease	  in	  ALL	  (Manuscript	  3).	  We	  focus	  on	  
the	  GPI-­‐80/VNN2	  protein	  because	   it	   is	  exclusively	  expressed	  by	  resistant	  cases,	   including	  TCF3-­‐HLF-­‐
positive	  ALL.	  Remarkably,	  it	  has	  been	  shown	  that	  VNN2	  is	  essential	  for	  the	  self-­‐renewal	  and	  survival	  
	   	   Discussion	   	  
42	  
	  
of	   fetal	   liver	   hematopoietic	   stem	   cells	   (113),	   and	   contributes	   to	   the	   migration	   and	   adhesion	   of	  
neutrophils	   (106).	   This	   evidence	   suggests	   a	   potential	   role	   of	   VNN2	   in	   sustaining	   the	   cellular	  
proliferation	  of	  the	  leukemia	  and	  leading	  to	  a	  more	  clinically	  aggressive	  phenotype.	  Indeed,	  relapse	  
in	   extra-­‐medullary	   organs	   and	   expression	   of	   myeloid	   marker	   is	   clinically	   associated	   with	   poor	  
prognosis.	   Importantly,	  we	  could	  validate	  that	  the	  expression	  of	  VNN2	  in	  PDXs	  remains	  stable	  over	  
passages.	  Small	  fluctuation	  of	  the	  positivity	  could	  be	  found	  in	  a	  few	  samples,	  in	  which	  VNN2	  was	  not	  
expressed	  by	  all	  the	  cells	  of	  the	  tumor.	  This	  could	  be	  due	  to	  an	  out	  growth	  of	  VNN2	  negative	  clones.	  	  
	  
4.3	   Contribution	   of	   the	   genomic	   study	   of	   TCF3-­‐HLF-­‐positive	   ALL	   to	   our	  
understanding	  of	  leukemogenesis	  	  
Our	   study	   identified	   a	   novel	   so	   far	   unrecognized	   genomic	   pattern	   in	   TCF3-­‐HLF-­‐positive	   ALL.	   We	  
detected	  a	  recurrent	  heterozygous	  deletion	  of	  PAX5	  (60%	  of	  the	  cases)	  and	  SNV	  in	  the	  transcription	  
factor	  TCF3	  (30%	  of	  the	  cases),	  which	  acts	  upstream	  of	  PAX5,	  and	  likely	  results	  in	  alterations	  of	  the	  
PAX5	   function.	   In	  addition,	  mutations	   in	  an	  early	  form	  of	  the	  B-­‐cell	  receptor	  VPREB1	  were	  found	  in	  
one	   case	   without	   lesions	   in	   PAX5	   and	   TCF3	   (Fig	   17).	   Additional	   evidence	   that	   sustained	   the	  
importance	   of	   this	  PAX5	   alteration	   in	   the	  TCF3-­‐HLF-­‐positive	   ALL	   is	   the	   detection	   of	   a	   reduction	   of	  
PAX5	   transcript	   levels	   in	   all	   cases.	  We	   did	   not	   identify	   recurrent	  mutations	   in	   B-­‐cell	   development	  
factors	  that	  act	  at	  different	  stages	  in	  lymphoid	  cell	  development,	  such	  as	  IKFZ1,	  which	  was	  found	  to	  
be	   associated	   with	   BCR-­‐ABL1-­‐positive	   ALL,	   BCR-­‐ABL1-­‐like	   ALL	   and	   with	   poor	   prognosis	   when	  
combined	  with	  other	  lesions	  (57,	  119).	  Thus,	  a	  distinct	  pattern	  of	  cooperative	  lesions	  appears	  to	  be	  
required	  for	  TCF3-­‐HLF-­‐positive	  ALL.	  This	  has	   important	   implications	  for	  disease	  modeling.	  So	  far,	  all	  
attempts	   to	  engineer	   the	   translocation	   in	  mice	  have	  not	   recapitulated	   the	  human	  disease	   (63,	  64).	  
Our	  data	  suggest	  that	  the	  translocation	  should	  be	  modeled	  in	  the	  context	  of	  PAX5	  haploinsufficiency.	  	  
	  
Figure	   17.	  Model	   of	   the	  molecular	   pathogenesis	   of	   TCF3-­‐HLF	   positive	   ALL	   based	   on	   our	   findings.	   Recurrent	   lesions	   in	  
genes	  involved	  in	  the	  lymphoid	  development,	  RAS	  pathway	  and	  cell	  cycle	  have	  been	  found	  in	  treatment	  resistant	  TCF3-­‐HLF	  
-­‐positive	  ALL.	  (N=12	  samples	  were	  included	  in	  our	  study,	  n=1	  from	  a	  recent	  publication	  showing	  concordant	  results	  (46)).	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4.4	   Development	   of	   a	   large	   scale	   drug-­‐screening	   platform	   for	   primary	   ALL	  
samples	  
4.4.1	   Co-­‐culture	  of	  primary	  leukemia	  cells	  on	  mesenchymal	  stromal	  cells	  
Cell	   lines	  are	  a	  valuable	  model	  system	  to	  study	  biological	  mechanisms	  and	  guide	  the	  early	  phase	  of	  
drug	  development.	  In	  2012	  Barretina	  (120)	  and	  Garnett	  (121)	  described	  two	  large-­‐scale	  independent	  
studies	  on	  human	  cancer	  cell	  lines.	  Many	  cell	  lines	  were	  profiled	  at	  the	  genomic	  and	  transcriptomic	  
levels,	   and	   tested	   for	   sensitivity	   to	   approved	   and	   potential	   new	   drugs.	   They	   illustrated	   some	  
expected	  associations	  between	  drug	  response	  sensitivity	  and	  genotype,	  but	  the	  utility	  of	  this	  system	  
for	  the	  discovery	  of	  relevant	  functional	  networks	   in	   leukemia	  remains	  to	  be	  assessed.	   Indeed,	  such	  
cells	   lines	   represent	   exceptional	   cases	   in	   which	   selection	   of	   additional	   features	   results	   in	  
independence	  from	  the	  microenvironment.	  	  
Other	  groups	  recently	  performed	   in	  vitro	  drug	  screenings	  by	  using	  patient	  samples.	  Promising	  data	  
were	   generated	   by	   Tyner	   et	   al.	   (80)	   and	   Pemovska	   et	   al.	   (81),	   who	   performed	   functional	   drug	  
sensitivity	   assays	   of	   ALL	   in	   a	  monoculture	   system.	   However,	   this	   type	   of	   culture	   setting	   does	   not	  
provide	  the	  protective	  effect	  of	  the	  microenvironment	  (bone	  marrow	  niche)	  and	  does	  not	  allow	  for	  
the	  survival	  of	  a	  considerable	  fraction	  of	  ALL	  samples,	  as	  we	  show	  in	  Manuscript	  2.	  	  	  
Hartwell	   et	   al.	   (82)	   established	  a	   screening	  platform	  based	  on	   co-­‐culture	  of	  primary	  patient	   (AML)	  
cells,	   with	  murine	   bone	  marrow	   stromal	   cells,	   attempting	   to	   overcome	   the	   limitations	   due	   to	   the	  
monoculture	  settings.	  We	  independently	  established	  a	  comparable	  platform	  to	  perform	  in	  vitro	  drug	  
screenings	  of	  human	  ALL	  samples	  in	  a	  more	  physiologic	  context	  (Manuscript	  1	  and	  2	  and	  Figure	  18),	  
by	  using	  primary	  patient	  (ALL)	  cells	  in	  co-­‐culture	  with	  human	  bone	  marrow	  cells.	  	  
This	  system	  offers	  several	  advantages:	  
-­‐ To	  couple	  in	  vitro	  drug	  screening	  with	  the	  PDX	  model	  for	  further	  functional	  investigation	  	  
-­‐ To	  integrate	  clinical	  and	  biological	  data	  from	  the	  corresponding	  patient	  material	  
-­‐ To	  screen	  a	  large	  number	  of	  defined	  cases	  
-­‐ To	  screen	  large	  compound	  libraries	  at	  good	  resolution	  by	  using	  several	  drug	  concentrations	  	  
4.4.2	   Survival	  and	  proliferation	  	  
Survival	  and	  proliferation	  are	  two	  essential	  points	  that	  need	  to	  be	  considered	  during	  drug	  sensitivity	  
assessments.	   Drug	   sensitivity	   profiles	   of	   cells	   that	   are	   undergoing	   apoptosis	   independent	   of	   the	  
treatments	  are	   likely	  not	  representative	  of	   the	   leukemia	  sensitivity	   in	  vivo.	  Moreover,	   the	  effect	  of	  
chemotherapeutic	   agents	   and	   compounds	   targeting	   proteins	   involved	   in	   the	   cell	   cycle,	   like	   polo	  
kinase	  and	  aurora	  kinase,	  strongly	  depend	  on	  cell	  proliferation.	  	  
In	  our	  platform,	  analysis	  of	  the	  proportion	  of	  cells	  in	  S-­‐phase	  at	  the	  time	  of	  the	  drug	  screening	  read-­‐
out	  revealed	  a	  high	  variability	  across	  the	  samples.	  Although	  all	  samples	  tested	  had	  a	  fraction	  of	  cells	  
in	  S-­‐phase,	  the	  proportion	  would	  vary	  from	  10%	  up	  to	  70%.	  This	  variation	  could	  generate	  a	  bias	  in	  the	  
response	  analysis	  to	  compounds	  targeting	  cell	  the	  cycle.	  That	  is,	  the	  level	  of	  sensitivity	  could	  reflect	  
the	  amount	  of	  cells	  in	  S-­‐phase,	  rather	  than	  intrinsic	  mechanisms	  of	  resistance.	  Indeed,	  in	  the	  case	  of	  
T	   ALL	  we	   could	   see	   a	   correlation	   between	   the	   sensitivity	   to	   drugs	   targeting	   the	   cell	   cycle	   and	   the	  
fraction	  of	  cells	  in	  S-­‐phase	  (Manuscript	  2).	  A	  similar	  correlation	  was	  also	  described	  in	  Manuscript	  1:	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TCF3-­‐HLF-­‐positive	   cases	   had	   a	   lower	   fraction	   of	   cell	   in	   S-­‐phase	   as	   compared	  with	   the	   TCF3-­‐PBX1-­‐
positive	   ALL	   cases.	   And	   indeed,	   they	   were	   also	   more	   resistant	   to	   drugs	   targeting	   cell	   cycle	  
(vincristine,	   paclitaxel,	   barasertinib).	   The	   fact	   that	   we	   detect	   subgroups	   with	   distinct	   cell	   cycle	  
features	  and	  apoptosis	  rates	  on	  our	  platform	  warrants	  further	  investigation,	  as	  this	  information	  may	  
be	  of	  clinical	  relevance.	  Our	  study	  of	  the	  paradigm	  subtype	  for	  highly	  resistant	  disease	  TCF3-­‐HLF	  is	  a	  
good	  example.	   Indeed,	  we	  consistently	  detected	  a	  higher	  fraction	  of	  quiescent	  cells	   in	  the	  resistant	  
TCF3-­‐HLF-­‐positive	   ALL	   subtype.	   This	   may	   explain	   the	   lower	   susceptibility	   to	   clinical	   drugs	   like	  
antimitotics	   and	   antimetabolites.	   But	   in	   contrast,	   evidence	   also	   suggests	   that	   a	   loss	   of	   cell	   cycle	  
checkpoint	  controls	  can	  be	  associated	  with	  resistant	  disease,	  as	   for	  example	  mutations	   in	  TP53	  are	  
more	  frequently	  observed	  at	  relapse	  (53)	  and	  rapid	  progression	   in	  mouse	  xenografts	  was	  shown	  to	  
be	  associated	  with	  early	  relapse	  in	  ALL	  (73,	  122).	  	  These	  facts	  will	  have	  to	  be	  taken	  into	  consideration	  
when	  integrating	  data	  for	  precision	  medicine	  in	  ALL.	  
4.4.3	   Correlation	  of	  in	  vivo	  and	  in	  vitro	  drug	  activity	  in	  our	  models	  
Obviously	   an	   in	   vitro	   platform	   will	   have	   major	   limitations	   compared	   with	   an	   individual	   patient’s	  
situation.	   Testing	   drugs	   in	   patients	  will	   reveal	   important	   features	   that	   are	   related	   to	   the	   patient’s	  
ability	  to	  absorb,	  distribute,	  metabolize,	  and	  eliminate	  the	  drug	  (pharmacokinetics),	  all	  of	  which	  are	  
not	  reflected	  in	  the	  in	  vitro	  settings.	  The	  biochemical	  and	  physiological	  effects	  and	  the	  mechanism	  of	  
drug	  action	  at	  organ	  and	  cellular	  levels	  (pharmacodynamics)	  are	  also	  different.	  Pharmacokinetic	  and	  
pharmacodynamic	  aspects	  are	  very	  important	  for	  the	  identification	  of	  safe	  and	  effective	  therapeutic	  
management	  of	  drugs	  in	  patients.	  Second,	  the	  2D	  co-­‐culture	  system	  with	  mesenchymal	  stromal	  cells	  
cannot	  replace	  the	  3-­‐D	  bone	  marrow	  niche,	  such	  as	  the	  interaction	  with	  other	  cell	  types,	  the	  native	  
tissue	  architecture,	  the	  influence	  of	  cytokines	  and	  other	  cell	  signaling	  molecules.	  For	  these	  reasons,	  
our	  approach	  will	  most	  likely	  be	  useful	  to	  identify	  interacting	  activity	  patterns,	  which,	  in	  combination	  
with	  other	  information,	  will	  lead	  to	  possible	  actionable	  features	  to	  be	  validated	  in	  the	  clinical	  setting.	  
It	   is	   possible	   that	   characteristics	   detected	   by	   the	   platform	  will	   be	   of	   immediate	   use	   in	   the	   clinical	  
setting:	   for	   example,	   predicting	   a	   completely	   resistant	   phenotype	   based	   on	   leukemia-­‐intrinsic	  
features	  or	  detecting	  specific	  sensitivity	  to	  a	  given	  drug	  based	  on	  subtype	  specific	  features.	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4.5	   Proof	   of	   concept	   data	   to	   support	   the	   use	   of	   in	   vitro	   drug	   profiling	   in	  
translational	  research	  
Strong	   preliminary	   data	   on	   this	   platform	   show	   that	   the	   biological	   features	   of	   the	   leukemia	   are	  
revealed	  by	  distinct	  profiles.	  Drug	  activity	  profiles	  vary	  from	  patient	  to	  patient,	  even	  in	  subtypes	  that	  
are	  clearly	  characterized	  by	  a	  genetic	  feature	  such	  as	  TCF3-­‐HLF-­‐positive	  ALL,	  as	  shown	  here.	  	  
However,	   recurrent	   drug	   activity	   information	   can	   be	   retrieved	   for	   clinically	   defined	   subsets.	   For	  
example,	  TCF3-­‐HLF-­‐positive	  cases	  resulted	  resistant	  to	  drugs	  targeting	  the	  cell	  cycle	  (i.e.,	  vincristine,	  
paclitaxel,	   BI-­‐2536,	   barasertinib)	   and	   tirosine	   kinases	   (dasatinib,	   lestaurtinib),	   while	   a	   striking	  
sensitivity	  was	  shown	  for	  the	  BCL-­‐2	  specific	  inhibitor	  venetoclax	  (ABT199).	  	  
Our	   platform	  provides	   relevant	   functional	   screening	   for	   detecting	   drug	   sensitivity.	   This	  was	   clearly	  
demonstrated	  for	  venetoclax.	  For	  example,	  based	  on	  previous	  studies,	  sensitivity	  to	  venetoclax	  could	  
not	   always	   be	   associated	  with	   high	   levels	   of	   BCL-­‐2.	   It	   has	   been	   shown	   that	   high	   BCL-­‐2	   expression	  
correlates	  with	  sensitivity	  to	  venetoclax	  in	  NHL	  cell	  lines	  and	  T	  cell	  lines	  (95,	  98),	  but	  in	  a	  later	  study	  
the	  ratio	  BCL-­‐2:BCL-­‐XL	  was	  suggested	  to	  be	  predictive	  of	  the	  response	  to	  venetoclax	  in	  T	  ALL	  (100).	  	  
Due	  to	  the	  multiclonal	  composition	  of	  ALL,	  multiple	  drug	  combinations	  are	  used	  in	  clinical	  treatment	  
regiments	   (123).	   However,	   relapse	   still	   occurs.	   shRNA	   libraries	   have	   been	   used	   to	   investigate	  
pathways	   critical	   to	   drug	   resistance,	   for	   example	   in	   BCR-­‐ABL1-­‐positive	   ALL	   resistant	   to	   the	   	   TKI	  
imatinib	   (116).	   In	   vitro	   high-­‐throughput	   screening	  assays	   (124)	   and	   in	   vivo	   preclinical	  models	   (125)	  
using	  PDXs	  ALL	  have	  been	  also	  used	  to	  identify	  compounds	  able	  to	  sensitize	  ALL	  to	  the	  clinical	  drugs.	  
Our	   system	  will	   contribute	   to	   investigate	  possible	  drug	   combinations,	   guided	  by	   the	   integration	  of	  
genomics,	  in	  vitro	  drug	  profiling	  and	  in	  vivo	  validation	  in	  xenografts.	  	  
So	  far,	  based	  on	  data	  shown	  in	  Manuscript	  1	  and	  2	  for	  the	  novel	  compound	  venetoclax,	  and	  previous	  
publications	   of	   our	   laboratory	   for	   the	   clinical	   drug	   (dexamethasone)	   (75,	   126),	   in	   vitro	   activity	  
correlated	  with	  drug	  activity	   in	   xenografts	   in	   vivo,	   suggesting	   that	   indeed	   this	  platform	  will	   extend	  
our	  capability	  for	  productive	  research.	  
In	   vivo	   experiments	   combining	  dexamethasone	  and	  vincristine	  –	  both	   clinical	  drugs	  –	  with	  ABT199	  
revealed	   promising	   preliminary	   data	   (not	   shown	   here).	   Indeed,	   based	   on	   transgenic	   mice	  
overexpressing	   murine	   Bcl-­‐2,	   or	   mice	   expressing	   a	   conditional	   human	   BCL2	   gene,	   it	   has	   been	  
suggested	   that	   BCL-­‐2	   facilitates	   tumor	   cell	   maintenance	   and	   survival,	   but	   is	   not	   sufficient	   for	   the	  
development	   leukemia	   (127,	   128).	   Therefore,	  BCL-­‐2	  overexpression	   is	  not	   considered	   the	  driver	  of	  
the	  leukemia	  and	  it	  seems	  improbable	  that	  even	  sustained	  inhibition	  of	  BCL-­‐2	  can	  be	  curative.	  	  
Importantly,	   we	   could	   test	   TCF3-­‐HLF-­‐positive	   patient	   samples	   on	   our	   drug	   screening	   platform	  
(Manuscript	  2)	  and	  compare	   to	   the	   samples	   included	   in	  our	  biobank	   including	  TCF3-­‐HLF	   and	  TCF3-­‐
PBX1-­‐positive	  ALL,	   and	  other	   subtypes	   showed	  here	   in	  Figure	  19.	  Notably,	  drug	  profiles	  of	   these	  2	  
cases	   were	   comparable	   to	   the	   other	   TCF3-­‐HLF-­‐positive	   cases	   previously	   tested.	   One	   of	   them	  
(depicted	   with	   red	   dot)	   was	   resistant	   to	   induction	   treatment	   with	   cytarabine,	   dexamethasone,	  
vincristine,	  methotrexate	  and	  these	  clinical	  data	  were	  also	  confirmed	  by	  our	   in	  vitro	  drug	  response	  
profile.	   Remarkably,	   our	   screening	   identified	   sensitivity	   for	   other	   clinical	   drugs,	   like	   doxorubicine,	  
mitoxantrone,	   bortezomib	   and	   novel	   agents	   in	   advanced	   phases	   of	   clinical	   trials	   like	   venetoclax.	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These	   data	   underscore	   the	   relevance	   of	   our	   drug-­‐screening	   platform	   to	   evaluate	   the	   response	   of	  
patient	  samples	  to	  clinical	  or	  promising	  novel	  drugs.	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  
Figure	   19.	   Drug	   profiling	   data	   of	   refractory	   TCF3-­‐HLF-­‐positive	   patients	   compared	   to	   our	   experience	   for	   the	   same	  
therapeutic	   agents	   on	   the	   platform.	   TCF3-­‐HLF-­‐positive	   ALL	   patients	   are	   in	   red	   and	   dark	   red.	   For	   comparison,	   the	  
corresponding	  drug	  activity	  is	  indicated	  for	  the	  PDXs	  of	  TCF3-­‐HLF	  (n=5,	  orange),	  TCF3-­‐PBX1	  (n=5	  green)	  positive	  ALL	  and	  25	  
additional	  ALL	  samples	  (grey)	  tested	  on	  the	  same	  platform,	  including	  standard	  risk	  (SR,	  n=5,	  square),	  medium	  risk	  (MR,	  n=4,	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4.6	   	  Impact	  of	  our	  models	  on	  translational	  research	  
Taken	  together	  we	  envision,	  in	  the	  near	  future,	  that	  our	  models	  will	  have	  a	  significant	  impact	  on	  the	  
field	  from	  different	  aspects:	  
1. The	   molecular	   portrait	   of	   TCF3-­‐HLF-­‐positive	   ALL	   that	   we	   describe	   here	   provides	   relevant	  
information	  for	  future	  research	  efforts	  such	  as	  mouse	  model	  generation,	  functional	  analysis	  
of	  the	  mutated	  genes	  and	  activated	  pathways	  that	  might	  be	  targets	  for	  new	  therapy.	  	  	  
2. The	  collection	  of	  PDX	  drug-­‐screening	  profiles	   shown	   in	   this	   thesis	   could	  be	  used	   to	  predict	  
the	   clinical	   response	   of	   those	   that	   have	   similar	   genetic	   features,	   and	   identify	   alternative	  
therapeutic	  options.	  Genomic	  characterization	  of	  the	  patients	  and	  the	  repository	  profile	  data	  
would	  help	  to	  identify	  patients	  eligible	  for	  specific	  treatment	  protocols	  already	  at	  diagnosis,	  
thereby	  avoiding	  inactive	  treatments	  or	  cytotoxic	  effects.	  
3. Evaluation	  of	  the	  drug-­‐profiling	  platform	  as	  a	  tool	  to	  detect	  drugable	  targets	  in	  ALL	  patients	  
who	  do	  not	   respond	   to	   induction	   treatment.	  Our	   laboratory	  already	   initiated	  a	  multicenter	  
project	  to	  profile	  such	  cases	  systematically	  at	  the	  genomic	  and	  functional	  level.	  
4. Use	   of	   systematic	   drug-­‐profiling	   at	   relapse	   in	   treatment	   resistant	   cases	   to	   evaluate	   its	  
predictive	  potential	  and	  establish	  novel	  therapeutic	  options.	  
5. Acceleration	  of	  the	  discovery	  of	  unexpected	  drug	  resistance	  and	  sensitivity	  phenotypes.	  Our	  
data	  already	  suggest	  several	  candidate	  drugs	  (BH3-­‐mimetics,	  SMAC-­‐mimetics,	  TKI,	  BRD4	  and	  
HDACs)	  with	  interesting	  activity	  profiles	  in	  ALL	  subsets	  for	  which	  no	  drugable	  targets	  can	  be	  
identified	  so	  far,	  like	  TCF3-­‐HLF	  positive	  ALL,	  MLL	  rearranged	  ALL,	  T-­‐ALL.	  
Clinical	  importance	  of	  VNN2	  
1. Biomarker	  to	  screen	  for	  TCF3-­‐HLF-­‐positive	  ALL	  by	  flow	  cytometry	  and	  select	  the	  samples	  that	  
need	   to	   be	   validated	   by	   FISH	   at	   diagnosis.	   Moreover	   VNN2	   can	   be	   used	   for	   analysis	   of	  
residual	  leukemia	  cells	  during	  patient	  treatment.	  
2. VNN2	  expression	  appears	  to	  be	  associated	  with	  a	  higher	  risk	  of	  relapse.	   Implementation	  of	  
VNN2	   at	   diagnosis	   would	   be	   useful	   in	   detecting	   relapse	   cases	   that	   are	   not	   identified	   by	  
current	  tools.	  	  
3. Based	   on	   the	   work	   shown	   in	   this	   thesis	   (Manuscript	   3)	   a	   prospective	   analysis	   of	   VNN2	  
expression	   in	   diagnostic	   samples	   has	   already	   started	   (Prospective	   analysis	   proposal)	   in	  
different	  European	  centers	  (Switzerland,	  Italy,	  Austria)	  to	  validate	  the	  clinical	  relevance	  and	  
the	  future	  implementation	  of	  VNN2	  as	  an	  additional	  diagnostic	  biomarker	  predictive	  of	  poor	  
outcomes.	  First	  preliminary	  data	  confirm	  the	  existence	  of	  a	  small	  subset	  of	  VNN2	  positive	  ALL	  
in	  the	  range	  of	  10%	  percent.	  
4. Genomic	  characterization	  of	  VNN2	  positive	  samples	  is	  ongoing	  and	  we	  aim	  to	  integrate	  these	  
data	   with	   the	   PDX	   model	   to	   investigate	   the	   biological	   basis	   underlying	   cellular	   programs	  
associated	  with	  VNN2	  in	  leukemia.	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TCF3-HLF−positive acute lymphoblastic leukemia (ALL) is currently incurable. Using an integrated approach, we  
uncovered distinct mutation, gene expression and drug response profiles in TCF3-HLF−positive and treatment-responsive  
TCF3-PBX1−positive ALL. We identified recurrent intragenic deletions of PAX5 or VPREB1 in constellation with the fusion  
of TCF3 and HLF. Moreover somatic mutations in the non-translocated allele of TCF3 and a reduction of PAX5 gene dosage in  
TCF3-HLF ALL suggest cooperation within a restricted genetic context. The enrichment for stem cell and myeloid features in  
the TCF3-HLF signature may reflect reprogramming by TCF3-HLF of a lymphoid-committed cell of origin toward a hybrid,  
drug-resistant hematopoietic state. Drug response profiling of matched patient-derived xenografts revealed a distinct profile for 
TCF3-HLF ALL with resistance to conventional chemotherapeutics but sensitivity to glucocorticoids, anthracyclines and agents in 
clinical development. Striking on-target sensitivity was achieved with the BCL2-specific inhibitor venetoclax (ABT-199).  
This integrated approach thus provides alternative treatment options for this deadly disease.
Genomics and drug profiling of fatal TCF3-HLF−positive 
acute lymphoblastic leukemia identifies recurrent 
mutation patterns and therapeutic options
One of the hallmarks of pediatric ALL is the presence of subtype-
defining chromosomal translocations that cause gene fusions involv-
ing master regulators of hematopoietic development. These initiating 
lesions often cooperate with specific somatic aberrations, including 
monoallelic deletions of B cell developmental genes, such as PAX5, 
IKZF1 and EBF1 (ref. 1). Other cooperative liaisons are represented 
by trisomy 21q22 with CRLF2 activation2–4 or near-haploid ALL 
with activation of receptor tyrosine kinase or RAS signaling5. RAS 
pathway mutations appear in high-risk ALL but are often lost with 
disease progression, which suggests involvement of additional tum-
origenic factors6,7. The patterns of recurrent genomic alterations 
need to be better understood, because apart from tyrosine kinase 
inhibitor−supplemented treatment of BCR-ABL1−positive ALL, the 
only proven successful first-line treatment strategies for high-risk 
ALL are chemotherapy intensification and early allogeneic hemat-
opoietic stem cell transplantation8.
The translocation t(1;19)9 that results in a fusion of the transcrip-
tional activation domain of the B cell developmental transcription fac-
tor TCF3 to the DNA-binding domain of PBX1 occurs in about 5–10% 
of precursor B cell (pre-B cell) ALL patients and is associated with a 
median five-year event-free survival probability of 78–85%10. In con-
trast, the translocation t(17;19)(q22;p13), resulting in the fusion gene 
TCF3-HLF, defines a rare subtype of ALL (<1% of pediatric ALL) that 
is typically associated with relapse and death within two years from 
diagnosis11,12. Both translocations disrupt one allele of TCF3, which 
drives the B cell differentiation program upstream of the transcrip-
tion factor PAX5 (ref. 13). As an initiating event, expression of TCF3-
HLF leads to transcriptional reprogramming in pre-leukemic cells. 
Possible direct targets of TCF3-HLF include the transcription factor 
gene LMO2, which is implicated in initiation of T cell ALL14,15, and 
the transcriptional repressor SNAI1 (SLUG), which regulates 
embryonic development and apoptosis16,17. Further targets have 
been proposed, including BCL2 (ref. 14). The TCF3-HLF fusion 
likely requires additional events to cause leukemia, because 
TCF3-HLF transgenic and knock-in mice did not recapitulate the 
human phenotype18,19.
Here we report that the genomic and transcriptomic landscape 
of TCF3-HLF−positive ALL differs markedly from TCF3-PBX1− 
positive ALL. The TCF3-HLF fusion likely occurs in B lymphoid pro-
genitors in the context of PAX5 haploinsufficiency and is associated 
with transcriptional reprogramming toward an immature, hybrid 
hematopoietic state. Drug response profiling in patient-derived 
xenografts, which maintained the genomic and global transcriptome 
landscapes of the corresponding primary leukemic samples, identi-
fied resistance patterns to drugs commonly used for the treatment of 
TCF3-HLF−positive patients. A general trait of TCF3-HLF−positive 
ALL in our study is extreme sensitivity toward the BCL2-specific inhibi-
tor ABT-199 (venetoclax), indicating new therapeutic options for this 
fatal ALL subtype.
RESULTS
The TCF3-HLF ALL patient cohort 
We applied high-throughput sequencing analysis integrating short 
and large insert size paired-end whole-genome, whole-exome and 
transcriptome sequencing to a discovery cohort consisting of five 
diagnostic pre-treatment samples of TCF3-PBX1–positive ALL 
(samples 1a–5a) and TCF3-HLF–positive ALL (samples 6a–9a and 
11a). As nontumor controls we used matched bone marrow sam-
ples collected after induction treatment for minimal residual disease 
(MRD) evaluation (maximum leukemic cell load ≤10−3; samples 
A full list of authors and affiliations appears at the end of the paper.
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1b–9b and 11b; Supplementary Table 1). 
For validation, we used additional DNA samples from seven 
TCF3-HLF–positive cases (diagnostic samples 10a, 12a, 13a, 14a, 15a, 
16a, 17a, remission samples 10b, 12b, 13b) and 24 TCF3-PBX1–positive 
cases (Supplementary Tables 2 and 3). In most cases TCF3-HLF–posi-
tive ALL responded to induction chemotherapy but remained MRD-
positive. Nine children included in this study died owing to disease 
progression and treatment-related toxicities within 2 years on average, 
and only one patient is in remission after a short follow-up time, reflect-
ing the dismal prognosis of TCF3-HLF–positive ALL.
TCF3 breakpoints suggest a committed lymphoid cell of origin
Consistent with previous reports20,21, all TCF3 translocation 
breakpoints were restricted to three hotspot regions (Fig. 1a,b and 
Supplementary Fig. 1). Those were associated with small non-
template nucleotide insertions indicative of terminal deoxynu-
cleotide transferase (TdT) activity characteristic of an early B cell 
stage (Supplementary Table 4). In TCF3, the breakpoints clus-
tered in close proximity to CpG elements in the absence of classi-
cal RAG consensus sequence sites (Supplementary Fig. 1), which 
is a characteristic feature of translocations that occur in lymphoid 
progenitors at the pro-/pre-B stage. This may represent illegitimate 
RAG-mediated recombination at cryptic sites, possibly in the context 
of deaminated CpG nucleotides as proposed for TCF3-PBX1 translo-
cations22. Consistent with the idea that TCF3-HLF fusion may occur 
at a lymphoid-committed rather than a pluripotent progenitor stage, 
we detected this translocation only in sorted pre-B cell populations 
containing leukemic cells but neither in stem cells nor in myeloid 
progenitor cells (Supplementary Fig. 2).
TCF3-HLF ALL and impaired pro– to pre–B cell transition 
Pre–B cell ALL is frequently associated with somatic copy number 
alterations affecting B cell developmental genes. PAX5 deletions 
are generally observed in 13% of ALL cases and in up to 28% of 
high-risk ALL23. We observed enrichment for monoallelic PAX5 dele-
tions in TCF3-HLF–positive ALL, identifying such events in 67% of the 
cases (Fig. 1c and Supplementary Table 2). Illegitimate RAG-mediated 
recombination appears to be implicated in the generation of such events 
in TCF3-HLF–positive ALL, given the close proximity to RSS motifs 
(Supplementary Table 5). In most samples without PAX5 deletion, we 
identified hemi- and homozygous deletions of VPREB1, which encodes 
a component of the surrogate light chain of the pre–B cell receptor 
(Fig. 1c and Supplementary Table 6), independent of the lambda light 
chain locus. VPREB1 deletions in pediatric ALL result in failure to 
form a viable surrogate light chain in the pre-B cell receptor, an event 
associated with lower overall survival24. In addition, we detected BTG1 
gene deletions in three of eight TCF3-HLF–positive cases without PAX5 
deletions (Supplementary Fig. 3a,b). BTG1 deletions occur frequently 
in ALL positive for ETV6-RUNX1 (19%) or BCR-ABL1 (26%) and may 
confer a proliferative advantage25. In contrast, we detected no deletion, 
but only a single PAX5 nonsense mutation in 29 TCF3-PBX1–positive 
cases (Fig. 1 and Supplementary Table 3). Our results indicate that 
cooperative genetic events affecting genes regulating the pro- to pre-B 
cell transition, in particular PAX5, BTG1 and VPREB1, but not IKZF1, 
are selected in TCF3-HLF–translocated cells. Other deleted genes asso-
ciated with pre-B cell ALL26 were JAK2 and CDKN2A/B (patient 7a and 
11a) and transcriptional regulators such as ERG, NCOR1, TOX, BACH2, 













































































































































































cFigure 1 Genetic lesions identified in pediatric 
TCF3-HLF– and TCF3-PBX1–positive ALL.  
(a) Breakpoints in TCF3, PBX1 and HLF  
cluster in genomic hotspot regions. Boxes 
correspond to exonic regions; arcs represent 
fusions in patient samples. (b) TCF3 breakpoints 
cluster in two TCF3 intronic regions: between 
exons 16 and 17 (type I) and between exons  
15 and 16 (type II). On the transcript level,  
type I translocations join TCF3 exon 16 to HLF 
exon 4, including inserted nontemplate and 
intronic sequences and new splice acceptor 
sites (patients 8 and 9). Type II translocations 
occur downstream of exon 15 and exclude  
TCF3 exon 16 from the fusion transcript 
(patients 6, 7 and 11). (c) Schematic  
of somatic structural and nucleotide  
variations in samples. TCF3-HLF–positive  
ALL is characterized by mutually exclusive 
PAX5, BTG1 and VPREB1 deletions and 
nonsynonymous nucleotide variations in TCF3 
(p.Asp561Val, ‘D561V’ in patient 8). Indel, 
insertion-deletion. Recurrently affected genes 
are indicated by bold symbols. (d) Models 
of wild-type and mutant TCF3 based on the 
crystal structure of TCF3 in complex with the 
transcription factors SCL, LMO2 and LDB1 
bound to DNA58. Upon LMO2 binding, bonds 
are formed between TCF3 and SCL, including 
a hydrogen bond (dashed line) between D561 
and R230, reducing the DNA binding capacity 
of the complex. Inset, D561V introduces a 
hydrophobic valine residue close  
to polar residues that may interfere with 
hydrogen bonding, thus altering the  
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Recurrent RAS pathway mutations in TCF3-HLF ALL
We identified only a few additional somatic alterations affecting protein- 
coding sequences in both TCF3-PBX1- and TCF3-HLF–positive ALL 
(Fig. 1c, and Supplementary Tables 6 and 7), involving among others, 
genes associated with pre-B cell ALL26 (TCF3, PAX5 and LEF1) and 
transcriptional and chromatin regulation (ZNF263, MLL2, HIST1H3A 
and C6orf89). We observed a prominent association of TCF3-HLF–
positive ALL with activating mutations in RAS signaling pathway genes 
(NRAS, KRAS and PTPN11), detectable in four of five discovery cases 
(Fig. 1c) and in three of five additional TCF3-HLF–positive validation 
samples (PTPN11 and SPHK1) (Supplementary Table 2). We identi-
fied no RAS pathway mutations in the TCF3-PBX1–positive discovery 
cohort and only one oncogenic NRAS mutation in the 24 TCF3-PBX1–
positive validation cases (Supplementary Table 3). NRAS and KRAS 
mutations were generally detected in subclones (Supplementary 
Table 7). We discovered a new fusion gene, KHDRBS1-LCK, due 
to an interstitial chromosomal deletion in one TCF3-HLF–positive 
sample (6a), triggering the overexpression of the LCK tyrosine kinase 
(Supplementary Fig. 4). This was also present in three of 74 randomly 
selected ALL samples, demonstrating that KHDRBS1-LCK fusion is 
recurrent in ALL (Supplementary Fig. 5). LCK is a drug target in 
RAS-dependent cancer cells that have higher LCK expression27, sug-
gesting a possible interplay with RAS-related signaling networks in 
TCF3-HLF–positive ALL. Oncogenic activation of LCK associated 
with t(1;7)(p34;q34) translocation had been reported in the T cell 
leukemia cell line HSB2 (ref. 28). Our data indicate a frequent associa-
tion of proliferation-driving mutations in TCF3-HLF–positive ALL in 
the context of stalled B cell differentiation.
Mutations affecting the second TCF3 allele in TCF3-HLF ALL
We identified a mutation in the basic helix-loop-helix region of 
TCF3 (p.Asp561Val, D561V, Fig. 1c,d) affecting the non-translocated 
chromosome in one TCF3-HLF–positive case (8a). Mutations at this 
position have been reported in sporadic Burkitt lymphoma29 and may 
reduce binding to its negative regulator ID3 (ref. 29). Based on available 
crystal structure data, p.Asp561Glu may affect the interaction of TCF3 
with the transcription factor SCL (also known as TAL1; Fig. 1d), 
possibly altering TCF3 protein complexes. We detected a second 
TCF3 mutation (p.Ser467Gly) in another TCF3-HLF–positive case 
(13a, Supplementary Table 2). The functional consequences of this 
mutation are currently unclear. We could not detect any somatic 
mutations in TCF3 by targeted sequencing of 1,033 unselected ALL 
patients from the European multicenter trial AIEOP-BFM ALL 
2000, suggesting a specific association with TCF3-HLF–positive 
ALL (Supplementary Table 8). Thus, deregulation of normal 
TCF3 function may also contribute to TCF3-HLF–positive ALL. 
Corroborating our findings, a recent study included a single TCF3-
HLF case, as part of a cohort comparing diagnostic and relapse 
ALL samples, which showed a PAX5 deletion and two mutations in 
TCF3 (p.His460Tyr and p.Gly470fs), all of which were conserved at 
relapse30. The relapse sample featured a VPREB1 deletion as well as a 
shift in subclonal mutations in NRAS (p.Gly12Asp and p.Gly12Val), 
reinforcing the idea of cooperative effects between TCF3-HLF, and 
alteration of PAX5 and VPREB1 gene dosage. Taken together, seven 
of 11 TCF3-HLF cases were hemizygous for PAX5, whereas five 
samples featured VPREB1 deletions (Supplementary Fig. 6).
Reprogramming toward a more immature state in TCF3-HLF ALL
Consistent with the occurrence of TCF3-HLF and TCF3-PBX1 trans-
locations in lymphoid precursors, both leukemia subtypes had in com-
mon a gene expression signature of B lymphoid cells (including PAX5, 
BLK, CD19, CD22, CD79B, TCF3, EBF1, VPREB1, RAG1, ROR1, BLNK 
and DNTT; Supplementary Tables 9 and 10), but differential expres-
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Figure 2 TCF3-HLF programs leukemia to a hybrid hematopoietic  
transcriptional state. (a) Heatmap of the 401 differentially expressed  
genes between the two ALL subtypes (edgeR, |log2(fold change)| ≥ 1,  
false discovery rate (FDR) ≤ 0.001). (b) Enriched hematopoietic  
stages in TCF3-HLF–positive (orange) and TCF3-PBX1–positive  
(green) ALL. Stages shown include hematopoietic stem cells (HSC),  
common myeloid progenitors (CMP), lymphoid-specified progenitors  
(GMP and MEP), neutrophils (NEUTRO), monocytes (MONO),  
multilymphoid progenitor (MLP), early T cell precursors (ETP),  
pro-B cells (PROB), T cells (TCELL) and B cells (BCELL). Gene set enrichment analysis was carried out using a Genomatix genome analyzer and gene set 
enrichment analysis (GSEA)77 (GSEA: FDR ≤ 0.02; Genomatix genome analyzer: adjusted P ≤ 0.02). The source of the significantly enriched gene sets is noted by 
the superscript: 1, curated gene sets of hematopoietic precursors31; 2, human immunologic gene signatures (MSigDB v4.0)32; 3, text mining−based tissue-specific 
gene sets78. (c) Enrichment plot for the HSC signature31. FDR, false discovery rate. NES, normalized enrichment score. (d) Components of the TCF3-HLF–positive 
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the two TCF3-translocated subtypes (Fig. 2a, 
and Supplementary Tables 11 and 12). 
In silico prediction of transcription factor 
binding sites in the corresponding promoter 
regions revealed enrichment for PBX (Z score 
= 3.72) and HLF (Z score = 2.99) binding 
motifs associated with TCF3-PBX1 and TCF3-HLF gene signatures, 
respectively (Supplementary Tables 13 and 14). Further, PBX1 and 
HLF were the only transcription factors among those with enriched 
binding motifs that were significantly differentially expressed between 
the two ALL subtypes, and between leukemia and remission samples. 
The chimeric HLF transcript was strongly induced in TCF3-HLF, 
but we detected no wild-type HLF expression. We predicted 39 
potential HLF targets, including the known target SNAI2 (SLUG)16, 
GPC4 and BMP3 involved in stem cell proliferation, which showed 
induced expression in TCF3-HLF samples (Supplementary Table 15). 
Other potential TCF3-HLF targets that regulate developmen-
tal programs and cell survival, such as LMO2 (ref. 14) and BCL2  
(ref. 14), were not predicted. However, their expression was increased 
in TCF3-HLF–positive ALL.
Gene set enrichment analysis using gene sets from sorted human 
hematopoietic stem cells and early progenitor populations31 as well 
as curated oncogenic (C6) and human immunologic (C7) signatures 
from MsigDB32 revealed an enrichment for stem cell and myeloid 
signatures in TCF3-HLF–positive ALL. In contrast, lymphoid fea-
tures were more prominent in TCF3-PBX1–positive ALL (Fig. 2b and 
Supplementary Table 16). The hematopoietic stem cell signature31  
ranked among the top gene sets enriched in TCF3-HLF–positive 
ALL (Fig. 2c and Supplementary Table 17). We obtained similar 
results using an independent method based on text mining anno-
tations (Fig. 2d, and Supplementary Tables 18 and 19). We also 
consistently detected high expression of the stem cell marker LGR5  
(ref. 33) in TCF3-HLF–positive ALL, suggesting a reactivation of imma-
ture features shared with other stem cell populations. Consistent with 
previous reports, the myeloid marker CD33 was expressed in TCF3-
HLF–positive blasts, which provides a target for antibody-directed 
therapy12,34. Other differentially expressed genes, such as BMP2  
(ref. 35), could present additional therapeutic targets.
Our results are consistent with a model in which TCF3-HLF arises 
in lymphoid cells and promotes transcriptional reprogramming 
toward a hybrid hematopoietic state. We also detected features of 
mesenchyme-derived tissues in TCF3-HLF–positive ALL, which 
may indicate a profound cellular reprogramming toward a drug-
resistant state.
Mutation profiles of TCF3-HLF ALL are conserved in xenografts
We generated leukemia xenografts in nonobese diabetic severe com-
bined immunodeficiency (NOD/SCID)/IL2rγnull (NSG) mice for all 
cases included in this study (Supplementary Table 20)36,37. We also 
established for the first time to our knowledge leukemia xenografts 
from follow-up samples with MRD, some with less than 0.1% ALL 
cells after induction chemotherapy (Fig. 3a, and Supplementary 
Tables 1 and 20). Leukemia and MRD engraftment was rapid with 
conserved and predictable kinetics for xenografts derived from the 
same patient (Supplementary Fig. 7), suggesting that no major adap-
tation to the mouse microenvironment was needed for proliferation. 
Most SNVs and intra-chromosomal deletions that had been present 
at diagnosis were conserved in the corresponding xenografts (Fig. 3b 
and Supplementary Table 7). Only deletions detected in the relapse 
sample 11c were not conserved in the corresponding xenografts, 
and a deletion in BTG1 emerged in one MRD-derived sample (7b, 
Supplementary Fig. 3c,d). A few mutations were lost in MRD or 
relapse xenograft samples, including GNB1 and DDX3X, indicating 
that these are probably dispensable or may cause drug sensitivity. 
Mutations in the RAS pathway were largely maintained in xenografts. 
However, the NRAS mutation p.Gln61His identified in the primary 
Figure 3 The genomic landscape of TCF3-HLF–  
and TCF3-PBX1–positive ALL is preserved  
in patient-derived leukemia xenografts.  
(a) Xenografts were established from  
cryopreserved patient samples at diagnosis  
(samples “a”), at follow-up with minimal  
residual disease (MRD, <1 leukemic cell in  
10,000 cells, samples “b”) or from disease 
progression (samples “c”) and subjected to  
whole exome and transcriptome sequencing  
as well as multiplex ligation-dependent probe  
amplification (MLPA). All available MRD  
samples from TCF3-HLF–positive cases were 
successfully engrafted. (b) Comparison of all 
transcriptionally expressed nucleotide variations 
and of selected recurrent deletions frequently 
found in pediatric ALL in corresponding patient 
(P) and xenograft (X) samples. Deletions and  
nucleotide variations are colored according  
to their frequency in the analyzed leukemic  
cell population. Deletion frequencies were 
calculated by integrating whole genome and 
whole exome sequencing data with MLPA data. 
Nucleotide variation frequencies were calculated 
by integrating whole genome, whole exome and 
transcriptome sequencing data. Recurrently 
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MRD sample 7b was not detected in the corresponding xenograft. 
Instead, we identified a heterozygous damaging mutation in KRAS 
(p.Lys147Glu) associated with Noonan syndrome38. In patient 9a, we 
identified two subclones displaying either a KRAS (p.Gly13Asp) or an 
NRAS (p.Gly12Ser) mutation. The corresponding xenograft retained 
only the KRAS mutated subclone. Thus, maintenance and acquisition 
of RAS pathway mutations in xenografts support the notion that they 
occur later during selection at a multiclonal level and confer a selec-
tive advantage in TCF3-HLF–positive ALL. No other SNVs emerged 
de novo in the xenografts. In summary, the molecular characteristics 
of both leukemia subtypes were largely conserved in the xenografts, 
confirming the validity of this model.
TCF3-HLF−associated gene expression is maintained in xenografts
Hierarchical clustering based on the gene signature specifying the two 
leukemia subtypes showed that the expression profile and the subtype 
specificity of the primary leukemia were maintained in the xenografts 
(Fig. 4). The genes most significantly upregulated in matched patient 
and xenograft samples from TCF3-HLF–positive leukemia specified 
stem cell features (Supplementary Tables 21 and 22). Similar to 
the case in patient samples, we detected features of mesenchyme-
derived tissues in xenografts derived from TCF3-HLF–positive ALL. 
TCF3-HLF–positive leukemias and xenografts displayed systematic 
downregulation of PAX5 expression to halved levels. Though mono-
allelic deletions of PAX5 were a prominent feature of TCF3-HLF–positive 
ALL, we also saw reduced expression in diploid cases, hinting at alter-
native molecular mechanisms. The recapitulation of this pattern in 
the xenograft samples enforces the notion that TCF3-HLF–positive 
leukemia emerges in a specific cellular context with reduced PAX5 
expression (Supplementary Fig. 8). The essential molecular fea-
tures of TCF3-HLF–positive samples were maintained in xenografts, 
providing a useful model of this disease.
Drug activity profiling of TCF3-HLF and TCF3-PBX1 ALL
To determine drug sensitivity and resistance profiles, we established 
ALL cocultures on human mesenchymal stromal cells under serum-
free conditions39. Both subtypes depend on stroma for survival 
(Supplementary Fig. 9). TCF3-PBX1–positive ALL had a higher 
proportion of cells in S phase than TCF3-HLF–positive ALL on 
such cultures, reflecting consistent biologi-
cal differences. By screening 98 bioactive 
agents, including many agents in clinical 
development (Supplementary Table 23), 
on an automated microscopy–based plat-
form, we unambiguously discriminated 
the two translocations based on their drug 
sensitivity profiles, using either single (log 
half maximal inhibitory concentration (IC50), 
Fig. 5a and Supplementary Fig. 10) or mul-
tiple response parameters (logIC50, log 90% 
effective concentration (EC90), logEC50 and 
area under the curve (AUC), Fig. 5b and Supplementary Table 24). 
To capture informative differences, we compared the responses of 
xenografts derived from TCF3-HLF–positive ALL to xenografts 
derived from other high-risk pre-B and T ALL patients on the same 
platform (Fig. 5c and Supplementary Table 25). This provided infor-
mation about the activity range of each drug on the respective ALL 
subtype. TCF3-HLF−positive cases were consistently more resistant 
to various drugs from the same class, including nucleotide analogs 
(for example, cytarabine), mitotic spindle inhibitors (for exam-
ple, vincristine), polo-like and aurora kinase inhibitors. Given the 
importance of cytarabine and vincristine in standard ALL therapy, 
the implications of these observations need to be further explored. 
TCF3-HLF−positive ALL was very resistant to dasatinib in this assay, 
whereas TCF3-PBX1−positive ALL responded well. This partly chal-
lenges a recent report40, which had proposed dasatinib as an alter-
native for the treatment of these leukemias based on strong in vitro 
activity in one TCF3-HLF– and ten TCF3-PBX1–positive primary 
ALL samples. However, in vivo studies will be required to verify these 
differences in drug response, as differences in cell-cycle activity may 
influence the pattern of response in vitro.
TCF3-HLF−positive ALL were sensitive to glucocorticoids (pred-
nisone and dexamethasone) and to other drugs that could be rele-
vant for the treatment of resistant ALL, including mTOR inhibitors, 
anthracyclines, bortezomib, the HSP90 inhibitor AUY922 and pano-
binostat. However, in spite of the good response of patients with 
TCF3-HLF–positive leukemia to prednisone therapy and the observed 
responsiveness of TCF3-HLF−positive ALL cells to glucocorticoids and 
anthracyclines that are commonly used in ALL treatment, patients who 
undergo this treatment relapse. Our transcriptome data suggested that 
resistance to apoptosis due to high expression of the anti-apoptotic 
oncoprotein BCL2 might promote cancer cell survival and constitute 
a druggable target (Supplementary Fig. 11). BCL2 is a putative tran-
scriptional target of TCF3-HLF14. Of note, PAX5, commonly deleted 
in our cohort, normally represses BCL2 transcription41.
TCF3-HLF ALL is extremely sensitive to the BCL2 antagonist 
venetoclax
To assess the role of BCL2 overexpression in TCF3-HLF–positive 
ALL and to provide preclinical evidence for therapeutic activity, 
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Figure 4 Major components of the gene 
expression signature of TCF3-HLF− and  
TCF3-PBX1–positive ALL are conserved in 
patient-derived xenografts. Hierarchical 
clustering of primary and patient derived 
xenograft (PDX) ALL samples based on the 
expression of the 401 genes of the signature 
defined with primary samples (Fig. 2) shows 
that xenografts clearly group with their 
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we tested the BCL2-targeting drug veneto-
clax (ABT-199) in our xenograft model 
(Fig. 5c). This BH3-mimetic compound is a 
highly specific small molecule inhibitor that 
competes with pro-apoptotic BCL2 family 
proteins for binding to BCL2, and shifts the 
balance of pro-death and pro-survival sig-
nals inside the cell in favor of cell death42. 
Venetoclax is in clinical development (phase II 
and III trials) for chronic lymphocytic leukemia and lymphoma, and 
holds promise for ALL and acute myeloid leukemia.
TCF3-HLF−positive ALL samples were more sensitive to 
venetoclax than TCF3-PBX1–positive samples (Fig. 6a), which 
correlated with higher BCL2 transcript and protein expression 
(Fig. 6b). A two-week treatment course of daily venetoclax adminis-
tration delayed leukemia progression significantly in ALL xenografts 
from three different TCF3-HLF–positive cases (Fig. 6c,d). Treatment 
of mice in the control arm that reached maximal leukemia burden 
resulted in very rapid reduction of the leukemic load (Fig. 6e). 
Xenografts from MRD or relapse remained sensitive to veneto-
clax (Supplementary Fig. 11). Profiling of primary cells from two 
additional cases with refractory ALL confirmed exquisite sensitiv-
ity to venetoclax (Supplementary Fig. 12). Combined treatment 
of patient-derived xenografts from patients 6–11 with venetoclax 
and either vincristine or dexamethasone indicated a potentially 
synergistic effect in some of those patients (Supplementary Fig. 13 
and Supplementary Table 26). Our data identified BCL2 depend-
ency in TCF3-HLF ALL as a druggable target, and illustrate 
how integration of drug response profiling and molecular genetic 
analyses can inform the development of innovative treatment 
strategies in patients with unmet therapeutic needs.
DISCUSSION
To our knowledge, a long-term cure has never been achieved for 
patients with TCF3-HLF–positive ALL. Our study revealed a recur-
rent pattern of TCF3-HLF accompanied by abnormalities that affect 
transcriptional regulation of lymphoid development. We found fre-
quent deletions of PAX5 and VPREB1 in association with TCF3-HLF, 
but did not detect deletions of Ikaros family members, which are com-
monly affected in ALL1,23. We also uncovered recurrent mutations 























































































































































baFigure 5 Drug activity profiling of TCF3-
translocated leukemia reveals relevant 
differences in drug sensitivity. (a) Unsupervised 
clustering based on the drug activity profile  
of 98 compounds (log IC50). Fitted values  
are provided in Supplementary Table 24 
(absolute IC50). Numbers identify the 
compounds shown in c. (b) Principal  
component analysis of the response  
variables IC50, EC50, EC90 and AUC 
(Supplementary Table 24) show TCF3-PBX1–
positive and TCF3-HLF–positive ALL in two 
distinct clusters. The separation of  
TCF3-PBX1–positive and TCF3-HLF–positive 
ALL is determined by responses to topoi-
somerases, BCL2 inhibitors, glucocorticoids  
and antimitotic agents, which correlate with the 
first three principal components. (c) Selection  
of drugs based on differences in sensitivity  
or resistance in TCF3-PBX1–positives and  
TCF3-HLF–positives. For comparison, the  
corresponding drug activity is indicated for  
25 additional ALL samples tested on the same 
platform, including standard risk (SR, n = 5), 
medium risk (MR, n = 4) and high risk  
(HR, n = 16) cases (Supplementary Table 25).  
Boxplots extend from the first to the third 
quartiles (hinges) of the response range for  
each compound. Whiskers correspond to values 
from the hinge to the lowest or highest values  
within 1.5× of the distance between the first  
and third quartiles, respectively. Drugs with 
differential activity include docetaxel, paclitaxel, 
vincristine, AT9283, barasertib, BI2536, torin-1,  
dasatinib, lestaurtinib and XL228 (P ≤ 0.05). 
Drugs which are active across the patients 
include doxorubicin, idarubicin, mitoxantrone, 
bortezomib, panobinostat, NVP-AUY922,  
ABT-199 (venetoclax) and navitoclax. Asterisks 
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lymphoid development, potentially impair-
ing structural interactions with other tran-
scription cofactors29. PAX5 expression was 
reduced by twofold in all TCF3-HLF–posi-
tive cases, underscoring the possibility of 
an interaction between TCF3-HLF, TCF3 
and PAX5. PAX5 is required for B lymphoid 
lineage commitment and maturation43, and 
is frequently deleted in high-risk ALL with 
complex patterns of copy number abnormali-
ties23. Similarly, deletions in IKFZ1, which is 
required for the development of B and T lymphoid lineages and has 
additional stem cell–like functions44, are detected both in high-risk 
BCR-ABL1–positive and −negative ALL, and in the more favorable 
ERG-altered ALL subtype45, but never in TCF3-HLF–positive ALL. 
We also detected focal deletions of VPREB1 in TCF3-HLF ALL, which 
may lead to a developmental arrest associated with lack of pre–B cell 
receptor formation and the resulting loss of negative feedback on 
RAG-mediated recombination46. VPREB1 deletions were present at 
a similar frequency compared to other high-risk ALLs, such as BCR-
ABL1–like and BCR-ABL1–positive ALL (~30–40% of cases)47 or 
hypodiploid ALL (~30%)24, associated with poorer overall survival in 
high-risk pre–B cell ALL patients24. However, specific ALL subtypes 
associated with good prognosis (for example, ETV6-RUNX1–positive 
ALL) also present high frequencies of VPREB1 deletions24, suggesting 
an important impact of the genomic context24. Thus, distinct patterns 
of association emerge that are likely to reflect important underly-
ing biological mechanisms. Based on our results, we propose that a 
reduction of PAX5 gene dosage constitutes a favorable context for the 
oncogenic activity of TCF3-HLF.
As observed for hypodiploid ALL5 and in subsets of MLL-rear-
ranged ALL48, we identified mutations in NRAS, KRAS and PTPN11 
in TCF3-HLF–positive ALL. In our xenograft models we detected var-
iable persistence of NRAS and a switch to KRAS mutations, indicating 
that RAS mutations are multiclonal and might not be strictly required 
for disease progression in TC3-HLF–positive ALL. Indeed, mutations 
in the RAS pathway are enriched at relapse in ALL7,30,48 but mostly in 
a subclonal pattern with losses or switches in NRAS and KRAS from 
diagnosis to relapse. These represent secondary events, possibly com-
pensating functional effects of the initiating events. Mutations in the 
RAS pathway might not represent optimal therapeutic targets, given 
their volatility and the potential to select for slower-proliferating, 
more resistant subclones. The TCF3-HLF gene expression signature, 
enriched for components of stem cell and myelomonocytic stages, was 
very similar among leukemias and maintained in xenografts, speci-
fying additional, novel markers associated with stem cell function, 
such as LGR5, which marks epithelial stem cells49 and embryonic 
and fetal hematopoietic progenitor cells in mice50. Thus, in analogy 
to experimental induction of pluripotent stem cells51,52, TCF3-HLF 
likely induces a whole set of factors that carry out reprogramming 
and leukemic transformation in the context of low PAX5 expression. 
Deletion of PAX5 in early B cell progenitors induced dedifferentiation 
to a state with myeloid and T cell potential43,53. Moreover, rescue with 
low-level expression of PAX5 in knockout mice generates a stalled 
biphenotypic B-lymphoid/myeloid state54. Together with an activating 
mutation in STAT5, PAX5 haploinsufficiency initiates ALL in mice41. 
Based on these data, we propose that the initiating TCF3-HLF fusion 
results in severe transcriptional reprogramming with dedifferentia-
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Figure 6 The BCL2 antagonist ABT-199  
(venetoclax) shows promising anti-leukemic  
activity in TCF3-HLF–positive xenografts.  
(a) In vitro dose response curves normalized 
against DMSO-treated controls. (b) Merged  
absolute reads per kilobase of exon model  
per million mapped reads (RPKM) values of  
xenografts derived from the same primary 
leukemia sample (top) and immunoblot for  
BCL2 (bottom) in patient-derived xenografts 
as indicated. Tubulin was used as a loading 
control. (c,d) In vivo response to ABT-199  
on TCF3-HLF–positive xenografts. Treatment 
(gray bars) with 100 mg kg−1 qd ABT-199  
(red) or with vehicle control (turquoise) were  
administered orally for 14 d (6–8 mice per 
treatment arm). Two treatment courses were  
administrated to xenograft 7a. For survival 
analysis an event was defined when at least 
25% of leukemic cells were detected by FACS 
(mCD45−hCD19+hCD45+) in the peripheral 
blood. Differences in the survival of mice 
receiving ABT-199 or vehicle control were  
determined by the Mantel-Cox test and verified 
by the Gehan-Breslow-Wilcoxon test. (e) Mice 
from the control arm of c,d were treated with 
ABT-199 when more than 50% of ALL cells 
were detected in the blood. Mean and s.d.  
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secondary cooperating lesions in early B cell differentiation genes 
including TCF3 and PAX5.
A central question remains pertaining to the cell of origin in dif-
ferent ALL subtypes. Our study provides important clues that should 
be further addressed using disease models. The molecular analysis 
of the TCF3-HLF and TCF3-PBX1 fusion gene breakpoints indicated 
that the TCF3-HLF, like the TCF-PBX1 translocation, originates in 
cells already committed to lymphoid differentiation. Furthermore, we 
found the associated somatic structural variants to be RAG-mediated, 
which is comparable to patterns identified recently in ETV6-RUNX1–
positive ALL, the most frequent pre-B cell ALL subtype, which is 
consistent with expression of RAG in TCF3-HLF–positive ALL55. We 
favor the hypothesis that the TCF3-HLF translocation occurs in a 
B cell progenitor and that the specific lineage context is constrained 
further in a restricted developmental stage by additional mutations. 
The detection of TCF3-HLF being restricted to leukemic cells sup-
ports this idea, although initiation in a more immature compartment 
cannot be formally excluded.
The molecular landscapes of TCF3-HLF–positive ALL were largely 
conserved in xenografts, providing a valuable, well characterized, 
model for preclinical testing. Drug activity profiling revealed that 
TCF3-HLF–positive cases were more resistant to several standard ALL 
drugs, such as nucleotide analogs (for example, cytarabin) and mitotic 
spindle inhibitors (for example, vincristine). We detected activity for 
other relevant drug classes, such as mTOR inhibitors, the proteasome 
inhibitor bortezomib, the HSP90 inhibitor AUY922 and the HDAC 
inhibitor panobinostat. The BCL2 inhibitor venetoclax (ABT-199)42 
was highly active in all TCF3-HLF–positive cases analyzed, which 
we confirmed using primary ALL cells from two additional cases 
with refractory disease. These results refine data obtained using the 
broader spectrum BH3 mimetic ABT-737 in TCF3-HLF–positive cell 
lines14. Given the activity of venetoclax also in other ALL subsets 
including immature T cell ALL (refs. 56,57 and our own unpublished 
data) and the lack of on-target thrombocytopenia caused by ABT-737, 
venetoclax should be explored for experimental therapy in refractory 
ALL in selected cases based on such functional data. Thus integrated 
genomic and functional analyses of TCF3-HLF–positive ALL provide 
insight into the molecular context and associated components and 
offer unprecedented possibilities to investigate new agents for the 
treatment of these children who currently lack effective therapeutic 
options.
URLs. Information on the two image processing programs used for 
in vitro drug screening and automated microscopy can be found at 
http://acc.ethz.ch/.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Sequencing data are available from the public 
POPGEN repository (2015-UFO-NG-1; Christian Albrechts University, 
Kiel) upon written request accompanied by a positive internal review 
board vote for research addressing leukemia-related questions. 
Sequencing data transfer can proceed upon positive review and 
signing of a material transfer agreement.
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Study individuals and sample selection. Samples and associated clinical 
information from patients included in sequencing and validation analyses were 
collected from different countries within the International BFM Study Group 
(I-BFM-SG). All patients were enrolled in multicenter trials on treatment of 
pediatric ALL conducted by individual member groups of the I-BFM-SG: 
the AIEOP-BFM study group (Austria, Germany, Italy and Switzerland), the 
FRALLE study group (France) and the United Kingdom (UK) National Cancer 
Research Institute (NCRI) Childhood Cancer and Leukemia Group59,60. All 
treatment trials were approved by the respective national institutional review 
boards, and informed consent for the use of spare specimens for research 
was obtained from study individuals, parents or legal guardians. The specific 
research project reported here was approved by the Ethics Committee of the 
Medical Faculty of the Christian Albrechts University, Kiel, Germany (vote 
D508/13). Depending on consent and availability of samples, all enrolled 
patients positive for the rare TCF3-HLF gene fusion were included. These 
patients were matched with TCF3-PBX1–positive patients.
Cell isolation and nucleic acid purification. Mononuclear cells were isolated 
by Ficoll-Paque gradient centrifugation (Pharmacia) from bone marrow or 
peripheral blood samples followed by extraction of nucleic acids according 
to standardized protocols using Qiagen DNA Blood Kits (Qiagen) for DNA 
and Qiagen RNeasy columns (Qiagen) for RNA. The quantity of nucleic acids 
was determined by spectrophotometry. DNA quality was assessed visually by 
inspection of agarose gel electrophoresis while RNA integrity was evaluated 
by using the Bioanalyzer 2100 (Agilent). Nucleic acids isolated from bone 
marrow aspirates collected in morphological remission served as individual 
germ-line surrogates/references.
Sequencing. Whole genome sequencing. For structural variants, Illumina v2 
mate-pair libraries with 5 kbp insert size and 2 × 101 bp reads were prepared 
from 10 µg of DNA and sequenced on the Illumina HiSeq 2000 platform 
(Illumina) to obtain a physical coverage of 30×. For copy number alterations, 
breakpoints and short variants (SNVs, short indels), Illumina TruSeq paired-
end libraries with 2 × 101 bp reads were prepared from 1 µg of DNA and 
sequenced on HiSeq 2000/2500 instruments to a coverage of 40× for reference 
samples and 80× for tumor samples.
Whole exome sequencing. To increase the sensitivity of detecting short 
variants in coding regions, 1 µg of DNA each from the diagnostic leuke-
mic and a corresponding remission sample of patients was used for whole 
exome sequencing. Whole exome capture employed a TruSeq enrichment kit 
(Illumina) and paired-end libraries with 2 × 101 bp reads on a HiSeq 2500 
according to the manufacturer’s protocol.
Whole transcriptome sequencing. Illumina TruSeq custom stranded paired-
end libraries with 2 × 51 bp reads were prepared from 1 µg RNA using the 
Ribo-Zero Gold Kit (Epicentre) and sequenced on a HiSeq 2000 with a loading 
of one library per lane.
Sanger sequencing validation. Structural variant breakpoints from 
whole-genome sequencing approaches and SNVs from exome sequencing were 
validated by Sanger sequencing.
Targeted sequencing of TCF3 and RAS pathway candidate genes. TCF3 
binding domain (E47 isoform, exon 18) mutations were screened for in 
1,033 ALL patients using Sanger sequencing. Primer sequences are listed in 
Supplementary Table 27. Sanger sequencing was also applied for validation 
of relative absence of RAS pathway mutations in 24 TCF3-PBX1–positive ALL 
samples. The latter analysis included KRAS exon 1, NRAS exons 1 and 2, FLT3 
exons 14 and 20, PTPN11 exons 3 and 13, and was conducted as described61.
Multiplex ligation-dependent probe amplification. Detection of genomic 
aberrations in B cell differentiation−associated and other genes frequently 
deleted in ALL (PAX5, IKZF1, ETV6, RB1, BTG1, EBF1, CDKN2A, CDKN2B 
and P2RY8-CRLF2) were investigated by the Multiplex Ligation-dependent 
Probe Amplification (MLPA) assay SALSA p335 kit (MRC-Holland) using 
125 ng of genomic DNA. The assays were performed according to the manu-
facturer’s protocol as described62. An intensity ratio between 0.75 and 1.3 was 
considered to represent normal copy number, a ratio between 0.25 and 0.75 
was considered a monoallelic deletion and a ratio <0.25, a biallelic deletion.
Bioinformatics analysis. DNA data processing. DNA reads were aligned to 
the human reference genome hg19 (downloaded from the UCSC Genome 
browser) using Elandv2 (ref. 63; mate pairs) and BWA64 (paired ends). For 
xenograft samples, the human DNA reads were deconvoluted after mapping 
to a combined reference consisting of human hg19 and mouse mm9.
Structural variant detection. Structural variants were detected using DELLY65 
and BIC-seq66 (DNA data) and TopHat2 (ref. 67) /deFuse68 (RNA data).
SNV detection. Somatic protein-changing SNVs were detected using estab-
lished pipelines incorporating GATK69, MuTect70, pibase71, Picard, SAMtools72 
and VarScan2 (ref. 73).
Indel detection. Somatic indels in coding regions were detected using 
SAMtools followed by Dindel74.
Transcriptome data analysis. RNA reads were aligned to hg19 using 
BWA and SAMtools and used for integrated data analysis. For xenograft 
samples, the human RNA reads were deconvoluted after mapping to a 
combined reference consisting of human hg19 and mouse mm9. Mapped 
reads were annotated using Ensembl v.70. Gene expression levels were quanti-
fied in reads per kilobase of exon model per million mapped reads (RPKM)75. 
RPKM calculation and differential gene expression (DGE) analysis was 
performed using the R package edgeR76. To identify DGE between ALL 
subtypes, and between leukemia and remission the following set-up was 
performed: TCF3-PBX1 vs. TCF3-HLF (comparison 1), TCF3-PBX1 vs. 
remission (comparison 2), TCF3-HLF vs. remission (comparison 3). The 
results were filtered by fold change (FC, |log2(FC)| ≥ 1) and false discovery 
rate (FDR, FDR ≤ 0.001). The final list of 401 genes was created by 
combining the intersection between comparison 1 and comparison 2 as well 
as between comparison 1 and comparison 3. The functional analyses of gene 
lists were done using gene set enrichment analysis (GSEA)77 and the Genomatix 
genome analyzer (v. 3.00801; Genomatix Software GmbH). The GeneRanker 
tool in Genomatix was used to test for enriched gene sets, which were 
based on gene-tissue annotations obtained by text mining78. For GSEA, pro-
tein-coding genes were filtered by a minimum expression of 1 RPKM in at 
least four samples among the primary pre−B cell ALLs. The remaining 11,315 
genes were tested for DGE between the ALL subtypes using edgeR. The 
provided FDR and fold-change values were used to obtain a ranking score 
to measure the degree of differential expression between the ALL subtype. 
A pre-ranked classic GSEA was performed using the ranking score, a gene set 
permutation and a FDR ≤ 0.02. The analysis included gene sets for hematopoi-
etic stages31 and signatures from MsigDB77 pathways (C2): KEGG, BIOCARTA, 
REACTOME; curated oncogenic signatures (C6); human immunologic 
signatures (C7).
In silico transcription factor binding site (TFBS) analysis. TFBSs in pro-
moter regions of genes (2 kbp upstream region) corresponding to the spe-
cific transcriptome signatures of TCF3-PBX1- and TCF3-HLF–positive ALL, 
respectively, were analyzed using the Genomatix Genome Analyzer (v3.10124). 
Based on a matrix of known TFBS motifs, the software tool predicted TFBSs 
in the investigated promoters and compared their frequency against (i) the 
background of TFBSs in the promoter regions of all known protein-coding 
genes in the Ensembl database (v.70, 22864 genes) and (ii) the background 
of TFBSs in the whole genome. A Z score was calculated based on the TFBS 
frequency in the investigated promoters and the expected frequency and s.d. 
were estimated from the background79. The resulting lists were filtered by the 
Z scores based on the two backgrounds (|genomic Z| ≥ 2, promoter Z ≥ 2). 
TFBSs overrepresented in genes upregulated in both TCF3-PBX1- and TCF3-
HLF–positive ALL were filtered out, to retain only TFBS specifically enriched 
in the respective subtypes.
Integrated data analysis. SNVs and indels were orthogonally validated by 
integrating genome, exome and transcriptome data of patients and xenografts, 
and further confirmed by Sanger sequencing. Structural variants were vali-
dated by integrating whole genome paired-end and mate-pair data and 
whole-transcriptome data, and finally by Sanger sequencing. Ensembl v.70 
and ANNOVAR80 were used to annotate the variants. Silent variants and 
known germline variants in the 1000 Genomes Project81 population data, in 
136 North German healthy controls (publicly available through GrabBlur82), 
or in the International Cancer Genome Consortium’s internal healthy controls 




































Preclinical characterization. Xenograft model. Animal experiments were 
approved by the veterinary office of the Canton of Zurich, Switzerland. 
Approval for experiments with human samples in the mouse xenograft model 
was obtained from the ethics commission of the Canton Zurich (approval 
number 2014-0383). In brief, primary ALL cells were recovered from cryop-
reserved samples and transplanted intrafemorally to NSG mice as previously 
described36. Mice were 5−10 weeks old; both males and females were randomly 
used. Leukemia progression was monitored by flow cytometry with rat anti-
mouse CD45 (eFluor450, clone 30-F11, REF 48-451-82, eBioscience), mouse 
anti-human CD45 (Alexa Flour 647, clone HI30, REF 304018, BioLegend), 
and mouse anti-human CD19 (PE, clone HIB19, REF 302208, BioLegend). 
ALL cells recovered from spleens of NSG mice were used for molecular 
characterization in in vitro and in vivo experiments.
Immunophenotyping. Immunophenotyping of patient and xenograft-
amplified human ALL cells after recovery from the spleen was performed as 
described before84. All included xenograft samples consisted of at least 95% 
human leukemic cells.
Cell culture. Human hTERT immortalized primary bone marrow mesenchy-
mal stromal cells (MSC; provided by D. Campana, St. Jude Children’s Research 
Hospital, Memphis, USA) were cultured in RPMI 1640 medium supplemented 
with 10% heat-inactivated FBS; l-glutamine (2 mM), penicillin/streptomycin 
(P/S; 100 IU/ml) and hydrocortisone (1 µM). Xenograft-amplified human ALL 
cells were co-cultured on MSC in AIM V medium (Gibco by Life Technologies) 
at a ratio of 10:1. All cultured cells were kept in the incubator at 37 °C, 5% 
CO2. For cryopreservation, cells were frozen in heat-inactivated FBS with 10% 
dimethylsulfoxide and subsequently stored in liquid nitrogen.
Cell viability assay. MSCs were seeded in 24-well plates at a number of 50,000 
cells per well in RPMI 1640 medium (10% heat-inactivated FBS). After 24 h pri-
mary ALL cells were thawed and seeded as suspension culture alone or in co-culture 
with MSCs at a number of 400,000 cells per well in AIM-V medium. Three 
days later, ALL cells were collected from monoculture or co-culture by 
scraping and stained with 7-AAD (BD Pharmingen). Cell viability (7-AAD 
negative population) was measured by FACS using counting beads (SPHERO 
Accu Count Blanc Particles, Spherotech Inc.) for cell counts normalization. 
Viabilities shown are average viabilities of duplicate wells (normalized to 
input) and s.d.
Cell cycle assay. MSCs were seeded in 96-well tissue culture plates at a 
concentration of 10,000 cells per well in 100 µl AIM-V medium. After 24 h 
ALL cells were added at a concentration of 100,000 cells per well in 90 µl 
AIM-V. The Click-iTEdU Alexa Fluor 488 Flow Cytometry Assay Kit (Life 
Technologies) in combination with propidium iodide was used to measure 
proliferation and to identify the different phases of the cell cycle on days 1 
and 3. Co-cultured cells were incubated with EdU (10 µM) for 20 h before 
cell cycle read-out with flow cytometry. The cell cycle assay was performed 
in triplicate, and at least two independent experiments were performed for 
each sample. Similar variances were obtained between the groups that were 
statistically compared.
In vitro drug screening and automated microscopy. MSCs were seeded in 384-
well plates at a concentration of 2,500 cells per well in 30 µl AIM-V medium. 
After 24 h, ALL cells were added at a concentration of 25,000−30,000 cells per 
well in 27.5 µl AIM-V. Drugs were added as single agents after an additional 24 h 
using the pipetting robot epMotion 5070 (Eppendorf). Drug response was 
normalized to ALL cells treated with the drug vehicle alone. Experiments were 
performed in duplicate in five different dilutions (1, 10, 100, 1,000 and 10,000 
nM). For two samples comparable results were obtained in two independent 
drug screening experiments. After 72 h or 96 h of drug incubation, cells were 
stained using the CyQUANT direct cell proliferation assay (Life technologies). 
20 µl staining mix (AIM V medium, CyQUANT (1:300), repressor (1:20)) 
was added into each well followed by an incubation time of 1 h at 37 °C, 5% 
CO2. Subsequently, automated imaging was performed using the ImageXpress 
Micro microscope (Molecular Devices) equipped with a CoolSNAP HQ cam-
era (Photometrics) and a 10× plan fluor objective with 0.3 NA (Nikon). Nine 
images were taken per well, covering 50% of each well and captured employing 
the MetaXpress software (Molecular Devices). Images were processed using 
CellProfiler software (Broad Institute). Cells were classified and counted using 
the Advanced Cell Classifier software. This software uses random forest clas-
sification to assign ALL cells properly.
Immunoblot. Whole cell extracts were prepared from 1 × 106 cells using 
radioimmunoprecipitation assay (RIPA) buffer (20 mM Tris-Cl pH 7.5, 
150 mM NaCl, 1% NP-40, 1 mM EDTA pH 8.0, 0.1% SDS) supplemented with 
Complete mini protease inhibitor cocktail (Roche Life Science) for 20 min 
on ice, sonicated as necessary, and diluted with SDS loading buffer (250 mM 
Tris pH 6.8, 4% SDS, 0.02% bromophenol blue, 40% glycerol, 4% (vol/vol) 
β-mercaptoethanol). After SDS-PAGE, proteins were blotted onto nitro-
cellulose membranes. Membranes were blocked in 5% non-fat dry milk 
and incubated with primary Bcl-2 (clone 124; Dako) and tubulin antibod-
ies diluted 1:1,000 in milk. Horseradish peroxidase−labeled anti-mouse anti-
bodies were used for signal detection with chemiluminescence substrate and 
direct scanning.
In vivo experiments. ALL cells were recovered from cryopreserved xenograft 
samples, and per thawed sample 12 to 16 mice were transplanted with 
1,000,000 cells per mouse. After three days, randomized cohorts were treated 
with 100 mg/kg of ABT-199 (ABBVIE) or vehicle control with 6 to 8 mice 
per treatment arm85. ABT-199 or vehicle control were administered orally 
daily for two weeks. Mice of the ABT-199 group transplanted with sample 7a 
were additionally treated with a second block (100 mg/kg of ABT-199 for 14 d) 
starting at day 66, when the frequency of circulating leukemia cells started to 
increase again. Follow-up of circulating leukemia cells was performed every 
7 d by flow cytometry with rat anti-mouse CD45, mouse anti-human CD45, 
and mouse anti-human CD19; frequency of leukemia cells as ratio of mCD45- 
hCD45+ hCD19+ count to total lymphocytes. The investigator was blinded to 
the group allocation during the assessment of outcome. To evaluate the ability 
of ABT-199 to decrease tumor burden, four mice in the control group were 
treated when the frequency of leukemia cells in the peripheral blood was equal 
or higher than 50%. Follow-up of circulating leukemia cells was performed 
every 4−7 d. In vivo experiments were terminated when the frequency of cir-
culating leukemia cells reached 50% or earlier if the mice showed abnormal 
behavior. One in vivo experiment was performed per each sample.
Statistical analysis. Differences in the distribution of categorical variables 
among patient subsets were analyzed using Fisher’s exact or chi-squared test. 
Comparisons of continuous variables between groups were performed by t-test 
or Mann-Whitney U test.
Drug responses were evaluated by fitting DMSO-normalized response data 
with the four-parameter log-logistic function of the form:
f( ) = base + E base






as implemented in the drc package of R (version 2.3-96). Outliers were detected 
and removed before curve fitting using Bayesian change point analysis25  
(R package bcp, version 3.0.1). Non-convergent cases (for example, drugs with 
no activity) were identified based on linear fit parameters. Hierarchical cluster-
ing was performed to group patients according to their drug-response profiles 
(R package gplots version 2.14.2). Drugs with differential activity in patients 
with TCF3-PBX1– compared to TCF3-HLF–positive ALL were identified using 
a t-test (P ≤ 0.05). In in vivo experiments, 25% of circulating leukemia cells 
or termination of the experiment if 25% of leukemia was not reached were 
considered as an event in the Kaplan-Meier analysis. For sample 9a, 50% was 
used because of the rapid engraftment. Differences in the survival of mice 
receiving ABT-199 or vehicle control were determined by the Mantel-Cox test 
and verified by the Gehan-Breslow-Wilcoxon test.
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KEY	  POINTS	  
1. Drug	   response	   profiling	   reveals	   patient	   subgroups,	   such	   as	   BCL2-­‐dependent	   ALL,	   sensitive	   to	   new	  
agents	  that	  may	  be	  otherwise	  overlooked	  
2. Combining	  venetoclax	  with	  conventional	  ALL	  chemotherapeutics	  as	  dexamethasone	  and	  vincristine	  is	  





With	  the	  rapid	  development	  of	  new	  agents,	  more	  personalized	  approaches	  are	  needed	  to	  select	  patients	  with	  
chemotherapy	  resistant	  acute	  lymphoblastic	  leukemia	  (ALL)	  that	  may	  benefit	  from	  specific	  therapeutic	  options.	  
To	   complement	   information	   from	   existing	   diagnostic	   and	   genomic	   sources	  we	   developed	   a	   large	   scale	   drug	  
response	   profiling	   platform	   that	   is	   based	   on	   an	   established	   ALL	   co-­‐culture	   system	   on	   bone	  marrow	   stromal	  
cells,	  with	  the	  advantage	  of	  standardized	  conditions	  in	  serum-­‐free	  medium.	  	  Comparing	  the	  profiles	  of	  61	  ALL	  
samples	   enriched	   for	   relapsed	   and	   refractory	   ALL	  we	   identified	   informative	   patterns	   of	   drug	   sensitivity	   and	  
resistance.	   As	   a	   proof	   of	   concept,	   we	   focused	   on	   the	   striking	   response	   patterns	   to	   the	   BCL2-­‐specific	   BH3-­‐
mimetic	  venetoclax	  (ABT-­‐199).	  A	  relevant	  proportion	  of	  BCP-­‐ALL,	  including	  MLL-­‐AF4	  and	  TCF3-­‐HLF	  positive	  ALL	  
cases,	  and	  a	  subset	  of	  T-­‐ALL,	  were	  revealed	  to	  be	  highly	  sensitive	  to	  BCL2	  inhibition.	  Sensitivity	  to	  venetoclax	  in	  
vitro	   correlated	   with	   anti-­‐leukemic	   activity	   in	   ALL	   xenografts	   in	   vivo.	   Moreover	   combination	   testing	   on	   our	  
platform	   indicated	   synergistic	   activity	   of	   venetoclax	   with	   conventional	   anti-­‐leukemic	   agents	   such	   as	  
dexamethasone	  and	  vincristine,	  and	  with	  the	  new	  class	  BRD4	  inhibitors.	  In	  vivo,	  combination	  of	  venetoclax	  with	  
dexamethasone	  and	  vincristine	  completely	  prevents	  disease	  progression	  of	  very	  aggressive	  TCF3-­‐HLF	  ALL	  cases	  
when	   full	   relapse	  occurs	   in	   the	  control	  arms,	   comprised	  of	   single	  agent	  venetoclax	  or	  a	  dexamethasone	  and	  
vincristine	   combination	   treatment.	   Drug	   activity	   profiling	   should	   be	   evaluated	   prospectively	   in	   the	   clinical	  
setting	  to	  inform	  more	  personalized	  strategies	  to	  treat	  patients	  with	  resistant	  disease.	  
	  
INTRODUCTION	  
The	   treatment	  of	   relapsed	  and	   refractory	  ALL	   remains	   challenging,	  particularly	   for	   T-­‐ALL,	  on	  which	   the	  most	  
recently	   developed	   immunotherapies	   cannot	   be	   applied
1
.,With	   the	   progress	   in	   the	  mapping	   of	   the	   genomic	  
landscape	  of	  ALL
2
,	  new	  actionable	  targets	  have	  emerged,	   including	  activated	  tyrosine	  kinases	   in	  different	  ALL	  
subgroups
3,4,5
.	  Integration	  of	  genomic	  data	  and	  detection	  of	  intracellular	  signalling	  activity	  in	  resistant	  disease	  
may	   yield	   biomarkers	   for	   targeted	   therapy,	   such	   as	   activating	  mutations	   in	   RAS
6,7
	   or	   IL7R
8
.	  Nonetheless	   and	  
despite	   the	   fact	   that	   genetically	   defined	   subgroups	   of	   patients	   are	   commonly	   identified	   in	   existing	   large	  
cooperative	  studies
1,9
,	  only	  in	  a	  limited	  number	  of	  cases	  does	  molecular	  definition	  lead	  to	  clinical	  application	  of	  
targeted	   therapeutics.	   Such	   high	   risk	   groups	   lacking	   druggable	   targets	   include	   rare	   subsets	   with	   genetic	  





	   or	   cases	  with	   failure	   of	   remission-­‐induction	   therapy
12
.	  Unfavourable	   risk	   groups	   are	  
defined	  based	  on	  protracted	  response	  to	  chemotherapy,	  measured	  by	  persistence	  of	  minimal	  residual	  disease	  
(MRD)
1,13
,	   which	   is	   also	   a	   prognostic	   factor	   for	   the	   treatment	   of	   relapsed	   ALL
14
.	   MRD	   facilitates	   the	  
identification	  of	  subgroups	  that	  might	  benefit	  from	  experimental	  intervention.	  For	  the	  further	  development	  of	  
personalized	  medicine,	  more	  detailed	  genomic	  and	  biological	  characterization	  will	  be	  required	  to	  obtain	  more	  
precise	  pre-­‐	  or	  co-­‐clinical	  rationales	  to	  guide	  treatment.	  
	  
Given	   the	  genetic	  diversity	   and	   the	   complexity	  of	  molecular	   circuitries	   in	  ALL	   it	  will	   be	   challenging	   to	  define	  
druggable	   targets	   based	   solely	   on	   genomic	   information.	   Indeed	   extensive	   studies	   using	   cancer	   cell	   line	  
panels
15,16
	  illustrate	  the	  complexity	  of	  cancer	  genomics	  and	  the	  challenge	  to	  predict	  drug	  activity	  based	  on	  this	  
information.	  We	  hypothesized	  that	  drug	  activity	  profiling	  of	  ALL	  may	  detect	  sensitivity	  that	  may	  otherwise	  be	  
overlooked	  without	  a	  priori	  information	  on	  the	  genetic	  lesions	  or	  activated	  pathways.	  Indeed	  drug	  profiling	  of	  
patient-­‐derived	   acute	  myeloid	   leukemia	   cells	   detected	   kinase	   inhibitor	   activity	   that	   could	   in	   a	   few	   patients	  
predict	   responses	   to	   these	   agents
17
.	   Leukemia	   cases	   with	   characteristic	   tyrosine	   kinase	   mutations
18
,	   and	   a	  
subset	   of	   ALL	   with	   tonic	   pre-­‐BCR	   signalling
19
	   have	   also	   been	   identified	   in	   inhibitor	   screens.	   Here,	   we	   take	  
advantage	  of	  an	  expanding	  repository	  of	  patient-­‐derived	  xenografts	  (PDX)	  that	  model	  clinically	  relevant	  patient	  
cohorts,	   including	   patients	   with	   relapsed	   and	   refractory	   disease
20-­‐24
	   to	   develop	   an	   in	   vitro	   drug-­‐testing	  
platform.	   We	   adapted	   a	   serum	   free	   ALL	   co-­‐culture	   system	   on	   h-­‐TERT	   immortalized	   human	   bone	   marrow	  
derived	   mesenchymal	   stromal	   cells	   (MSC)	  
25,26
.	   This	   system	   provides	   reproducible	   conditions	   to	   maintain	  
leukemia	   cells	   alive	   for	   drug	   testing.	   We	   and	   others	   have	   shown	   that	   the	   response	   to	   conventional	   anti-­‐
leukemic	   agents	   in	   vitro	   is	   more	   restricted	   in	   samples	   from	   patients	   with	   clinically	   more	   resistant	   disease	  
compared	  to	  patient	  with	   favourable	  response	  to	  therapy
17,18,27,21-­‐23,28,
.	  Drug	  responses	  are	  evaluated	  with	  an	  
automated,	   machine	   learning-­‐based	   process	   that	   monitors	   viable	   ALL	   cells.	   Here	   we	   show	   that	   informative	  
 3	  
differences	  in	  drug	  response	  profiles	  can	  be	  detected	  within	  ALL,	  pinpointing	  actionable	  targets.	  As	  a	  proof	  of	  
concept	   we	   detect	   several	   subgroups	   of	   BCL2	   dependent	   ALL	   through	   a	   remarkable	   sensitivity	   to	   the	   BH3	  
mimetic	  venotoclax	  (ABT-­‐199)	  
29
.	  This	  confirms	  and	  expands	  independent	  observations	  that	  were	  achieved	  via	  
molecular	  profiling
30,31
	  and	  illustrate	  how	  rapid	  drug	  profiling	  could	  be	  integrated	  in	  future	  clinical	  workflows	  to	  
improve	   individualized	   therapy	   decisions.	   Finally	   very	   strong	   anti-­‐leukemic	   activity	   of	   the	   combination	   of	  
venetoclax	  and	  dexamethasone	  in	  ALL	  cases	  that	  were	  pre-­‐selected	  based	  on	  drug	  profiling	  illustrate	  how	  this	  





Human	   samples.	   Primary	   human	   ALL	   cells	   were	   recovered	   from	   cryopreserved	   bone	   marrow	   aspirates	   of	  
patients	  enrolled	   in	   the	  ALL-­‐BFM	  2000,	  2009	  and	  ALL-­‐REZ-­‐BFM	  2002	   studies.	   Informed	  consent	  was	  given	   in	  
accordance	  with	  the	  Declaration	  of	  Helsinki	  and	  the	  ethics	  commission	  of	  the	  Kanton	  Zurich	  (approval	  number	  
2014-­‐0383).	   Samples	   were	   classified	   as	   standard	   risk	   (SR),	   medium	   risk	   (MR),	   high	   risk	   (HR),	   very	   high	   risk	  




In	  vitro	  drug	  profiling	  platform.	  The	  in	  vitro	  drug	  response	  of	  ALL	  primary	  patient	  samples	  was	  assessed	  
in	   coculture	   with	   hTERT-­‐immortalized	   primary	   bone	   marrow	   mesenchymal	   stromal	   cells	   (MSC)
20
	   as	  
described	   previously
22
.	   Cell	   culture,	   drug	   library	   logistics	   and	   imaging-­‐based	   cell	   viability	   analysis	   are	  
described	  in	  the	  supplementary	  method	  section.	  
	  
Drug	  response	  quantification	  and	  statistical	  analysis.	  A	  fitting	  routine	  based	  on	  the	  four-­‐parameter	  log-­‐logistic	  






as	   implemented	   in	   the	   R	   the	   drc	   package	   (version	   2.3-­‐96)	   was	   applied	   to	   data	   normalized	   against	   DMSO-­‐
treated	  samples.	  Outliers	  were	  detected	  and	  removed	  prior	  to	  curve	  fitting	  by	  detecting	   local	  changes	   in	  the	  
slope	  with	   a	   linear	   fit.	  Non-­‐convergent	   cases	   (e.g.	   drugs	  with	   no	   activity)	  were	   identified	  based	  on	   linear	   fit	  
parameters.	  Hierarchical	  clustering	  was	  performed	  to	  group	  patients	  according	  to	  their	  drug	  response	  profile	  (R	  
package	  gplots).	  Drugs	   that	  determined	  data	  variance	  and	  clustering	  were	   identified	  by	  principal	   component	  
analysis.	   Differential	   responses	   of	   patient	   groups	   of	   interest	   to	   drugs	   were	   evaluated	   by	   using	   the	   non-­‐
parametric,	  one-­‐tailed	  Mann-­‐Whitney	  U-­‐test.	  
	  
Code	  availability.	  Fitting	  functions	  are	  available	  as	  R	  codes	  under	  https://github.com/pampernickel/Fit.funcs	  
	  
RESULTS	  
Reproducible	   drug	   response	   profiles	   can	   be	   established	   from	   primary	   ALL	   cells	   using	   an	   automated	  
microscopy	  based	  platform	  	  
To	  generate	  drug	  activity	  profiles	  from	  diagnostic	  patient	  material	  within	  one	  week	  we	  opted	  for	  co-­‐cultures	  on	  
hTERT-­‐immortalized	  MSC	  derived	   from	  normal	  human	  bone	  marrow	  cells
26
	   combined	  with	  an	   imaging-­‐based	  
cell	   viability	   readout	  on	  a	   customized,	  high-­‐throughput	  analysis	  platform
21
	   (Figure	  1).	   This	   system	  provides	  a	  
simple	   model	   of	   the	   tumour-­‐microenvironment	   and	   should	   support	   B-­‐cell	   precursor	   (BCP-­‐)	   and	   T-­‐ALL	   cell	  
survival	   in	  a	  majority	  of	   cases	  without	   the	  need	  of	  more	  complicated	  adjustments	  of	   cell	   culture	   conditions.	  
Contact	  with	  stroma	  cells	  may	  also	  confer	  more	  protection	  from	  the	  effect	  of	  therapeutic	  agents	  thus	  possible	  
providing	  a	  more	  stringent	  platform	  for	  drug	  testing
32
.	  We	  obtained	  drug	  response	  profiles	  of	  patient-­‐derived	  
primary	  ALL	  cells	  from	  61	  cases	  (Table	  S1)	  for	  a	  selection	  of	  60	  compounds	  (Table	  S2)	  either	  in	  preclinical	  and	  
clinical	  development,	  or	  already	  approved	  for	  other	  indications.	  Drug	  response	  profiles	  were	  analysed	  with	  an	  
integrated	  routine,	  including	  customized	  scripts	  that	  handle	  data	  normalization,	  outlier	  removal,	  dose	  response	  








curve	   fitting	  and	  statistical	  analysis	  of	  extracted	   fit	  parameters	  such	  as	   the	  area	  under	   the	  curve	   (AUC),	  half-­‐
maximal	   inhibitory	   concentrations	   (IC50)	   and	  maximum	  effect	   (Emax)	  measurements.	   The	  experiments	  were	  
performed	  starting	  from	  viably	  frozen	  aliquots	  of	  leukemia	  cells,	  which	  could	  serve	  as	  the	  reference	  database	  
for	   workflows	   that	   can	   be	   applied	   in	   the	   setting	   of	   international	   multicentre	   clinical	   trials.	   The	   61	   primary	  
samples	  (24	  T-­‐ALL	  and	  37	  BCP-­‐ALL	  cases)	  (Table	  S1)	  showed	  enhanced	  survival	  in	  MSC	  co-­‐culture	  compared	  to	  
suspension	  cultures	  on	  serum-­‐free	  medium,	  with	  a	  median	  cell	  viability	  of	  BCP-­‐ALL	  and	  T-­‐ALL	  after	  96	  hours	  on	  
MSCs	  of	  69%	  and	  94%	  of	  seeded	  cells,	  compared	  to	  1.2%	  and	  45.5%	  in	  monoculture	  (Figure	  2A).	  Some	  samples	  
(8/24	  T-­‐ALL	  and	  8/37	  BCP-­‐ALL	  cases)	  even	  exceeded	  the	  initial	  seeding	  density,	  indicating	  proliferative	  activity.	  
In	  all	  cases	  tested,	  13-­‐70%	  of	  cells	  were	   in	  S-­‐phase,	  with	  varying	  proportions	  of	  apoptotic	  cells,	  resulting	   in	  a	  
balance	  between	  proliferation	  and	  survival	  (Figure	  2B).	  These	  data	  support	  the	  amenability	  and	  robustness	  of	  
this	  system	  for	  functional	  studies	  by	  systematic	  drug	  profiling	  on	  primary	  human	  ALL.	  	  
	  
Informative	  differences	  are	  detected	  in	  drug	  response	  profiles	  from	  diagnostic	  pre-­‐treatment	  ALL	  cases	  	  
To	  capture	  characteristic	  drug	  responses	  on	  this	  platform,	  we	  established	  dose	  response	  profiles	  to	  a	  selection	  
of	   compounds	   using	   pre-­‐treatment	   diagnostic	   ALL	   samples	   from	   the	   cooperative	   ALL-­‐BFM-­‐2000	   study
33
,	  
enriched	   for	   high-­‐risk	   cases	   by	   MRD	   (Figure	   3).	   None	   of	   the	   tested	   compounds	   affected	   MSC	   viability	   at	  
concentrations	   lethal	   to	   ALL	   cells,	   indicating	   that	   our	   results	   are	   not	   compromised	   by	   a	   lethal	   effect	   on	   the	  
stromal	  component	  and	  that	  information	  on	  a	  potential	  therapeutic	  window	  can	  be	  captured.	  We	  detected	  	  
homogeneous	  anti-­‐leukemic	  activity	  for	  certain	  classes	  of	  drugs,	  including	  anthracyclines	  and	  the	  proteasome	  
inhibitor	   bortezomib.	   In	   contrast,	   there	  were	  marked	  differences	   in	   activity	   for	   other	   drug	   classes,	   including	  
infrequent	   but	   strong	   outlier	   activity	   for	   drugs	   that	   could	   be	   incorporated	   rapidly	   into	   salvage	   regimen.	   For	  
example,	  two	  T-­‐ALL	  cases	  responded	  well	   to	  dasatinib,	  while	  one	  BCP-­‐ALL	  and	  two	  T-­‐ALL	  cases	  responded	  to	  
imatinib	  in	  the	  low	  nanomolar	  range.	  Interestingly,	  the	  responses	  do	  not	  necessarily	  overlap	  with	  the	  dasatinib	  
response,	   suggesting	   distinct	   underlying	   molecular	   targets.	   These	   cases	   also	   responded	   to	   the	   broader	  
spectrum	   tyrosine	   kinase	   inhibitor	   XL-­‐228,	   suggesting	   the	   existence	  of	   relevant	   underlying	  molecular	   targets	  
that	  warrant	  further	  investigation	  in	  larger	  cohorts	  of	  ALL	  samples.	  In	  contrast,	  the	  three	  T-­‐ALL	  cases	  positive	  
for	  NUP-­‐ABL1	  translocations	  did	  not	  respond	  to	  dasatinib	  (IC50>10	  µM)	  and	  imatinib	  (IC50>10	  µM).	  Similarly,	  
strong	  but	  isolated	  activity	  was	  noticed	  for	  the	  IAP	  inhibitor	  LCL-­‐161,	  and	  the	  mTOR	  inhibitors	  temsirolimus	  and	  
PP242.	  As	  reported	  recently
19
	  TCF3-­‐PBX1	  rearranged	  ALL	  forms	  pre-­‐BCR+	  ALL	  with	  distinctly	  activated	  signalling	  
pathways	  and	  recognisable	  response	  to	  kinase	  inhibitors.	  In	  agreement	  with	  these	  published	  data,	  the	  six	  TCF3-­‐
PBX1-­‐positive	  BCP-­‐ALL	  cases	  in	  our	  panel	  showed	  sensitivity	  to	  dasatinib	  and	  XL-­‐228,	  but	  resistance	  to	  imatinib.	  
Moreover,	  when	   comparing	   two	   BH3-­‐mimetic	   agents	   that	   are	   in	   clinical	   development,	   navitoclax	   (ABT-­‐263),	  
which	   is	   directed	   against	   BCL2	   and	   BCL-­‐XL,	   and	   venetoclax,	   a	   selective	   BCL2	   inhibitor	   which	   was	   recently	  
developed	  to	  circumvent	  the	  on-­‐target	  BCL-­‐XL	  specific	  thrombocytopenia	  caused	  by	  navitoclax
29
.	  We	  detected	  
very	   strong	   activity	   of	   venetoclax	   in	   a	   subset	   of	   ALL	   that	   are	   also	   sensitive	   to	   navitoclax,	   indicating	   that	  
functional	  BCL2	  dependence	  could	  be	  detected	  by	  drug	  activity	  profiling	  in	  ALL.	  
Of	  note,	  hierarchical	  clustering	  of	  the	  drug	  response	  profiles	  suggest	  two	  major	  groups	  within	  BCP-­‐	  and	  T-­‐ALL,	  
whose	  separation	  is	  driven	  by	  differences	  in	  response	  to	  antimetabolites	  (cytarabine,	  gemcitabine),	  antimitotic	  
drugs	   (vincristine,	   docetaxel),	   the	   aurora	   kinase	   inhibitors	   AT9283	   and	   barasertib,	   and	   the	   Polo-­‐like	   kinase	   I	  
inhibitor	   BI-­‐2536.	   This	   indicates	   differences	   related	   to	   cell	   cycle	   regulation.	   Indeed,	   drugs	   targeting	   cycle	  
activity	  (docetaxel,	  6-­‐thioguanine,	  gemcitabine	  and	  cytarabine,	  topotecan,	  ZM-­‐447439	  and	  barasertib)	  showed	  
higher	  activity	  in	  samples	  with	  higher	  cycling	  activity	  as	  measured	  by	  fraction	  of	  cells	  in	  S-­‐phase	  (Figure	  S1,	  p-­‐
value	   <	   0.05).	   These	   observations	   will	   have	   to	   be	   considered	   for	   data	   interpretation	   in	   future	   correlative	  
studies.	  Drug	  response	  profiles	  were	  highly	  reproducible	  in	  biological	  replicates	  (Table	  S3).	  Our	  results	  further	  
suggest	  that	  drug	  profiling	  may	  capture	  individual	  heterogeneity	  in	  drug	  responses,	  and	  could	  identify	  clinically	  
relevant	  vulnerabilities	  in	  ALL	  on	  a	  more	  personalized	  basis.	  
	  
Novel	  anti-­‐leukemic	  activity	  can	  be	  identified	  in	  defined	  ALL	  subgroups	  with	  resistant	  disease	  
Given	   that	   absolute	   differences	   in	   dose	   responses	   between	   different	   drugs	   do	   not	   necessarily	   reflect	   their	  
respective	  pharmacodynamics	  and	  therapeutic	  range	   in	  vivo,	   it	  is	  important	  to	  compare	  drug	  activity	  profiling	  
data	   to	   a	  database	  built	   on	   response	  profiles	   from	   similar	   experimental	   conditions	   for	   a	   large	   cohort	   of	  ALL	  
 5	  
cases	  over	  time.	  We	  tested	  six	  additional	  samples	  derived	  from	  patients	  with	  relapsed	  ALL	  that	  were	  refractory	  
to	   salvage	   therapy	   (refractory	   relapse,	   RR),	  who	  did	   not	   achieve	   a	   second	  or	   third	   remission	   and	  qualify	   for	  
inclusion	   in	  early	  clinical	   trials.	  RR	  ALL	  exhibited	  a	  generally	  more	  resistant	   response	  phenotype,	   including	   to	  
chemotherapeutic	   agents	   used	   in	   ALL	   such	   as	   dexamethasone	   (5/6)	   cytarabine	   (4/6)	   and	   doxorubicin	   (3/6),	  
compared	  to	  other	  ALL	  cases.	  Patterns	  of	  sensitivity	  and	  resistance	  varied	  from	  case	  to	  case	  (Figure	  4A).	  RR	  ALL	  
cases,	  however,	  appear	  to	  be	  more	  sensitive	  to	  idarubicin	  and	  mitoxantrone,	  which	  are	  used	  more	  frequently	  
in	  the	  relapse	  setting
34,35
	  in	  relation	  to	  other	  ALL	  cases.	  Some	  of	  these	  samples	  were	  also	  very	  sensitive	  to	  new	  
agents	  in	  clinical	  development,	  such	  as	  barasertib	  (3/6),	  dasatinib	  (2/6),	  and	  bortezomib	  (3/6),	  suggesting	  that	  
this	  assay	  could	  provide	  additional	  information	  to	  select	  patient	  for	  candidate	  drugs.	  Of	  note,	  TCF3-­‐PBX1	  cases	  
were	  recently	  reported	  to	  be	  sensitive	  to	  dasatinib
36
,	  which	  again	   illustrates	  the	  potential	  of	   this	  platform	  to	  
detect	  functional	  entities	  (Figure	  4B).	  
	  
MLL-­‐AF4	  positive	  ALL	  represents	  a	  genetically	  defined	  subgroup	  of	  ALL	  with	  a	  particularly	  dismal	  outcome
37,38
.	  
All	  three	  MLL-­‐AF4	  positive	  cases	  showed	  a	  strong	  response	  to	  a	  number	  of	  interesting	  candidate	  compounds,	  
including	  the	  pan-­‐PI3K	  inhibitor	  buparlisib,	  the	  tyrosine	  kinase	  inhibitors	  dovitinib	  and	  midostaurin,	  and	  AKT1/2	  
inhibitors	   (Figure	   4A),	   consistent	   with	   the	   proposed	   susceptibility	   of	  MLL-­‐rearranged	   ALL	   to	   PI3K	   pathway	  
inhibition
39
.	  MLL-­‐AF4	  cases	  were	  also	  sensitive	  to	  other	  agents	  of	  clinical	  interest	  including	  molecules	  targeting	  
the	   P53/MDM2	   axis	   (Nutlin)	   shown	   to	   be	   active	   in	  MLL-­‐ALL	   xenografts
40
,	   and	   to	   the	   proteasome	   inhibitor	  
bortezomib,	   in	   agreement	  with	   Liu	   et	   al.
41
.	  We	   detected	   a	   strong	   activity	   of	   the	   BCL2-­‐specific	   BH3	  mimetic	  
venetoclax	  in	  all	  MLL-­‐AF4	  cases.	  Thus,	  as	  in	  MLL-­‐rearranged	  acute	  myeloid	  leukemia
42
,	  MLL-­‐AF4	  ALL	  appears	  to	  
be	  highly	  dependent	  on	  BCL2,	  providing	  a	  strong	  rationale	  to	   include	  this	  subgroup	  in	  a	  pediatric	  clinical	  trial	  
with	  this	  new	  agent.	  	  
	  
We	   also	   propose	   to	   systematically	   profile	   drug	   activity	   in	   relapsed	   T-­‐ALL,	   whose	   treatment	   remains	  
challenging
1
.	  24	  T-­‐ALL	  cases	   that	  are	   included	   in	   this	   study	  provide	  a	   framework	   for	   first	  experiments	   (Table	  
S1).	  These	  cases	  included	  mostly	  patients	  with	  high	  risk	  of	  relapse	  by	  MRD	  at	  first	  diagnosis,	  three	  T-­‐ALL	  relapse	  
cases	   that	  were	   refractory	   to	   relapse	   treatment	   and	   three	  matched	   first	   diagnosis	   and	   relapse	   cases	   (Figure	  
4A).	   We	   observed	   a	   broad	   range	   of	   drug	   responses	   across	   this	   sample	   set,	   with	   certain	   compounds	   as	  
idarubicine	  and	  mitoxantrone	  were	  relatively	  active,	  even	  more	  than	  doxorubicine,	   in	  T-­‐ALL	  relapse	  samples,	  
considering	   the	   general	   drug	   activity	   range	   in	   T-­‐ALL	   (Figure	   4A).	   A	   subset	   of	   T-­‐ALL	   relapse	   cases	  were	   very	  
sensitive	  to	  drugs	  that	  could	  be	  already	  used	  clinically,	  including	  the	  topoisomerase	  I	  inhibitor	  topotecan,	  which	  
is	  not	  used	  in	  standard	  regimens,	  barasertib	  which	  was	  also	  reported	  by	  others
43
,	  and	  dasatinib.	  Three	  ABL1-­‐
fusion	  negative	  T-­‐ALL	  cases	  were	  also	  highly	  sensitive	  to	  dasatinib,	  suggesting	  the	  existence	  of	  relevant	  albeit	  
unidentified	  underlying	  molecular	   lesions.	  Finally,	  strong	  activity	  of	  the	  BRD4	  inhibitor	  JQ1	  was	  observed	  in	  a	  
number	  of	  cases	  including	  relapses,	  again	  suggesting	  fundamental	  individual	  differences	  in	  T-­‐ALL	  that	  will	  have	  
implications	  for	  therapy.	  	  
	  
The	  BCL2-­‐specific	  inhibitor	  venetoclax	  is	  very	  active	  in	  several	  relevant	  ALL	  subsets	  
We	  detected	   significant	   venetoclax	   activity	   in	   a	   fraction	  of	   cases,	  which	   included	  TCF3-­‐HLF	   and	  MLL	   positive	  
BCP-­‐ALL,	   as	  well	   as	  other	  BCP-­‐ALL	  and	   several	   T-­‐ALL	   cases,	   corroborating	   recent	   reports
44-­‐46
	   (Figure	  5A).	  We	  
recently	   reported	   the	   genomic	   landscape	   of	  TCF3-­‐HLF	   ALL	   and	   showed	   very	   strong	   venetoclax	   activity	   in	   six	  
cases	  and	  in	  xenografts	  derived	  from	  residual	  disease	  after	  chemotherapy	  in	  matched	  samples
47
.	  These	  results	  
imply	  differences	  in	  BCL2	  and	  BCL-­‐XL	  dependence	  within	  T-­‐ALL.	  A	  recent	  study	  suggested	  a	  correlation	  between	  
T-­‐ALL	  maturation	   stage	   and	   sensitivity	   to	   venetoclax,	   with	   early	   T-­‐cell	   precursor	   ALL	   (ETP-­‐ALL)	   showing	   the	  
highest	  sensitivity
48
.	  We	  detected	  venetoclax	   responsive	  cases	  also	   in	  cortical,	  pre-­‐	  and	  mature	  T-­‐ALL	   (Figure	  
5B),	  extending	  data	  from	  an	  independent	  cohort	  of	  patients
46
.	  Furthermore,	  we	  found	  no	  correlation	  between	  
venetoclax	  sensitivity	  and	  mutations	   in	  NOTCH1,	  FBXW7,	  LEF1,	  STAT5,	   IL7R	  or	  PTEN	   (Figure	  3,	  Table	  S1).	  The	  
BCL2:BCL-­‐XL	  ratio	  was	  suggested	  as	  a	  determinant	  of	  sensitivity	  to	  venetoclax
48
.	  While	  all	  anti-­‐apoptotic	  BCL2	  
family	   proteins,	   BCL2,	   BCL-­‐XL	   and	  MCL-­‐1,	  were	  detected	   in	   T-­‐ALL	   samples	   (Figure	   S3),	   and	  BCL2	   levels	  were	  
found	  to	  be	   increased	   in	  TCF3-­‐HLF	  ALL
47
,	   	   the	  BCL2:BCL-­‐XL	   ratio	  did	  not	  always	  predict	   response	   (Figure	  5C).	  
 6	  
This	   suggests	   that	   in	   vitro	   drug	   testing	   results	   could	   complement	   suggested	  biomarkers	  of	   activity	   in	  patient	  
selection	  for	  early	  clinical	  treatment	  protocols	  that	  will	  include	  venetoclax.	  	  
	  
The	  response	  to	  venetoclax	  in	  vitro	  correlates	  with	  anti-­‐leukemic	  activity	  in	  xenografts	  
To	   explore	   the	   correlation	   between	   in	   vitro	   and	   in	   vivo	   responses	   to	   venetoclax,	   we	   compared	   treatment	  
results	   for	   three	   leukemia	  xenografts	  of	  cases	   that	  exhibited	  very	  strong,	   intermediate	  and	   low	  sensitivity	   to	  
venetoclax	   in	   vitro.	   (Figure	   6A).	   Xenografts	   treated	   with	   orally-­‐administered	   100	  mg/kg	   venetoclax	   delayed	  
leukemia	  progression	  in	  sensitive	  cases	  (IC50	  <	  100nM),	  but	  not	  in	  the	  non-­‐responder	  (Figure	  6B).	  Expectedly,	  
the	  T-­‐VHR-­‐03	  case,	  profiled	  with	  a	  low	  IC50	  (<1nM)	  and	  low	  AUC	  on	  our	  platform,	  showed	  a	  more	  prominent	  
response	  (HR=20,	  treated	  versus	  untreated,	  p<0.005)	   in	  vivo	  compared	  to	  the	  T-­‐HR-­‐11	  case	  (HR=0.07,	  treated	  
versus	   untreated,	   p<0.005),	  with	   low	   IC50	   (<100nM)	   but	   high	  AUC.	  Moreover	  we	   also	   observed	   very	   strong	  
venetoclax	  activity	  in	  mice	  with	  maximal	  leukemia	  burden	  (Figure	  6C).	  The	  sample	  T-­‐HR-­‐10,	  identified	  by	  drug	  
profiling	   as	   venetoclax-­‐resistant,	   did	   not	   show	   any	   response	   in	   vivo.	   We	   recently	   reported	   very	   similar	  




Drug-­‐screening	  platform	  can	  identify	  novel	  synergistic	  combinations	  of	  venetoclax	  and	  other	  drugs	  
As	  clinical	  activity	  of	  new	  agents	  is	  more	  likely	  to	  be	  detected	  in	  combination	  therapy	  in	  early	  clinical	  trials,	  we	  
adapted	  our	  workflow	  for	  combinatorial	  testing	  of	  selected	  compounds	  with	  venetoclax.	  We	  first	  evaluated	  six	  
T-­‐ALL	  cases,	  four	  of	  which	  were	  resistant	  to	  venetoclax	  at	  micromolar	  concentrations,	  and	  two	  were	  sensitive	  
at	   concentrations	   below	   100	   nm,	   corresponding	   to	   large	   differences	   in	   AUC	   (Figure	   S4).	  We	   used	   the	   AUC,	  
rather	   than	   IC50,	  as	   the	  AUC	  captures	  both	   IC50	  and	  Emax	  as	   relevant	  endpoints	  of	  drug	  activity.	  Given	   the	  
strong	  activity	  of	  venetoclax	  as	  a	  single	  agent,	  detection	  of	  synergy	  was	  challenging.	  More	  than	  additive	  effects	  
were	  detected	  in	  combination	  with	  vincristine	  (6/6	  cases),	  prednisolone	  and	  dexamethasone	  (5/6	  cases),	  and	  
topotecan	  (4/6	  cases).	  Additionaly,	  striking	  synergistic	  activity	  was	  detected	  for	  the	  combination	  of	  venetoclax	  
with	   the	   BRD4	   inhibitor	   JQ-­‐1	   and	  with	   the	   PI3K-­‐AKT	   inhibitor	   dactolosib	   (BEZ235)	   (Figure	   S4).	  We	   validated	  
these	  results	  in	  co-­‐titration	  matrices	  for	  optimized	  concentration	  ranges	  (Figure	  7A).	  For	  clinical	  translation,	  a	  
likely	  scenario	  would	  be	  to	  combine	  venetoclax	  with	  conventional	  chemotherapy	  for	  the	  treatment	  of	  relapse,	  
such	  as	  the	  UK-­‐ALL	  R3	  regimen,	  which	  includes	  vincristine,	  dexamethasone,	  mitoxantrone	  and	  asparaginase
34
.	  
Indeed	  venotoclax	  acts	  synergistically	  with	  vincristine	  or	  dexamethasone	  on	  selected	  venetoclax	  sensitive	  T-­‐ALL	  
and	  MLL-­‐AF4	  samples	  (Figure	  7B).	  Similar	  results	  were	  obtained	  for	  TCF3-­‐HLF	  ALL
47
	  
To	  model	  experimental	   therapy,	  we	  then	   tested	   the	  combination	  of	  venetoclax	  with	   the	  ALL	   induction	  drugs	  
vincristine	  and	  dexamethasone	   in	  vivo	   in	  TCF3-­‐HLF	  ALL,	  which	   is	   currently	   considered	   to	  be	   incurable,	   in	   the	  
leukemia	   xenograft	  model.	  Both	  venetoclax	  alone	  or	   treatment	  with	  vincristine	  and	  dexamethasone	  delayed	  
leukemia	   progression	   markedly,	   but	   the	   combination	   of	   the	   three	   drugs	   prevented	   leukemia	   progression	  
completely,	  beyond	  the	  effects	  detected	  in	  the	  control	  arms	  (Figure	  7C).	  Collectively	  our	  results	   indicate	  that	  
drug	   response	   profiling	   may	   provide	   important	   additional	   information	   on	   individual	   pharmacological	  
vulnerabilities	  in	  ALL	  and	  should	  therefore	  be	  further	  explored	  in	  the	  clinical	  setting.	  
	  
DISCUSSION	  
While	  excellent	  outcomes	  have	  been	  achieved	  with	  current	   treatment	  protocols,	   resistant	  disease	   remains	  a	  
major	  challenge	  in	  ALL
2
.	  Further	  intensification	  of	  conventional	  chemotherapy	  is	  unlikely	  to	  improve	  outcome,	  
and	   results	   in	   serious	   toxicity.	   Given	   the	   genetic	   complexity	   of	   ALL
49
,	   complementing	   genomic	   studies	   with	  
direct	  functional	  information	  from	  in	  vitro	  drug	  profiling	  may	  provide	  important	  new	  insights.	  Promising	  studies	  
have	   been	   reported	   recently	   for	   other	   hematologic	   malignancies
17,18
.	   We	   show	   that	   co-­‐culture	   on	   human	  
MSC
25,26
	  efficiently	  support	  a	  majority	  of	  primary	  ALL	  samples	  in	  serum-­‐free	  conditions,	  providing	  a	  reasonable	  
basis	  for	  standardization	  across	   laboratories.	  Taking	  advantage	  of	  a	   large	  repository	  of	  relevant	  PDX	  samples,	  
we	  have	  developed	  an	  automated	  microscopy-­‐based	  platform	  for	  monitoring	  effects	  of	  functional	  interference	  
in	  a	  simplified	  model	  of	  the	  bone	  marrow	  niche.	  We	  provide	  first	  evidence	  that	  informative	  differences	  in	  drug	  
response	   profiles	   can	   be	   detected	   in	   individual	   patient	   samples.	   While	   at	   first	   sight	   differences	   between	  
different	  ALL	  subgroups	  may	  not	  appear	  to	  be	  extensive,	  comparison	  of	   individual	  drug	  response	  patterns	  to	  
the	  data	  acquired	   for	  each	   small	  molecule	   tested	   in	  our	   large	   sample	   cohort	   identified	   recurrent	  patterns	   in	  
 7	  
distinct	  ALL	  subsets.	   Importantly,	   reproducible	   responses	   in	  specific	   subgroups	  were	   identified	   for	  drugs	   that	  
would	  not	  have	  been	  selected	  based	  on	  other	  criteria.	  Here	  we	   focus	  on	   the	   identification	  of	  ALL	  subgroups	  
that	  are	  highly	  sensitive	  to	  the	  BCL2-­‐specific	  inhibitor	  venetoclax	  (ABT-­‐199),	  suggesting	  a	  recurrent	  pattern	  of	  
BCL2-­‐dependency.	  
	  
The	  use	  of	  more	  selective	  BCL2-­‐family	  inhibitors	  may	  be	  effective	  in	  leukemia	  that	  depend	  on	  one	  of	  these	  anti-­‐
apoptotic	   regulators.	   Venetoclax	   does	   not	   convey	   the	   clinically	   limiting	   toxicity	   on	   thrombocytes	   that	   are	  
associated	  with	  on	   target	  BCL-­‐XL	   inhibition	  by	  other	  BH3-­‐mimetics
29
.	  However,	   venetoclax	   usage	  necessarily	  
implies	   the	  accurate	   identification	  BCL2-­‐dependent	   leukemias.	  We	   show	   that	   an	  appreciable	   subset	  of	   cases	  
that	  respond	  to	  the	  BCL2	  and	  BCL-­‐XL	   inhibitor	  navitoclax	  also	  respond	  to	  venetoclax	   in	  the	  nanomolar	  range,	  
including	  mostly	  BCP-­‐ALL	   subtypes,	  but	  also	   selected	  T-­‐ALL	  cases.	  We	   found	  striking	  activity	   in	  TCF3-­‐HLF	  ALL	  
and	  MLL-­‐AF4	   ALL,	   two	   genetically	   defined	   subtypes	   with	   poor	   outcome.	   We	   recently	   coordinated	   a	   large	  
consortium	  to	  study	  the	  genomic	  landscape	  of	  TCF3-­‐HLF	  ALL	  and	  have	  applied	  the	  platform	  described	  here	  to	  
detect	  a	  reproducible	  profile	  of	  drug	  sensitivity	  and	  resistance.	  Testing	  samples	  from	  a	  total	  of	  12	  cases	  with	  
TCF3-­‐HLF	  ALL	  and	  a	  control	  cohort	  of	  TCF3-­‐PBX1	  ALL,	  we	  detected	  very	  high,	  uniform	  sensitivity	  to	  venetoclax	  
in	   TCF3-­‐HLF	   ALL.	   This	   activity	   correlated	   with	   a	   delay	   in	   leukemia	   progression	   in	   vivo	   after	   single	   agent	  
treatment
47
.	  Here	  we	  provide	  strong	  additional	  preclinical	  evidence	  to	  support	  the	  idea	  of	  a	  more	  personalized	  
design	  for	  early	  clinical	  testing	  of	  venetoclax	  in	  ALL.	  We	  provide	  compelling	  evidence	  for	  venetoclax	  activity	  in	  
combination	   with	   two	   agents	   from	   the	   classical	   ALL	   four-­‐drug	   backbone	   regimen,	   vincristine	   and	  
dexamethasone.	  We	  found	  a	  number	  of	  cases	  sensitive	   to	  venetoclax	  on	  our	  platform,	   including	  all	  MLL-­‐AF4	  
cases	   that	  we	  tested,	  which	  responded	  within	  a	  comparable	  dose	  response	  range	  as	  TCF3-­‐HLF	  ALL.	  Both	  our	  
data	  and	  published	  data
48,46
	  strongly	  support	  integration	  of	  selected	  T-­‐ALL	  subsets	  in	  the	  clinical	  development	  
of	  venetoclax,	  provided	  a	  strategy	  is	  implemented	  to	  select	  patients	  based	  on	  drug	  response	  profiles	  and	  other	  
biomarkers.	  We	  confirm	  that	  venetoclax	  sensitive	  cases	  also	  respond	  to	  this	  agent	  in	  vivo.	  New	  agents	  are	  now	  
being	  increasingly	  tested	  early	  drug	  development	  in	  combination	  with	  a	  conventional	  chemotherapy	  backbone,	  
as	   in	   the	   successful	   case	   of	   bortezomib	   combined	   with	   a	   standard	   four	   drug	   ALL	   induction	   regimen
36,50
.	  
Venetoclax	   is	  currently	  being	   tested	   in	  combination	  with	  different	  agents	   for	  chronic	   lymphoblastic	   leukemia	  
and	   solid	   tumors
51,52
.	  Our	  data	   indicate	   that	   combination	  of	   venetoclax	  with	  established	  anti-­‐leukemic	  drugs	  
such	  as	  vincristine	  and	  dexamethasone	  will	  be	  of	  interest	  for	  a	  relevant	  subgroup	  with	  urgent	  medical	  needs.	  	  
	  
For	  clinical	  translation,	  a	  better	  understanding	  of	  the	  mechanisms	  involved	  in	  selective	  sensitivity/resistance	  to	  
BH3-­‐mimetics	  will	  be	  important.	  The	  interplay	  between	  the	  different	  BCL2	  family	  members	  and	  crosstalk	  with	  
other	  signalling	  pathways	  will	  however	  be	  difficult	  to	  capture	  with	  simple	  laboratory	  assays.	  The	  BCL2:BCL-­‐XL	  
expression	  ratio	  has	  been	  suggested	  as	  a	  predictive	  marker	  for	  venetoclax	  sensitivity
48
,	  but	  we	  have	  not	  been	  
able	  to	  detect	  this	  correlation	  in	  our	  series.	  As	  an	  alternative,	  BH3	  profiling	  using	  synthetic	  peptides	  has	  been	  
extensively	   investigated
53,54
.Recent	   access	   to	  more	   specific	   inhibitors	   of	   different	   BCL2-­‐family	  members	   now	  
provides	  a	  powerful	  and	  convenient	  alternative	  for	  functional	  profiling	  of	  cell	  death	  pathways	  in	  cancer.	  Such	  
an	   approach	   identified	   solid	   tumors	   sensitive	   to	   BCL2	   and	   BCL-­‐XL	   inhibition	   by	   navitoclax,	   but	   remained	  
selectively	   sensitive	   to	   BCL-­‐XL	   inhibition	   by	   a	   new	   specific	   inhibitor,	   which	   in	   combination	   with	   docetaxel,	  
prevents	   toxicities	   associated	   with	   the	   broader	   spectrum	   agent
52
.	   Thus	   integration	   of	   drug	   profiling	   should	  
provide	  important	  support	  to	  design	  and	  test	  new	  treatments.	  Combinatorial	  drug	  testing	  in	  vitro	  may	  provide	  
valuable	  additional	  information,	  but	  synergistic	  activity	  with	  small	  molecules	  that	  act	  potently	  as	  single	  agents	  
at	   low	   nanomolar	   concentrations	   such	   as	   navitoclax	   and	   venetoclax	   are	   difficult	   to	   detect	   in	   these	   assays.	  
Nevertheless	  we	   identified	   synergy	  between	   the	  BRD4	   inhibitor	   JQ1	  and	   venetoclax.	   JQ1,	  which	  provides	   an	  
interesting	  rationale	   for	   further	  evaluation,	  given	  the	   fact	   that	  BRD4	   inhibition	  was	  shown	  to	  modulate	  BCL2	  




Among	   intriguing	   outlier	   activities,	   we	   detected	   several	   cases	   that	   were	   very	   sensitive	   to	   dasatinib	   in	   the	  
absence	  of	   known	  ABL1-­‐rearrangements	   in	  T-­‐ALLs.	   Indeed,	  patients	  with	  mutations	   in	  activating	  kinases	  and	  
cytokine	   receptor	  pathways	   (so	  called	  BCR-­‐ABL1-­‐like	  ALL)	  may	  benefit	   from	  combination	  chemotherapy	  with	  
different	   tyrosine	   kinase	   inhibitors	   depending	  on	   their	  mutation	  patterns
4,56
.	  We	  have	  not	   yet	   identified	   the	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underlying	  molecular	  abnormalities	   in	   these	  cases,	  but	  our	  approach	  enables	  us	   to	  define	  a	   larger	  cohort	   for	  
molecular	  studies.	  In	  BCP-­‐ALL,	  activity	  of	  the	  dual	  ABL1/BTK-­‐SRC	  inhibitor	  dasatinib	  was	  detected	  in	  a	  Pre-­‐B	  Cell	  
Receptor	   signalling–dependent	   subset	   of	   ALL,	   including	   TCF3-­‐PBX1	   positive	   ALL,	   showing	   how	   pathway	  
interconnectivity	  can	  be	  further	  exploited	  therapeutically
57
.	  Accordingly,	  we	  detected	  dasatinib	  activity	  in	  TCF3-­‐
PBX1	  ALL	  cases	  on	  our	  platform	  (Figure	  4B).	  Based	  on	  the	  experience	  in	  BCR-­‐ABL1	  positive	  ALL,	  dasatinib	  can	  
readily	  be	  incorporated	  in	  current	  ALL	  regimens
58
.	  Furthermore,	  we	  see	  differences	  in	  activity	  for	  several	  drugs	  
that	   are	   immediately	   relevant	   in	   the	   context	   of	   clinical	   trials.	   These	   include	   variable	   responses	   to	  
anthracyclines,	  including	  mitoxantrone,	  a	  major	  component	  of	  current	  reinduction	  schemes	  for	  high	  risk	  ALL
34
	  
and	   to	   bortezomib,	   which	   will	   be	   investigated	   next	   in	   different	   settings	   for	   ALL
1
.	   It	   is	   therefore	   planned	   to	  
evaluate	   drug	   response	   profiling	   prospectively	   in	   the	   context	   of	   resistant	   disease	   using	   a	   selection	   of	  
therapeutic	  agents	  in	  order	  to	  establish	  cross-­‐laboratory	  standards	  and	  assess	  the	  potential	  clinical	  value	  of	  this	  
additional	   layer	  of	   functional	   information.	   Taken	   together,	  we	  provide	  proof	  of	   concept	  data	   that	   functional	  
profiling	  of	  patient	  samples	  with	  selected	  therapeutic	  agents	  will	  provide	  valuable	  insights	  for	  both	  preclinical	  
and	  clinical	  research.	  This	  approach	  is	  expected	  to	  contribute	  to	  the	  development	  of	  more	  precise	  strategies	  to	  
guide	  leukemia	  treatment	  for	  patients	  with	  resistant	  disease.	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FIGURE	  LEGENDS	  
Figure	  1.	  Workflow	  for	  co-­‐clinical	  drug	  response	  profiling	  of	  leukemia	  cells.	  	  
For	  large	  scale	  drug	  testing,	  co-­‐cultures	  with	  mesenchymal	  bone	  marrow	  stroma	  cells	  (MSCs)	  were	  established	  
to	  maintain	   primary	  ALL	   cells.	   An	   automated	  microscopy-­‐based	   image	   acquisition	   program	   that	   integrates	   a	  
machine	   learning	  algorithm	   for	  quantifying	  both	   live	  ALL	  and	  MSC	  cells	  was	  used	   to	  generate	  dose	   response	  
curves.	  The	  data	  was	  subsequently	  analysed	  with	  a	   toolkit	   that	  performs	  outlier	   removal,	   rapid	  curve	   fitting,	  
and	  extraction	  of	  different	  response	  parameters.	  The	  same	  platform	  can	  be	  used	  for	  analyzing	  combinatorial	  
drug	   testing	   results	   from	   co-­‐titration	   experiments.	   Systematic	   generation	   of	   xenografts	   provide	   a	  model	   for	  
functional	  validation.	  
	  
Figure	  2.	  MSCs	  provide	  adequate	  support	  for	  the	  majority	  of	  primary	  ALL	  cells.	  	  
(A)	  Cell	   viability	  analysis	  of	  T-­‐ALL	  and	  BCP-­‐ALL	   samples	  at	  day	  4	  normalized	   to	   seeded	  cell	  numbers	   shows	  a	  
significantly	  higher	  number	  of	   living	  cells	   in	  the	  co-­‐culture	  compared	  to	  suspension	  cultures	  using	  serum	  free	  
medium.	  Note	  that	  cell	  counts	  at	  day	  4	  are	  significantly	  higher	   in	  T-­‐ALL	   (n=22)	   than	  BCP-­‐ALL	   (n=25)	  samples.	  
****,	  p<0.0001	  (Paired	  t	  test).	  
(B)	  Analysis	  of	  cell	  cycle	  and	  apoptosis	  in	  T-­‐ALL	  samples	  (n=18).	  Rates	  of	  apoptosis	  and	  distribution	  of	  cell	  cycle	  
phases	  are	  displayed.	  Samples	  are	  ranked	  from	  highest	  (top)	  to	  lowest	  (bottom)	  survival.	  Viability	  was	  assessed	  
after	  4	  days	  in	  culture.	  
	  
Figure	  3.	  Drug	  response	  profiles	  of	  BCP-­‐ALL	  and	  T-­‐ALL	  cases.	  	  
Unsupervised	  hierarchical	  clustering	  of	  diagnostic	  BCP-­‐ALL	  (n=28)	  and	  T-­‐ALL	  (n=18)	  samples	  in	  co-­‐culture	  with	  
MSC	  according	  to	  their	  response	  (log[nM]	  IC50)	  to	  60	  compounds	  after	  72h.	  Compounds	  are	  arranged	  by	  target	  
classes.	   Sample	   information	   including	   translocations	   detected	   by	   FISH	   and	   mutations	   detected	   by	   targeted	  
sequencing,	  are	  summarized	  at	  the	  bottom.	  	  
	  
Figure	  4.	  Distinct	  drug	  activity	  patterns	  can	  be	  detected	  in	  specific	  sample	  groups.	  	  
(A)	  Selection	  of	  drugs	  with	  differential	  activity	  (log[nM]	  IC50)	  in	  refractory	  relapse	  (RR)	  (left	  panel,	  red,	  BCP-­‐ALL	  
n=3	   and	   T-­‐ALL	   n=3),	   MLL-­‐AF4	   rearranged	   ALL	   (middle	   panel,	   green,	   n=3)	   and	   T-­‐ALL	   (right	   panel,	   diagnostic	  
samples	  in	  blue,	  n=18;	  at	  relapse	  in	  orange,	  n=6),	  against	  a	  background	  of	  all	  other	  cases	  of	  the	  platform	  (grey,	  
total	  n=61).	  	  
(B)	  T-­‐ALL(blue,	  n=24)	  and	  TCF1-­‐PBX1	  (yellow,	  n=6)	  differential	  response	  (log[nM]	  IC50)	  to	  dasatinib.	  
	  
Figure	  5.	  The	  BCL-­‐2	  antagonist	  venetoclax	  is	  highly	  active	  in,	  MLL-­‐AF4,	  TCF3-­‐HLF	  and	  a	  subset	  of	  T-­‐ALL	  cases.	  	  
(A)	  In	  vitro	  response	  of	  T-­‐ALL	  samples	  (i,	  n=23),	  BCP-­‐ALL	  (ii,	  n=19),	  TCF1-­‐HLF	  (iii,	  n=4)	  and	  MLL-­‐AF4	  (iv,	  n=3)	  to	  
the	  BCL2	  inhibitor	  venetoclax	  in	  co-­‐culture	  on	  MSC.	  Cell	  viability	  was	  measured	  by	  flow	  cytometry	  using	  7-­‐AAD	  
72	  hours	  after	  treatment.	  Viabilities	  are	  normalized	  to	  DMSO-­‐treated	  controls.	  	  
(B)	  T-­‐ALL	  samples	  at	  different	  maturation	  stages	  based	  on	  EGIL	  criteria	  respond	  to	  venetoclax	  (log[nM]	  IC50).	  
(C)	  Mean	  ratio	  (+/-­‐	  SEM)	  of	  BCL2:BCL-­‐XL	  protein	  analysed	  by	  densitometry	  from	  two	  independent	  Western	  blot	  
experiments.	  ns.	  =not	  significant	  (p.val	  >	  0.05,	  two-­‐sided	  t-­‐test)	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Figure	  6.	  In	  vitro	  sensitivity	  to	  venetoclax	  correlates	  with	  in	  vivo	  response	  in	  xenografts.	  	  
(A)	  Response	  curves	  of	  three	  samples	  used	  in	  in	  vivo	  validation	  (red	  curves,	  sensitive	  samples	  with	  IC50	  at	  0.27	  
and	  50.1	  nM;	  blue	  curve,	  resistant	  sample	  with	  IC50	  at	  6166	  nM).	  	  
(B)	  Treatment	  with	  100	  mg/kg	  venetoclax	  administered	  orally	  delays	  leukemia	  progression	  in	  the	  two	  sensitive,	  







	  leukemia	  cells	  detected	  by	  flow	  cytometry)	  and	  the	  number	  of	  leukemia	  cells	  compared	  to	  
mouse	  lymphocytes	  over	  time	  (lower	  panel)	  are	  shown.	  Boxes	  shaded	  in	  grey	  indicate	  treatment	  blocks.	  	  
(C)	  Treatment	  of	  mice	  with	  overt	  leukemia	  (75%	  human	  leukemia	  cells	  in	  the	  peripheral	  blood)	  for	  two	  weeks	  
decreased	  leukemia	  burden.	  	  
	  
Figure	  7.	  Synergistic	  activity	  in	  vitro	  and	  in	  vivo	  of	  venetoclax	  with	  experimental	  and	  clinically	  relevant	  drugs.	  	  
(A)	   Representative	   examples	   of	   co-­‐titration	   assays	   for	   compounds	   detected	   to	   synergise	   with	   venetoclax	   in	  
preselected	  T-­‐ALL	  samples	  from	  initial	  combination	  screening.	  (i)	  topoisomerase	  I	  inhibitor	  topotecan,	  (ii)	  dual	  
PI3K	  and	  mTOR	  inhibitor	  dactolosib	  and	  (iii)	  BRD4	  inhibitor	  JQ1.	  	  
(B)	   Dose	   response	   curves	   are	   given	   for	   co-­‐titration	   assays	  with	   increasing	   concentrations	   of	   venetoclax	   and	  
dexamethasone	   or	   vincristine.	   Response	   curves	   representing	   the	   combination	   with	   three	   venetoclax	   doses	  
(concentrations	   indicated	   in	   color	   on	   the	   x-­‐axis)	   are	   shown.	   The	   area	   in	   which	   synergistic	   activity	   occurs,	  
defined	  based	  on	  Loewe	  additivity,	  is	  shaded	  for	  reference.	  
(C)	  Combination	  treatment	  of	  two	  TCF1-­‐HLF	  samples.	  Each	  treatment	  arm	  included	  six	  mice	  that	  were	  treated	  
as	   indicated.	   Kaplan-­‐Meier	   survival	   curves	   (upper	   panel,	   event	   defined	   as	   25%	   of	   mCD45-­‐hCD19+CD45+	  
leukemia	  cells	  detected	  by	  flow	  cytometry)	  and	  the	  number	  of	  leukemia	  cells	  compared	  to	  mouse	  lymphocytes	  
over	   time	  (lower	  panel)	  are	  shown.	  Vincristine	  was	  given	  on	  day	  1	  and	  8,	  Dexamethasone	  on	  d1-­‐5	  and	  8-­‐12,	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ABSTRACT	  
The	  glycophosphatidylinositol	  anchored	  surface	  protein	  Vanin-­‐2	  (VNN2,	  GPI-­‐80),	  which	  has	  been	  implicated	  in	  
leukocyte	  adherence	  and	  migration,	  identifies	  human	  fetal	   liver	  hematopoietic	  stem/	  progenitor	  cells	  (HSPCs)	  
with	   self-­‐renewal	   ability	   and	   is	   required	   for	   their	   hematopoietic	   function.	   Comparing	   the	   cell	   surface	  
glycoproteome	  of	  19	  acute	   lymphoblastic	   leukemia	  (ALL)	  samples,	  we	   identified	  VNN2	  as	  a	  unique	  feature	   in	  
patients	  with	  a	  very	  high	  risk	  of	  relapse	  by	  minimal	  residual	  disease.	  In	  a	  retrospective	  analysis	  of	  663	  patients	  
on	   the	  ALL-­‐BFM-­‐2000	   treatment	  protocol	  high	  VNN2	   transcript	   levels	  were	  associated	  with	  decreased	  event	  
free	   survival.	   We	   show	   in	   a	   subset	   of	   this	   cohort	   that	   VNN2	   detection	   by	   flow	   cytometry	   may	   serve	   as	   a	  
prognostic	  marker	  instead.	  Furthermore	  all	  of	  12	  TCF3-­‐HLF-­‐positive	  ALL,	  which	  defines	  a	  currently	  incurable	  ALL	  
subtype,	  were	  strongly	  surface	  VNN2,	  providing	  a	  simple	  procedure	  to	  preselect	  samples	  for	  specific	  diagnostic	  
testing.	  VNN2	  expression	  was	  not	  associated	  with	  other	  cytogenetic	  and	  copy	  number	  abnormality.	  	  Antibody	  
interference	   with	   VNN2	   resulted	   in	   delayed	   homing	   of	   ALL	   to	   the	   bone	   marrow	   of	   immunodeficient	   mice,	  
suggesting	  a	  potential	  role	  of	  VNN2	  in	  leukemia	  trafficking.	  Thus	  surface	  VNN2	  expression	  identifies	  TCF3-­‐HLF-­‐
positive	   ALL	   as	   well	   as	   subset	   of	   ALL	   with	   unfavorable	   biology	   that	   cannot	   be	   defined	   by	   other	   diagnostic	  
features	  and	  warrants	  prospective	  clinical	  investigation.	  	  
	  
INTRODUCTION	  
Therapeutic	   advancements	   combined	   with	   risk-­‐adapted	   treatment	   strategies	   have	   significantly	   improved	  
outcomes	   in	   patients	   with	   ALL.	   In	   pediatric	   ALL,	   overall	   cure	   rates	   are	   approaching	   85%,	   but	   there	   are	   still	  
subgroups	   for	  which	  prognosis	   is	   significantly	  worse	  and	  relapse	  ALL	   is	   still	  a	   leading	  cause	  of	  cancer-­‐related	  
deaths	   in	   the	   pediatric	   population.	   26%	   of	   B-­‐cell	   precursor	   acute	   lymphoblastic	   leukemia	   (BCP-­‐ALL)	   is	   not	  
associated	  with	  known	  genetic	  aberrations,	  but	  the	  remaining	  cases	  can	  be	  classified	   into	  genetically	  defined	  
subtypes	   such	   as	   ETV6-­‐RUNX1,	   TCF3-­‐PBX1	   and	   hyperdiploidy,	   which	   correlate	   with	   a	   favorable	   outcome,	  
whereas	   others,	   like	   the	   MLL	   rearrangements,	   BCR-­‐ABL1,	   and	   hypodiploidy,	   are	   associated	   with	   a	   poor	  
treatment	  response,	  and	  no	  patient	  survival	  for	  TCF3-­‐HLF-­‐positive	  cases.	  Although	  TCF3-­‐HLF-­‐translocation	  has	  
been	   already	   described	   in	   the	   90s	   (1,	   2),	   there	   are	   no	   established	  methods	   that	   allow	   its	   discrimination	   in	  
routine	  clinical	  test	  at	  diagnosis.	  Current	  treatment	  protocol	  stratifies	  ALL	  patients	  based	  on	  a	  combination	  of	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different	   approaches	   that	   consider	   clinical	   factors	   (immunophenotyping,	   age	   and	   white	   cell	   count),	   genetic	  
abnormalities	   and	   treatment	   response	   of	   the	   patient.	   So	   far	   expression	   patterns	   of	   markers	   determining	  
lineage	  and	  developmental	  stage	  of	  hematopoietic	  differentiation	  has	  been	  essential	  for	  the	  generation	  of	  the	  
current	  stratification	  schemes	  applied	  in	  the	  clinic	  at	  diagnosis.	  While	  in	  vivo	  response	  to	  treatment	  evaluated	  
through	   the	  molecular	   quantification	   of	  minimal	   residual	   disease	   (MRD)	   during	  ALL	   induction	   therapy	   is	   the	  
most	   powerful	   predictor	   of	   the	   risk	   of	   disease	   recurrence,	   but	   can	   be	   applied	   only	   after	   33	   days	   from	   the	  
beginning	  of	  the	  treatment.	   In	  the	  AEIOP-­‐BFM-­‐ALL	  2000	  (3)	  study	  15%	  of	  the	  patients	  were	  classified	  as	  High	  
Risk	  (HR)	  of	  relapse	  and	  the	  remaining	  cases	  were	  Intermediate	  (IR,	  42,6%)	  and	  Standard	  (SR,	  42,6%)	  risk.	  The	  
5-­‐year	  relapse	  rates	  of	  each	  MRD-­‐based	  risk	  group	  were	  2%	  in	  SR,	  22%	  in	  IR	  and	  80%	  in	  HR	  group.	  Therefore	  
current	   stratification	   scheme	   and	   survival	   rates	   data	   emphasize	   the	   need	   of	   new	   markers	   for	   the	   early	  
detection	  of	  HR	  cases	  and	  IR	  patients	  that	  relapse	  that	  constitute	  almost	  half	  of	  the	  BCP-­‐ALL	  patients	  (4).	  	  	  
These	   evidences	  underling	   the	  need	  of	   alternative	   approaches	   for	   the	   identification	  of	   IR	   and	  HR	   cases	   that	  
relapse,	  and	  patients	  with	  the	  incurable	  TCF3-­‐HLF	  genetic	  subtype	  at	  the	  day	  of	  diagnosis.	  
	  
Here	  we	  identify	  glycosylphosphatidyinositol-­‐anchored	  surface	  protein	  (GPI-­‐80	  also	  known	  Vanin2	  or	  VNN2)	  as	  
a	   novel	   promising	   prognostic	  marker	   for	   the	   identification	   at	   diagnosis	   a	   fraction	   of	   cases	  with	   high	   risk	   of	  
relapse	  and	  the	  resistant	  TCF3-­‐HLF-­‐positive	  ALL.	  We	  investigated	  the	  overall	  GPI-­‐80	  expression	  by	  ALL	  and	  its	  
clinical	  relevance.	  	  Data	  suggest	  that	  the	  implementation	  of	  GPI-­‐80	  flow	  cytometry	  analysis	  in	  the	  established	  
panel	   of	   the	   clinical	   immunophenotyping	   of	   ALL	  will	   provides	   new	   insights	   for	   the	   improvement	   of	   the	   risk	  
stratification	  of	  IR	  and	  HR	  for	  relapse	  cases	  and	  importantly	  for	  the	  resistant	  TCF3-­‐HLF-­‐positive	  ALL	  subtype.	  	  
	  
RESULTS	  
Detection	  of	  VNN2	  (GPI-­‐80)	  at	  the	  leukemia	  cell	  surface	  is	  associated	  with	  resistance	  to	  treatment	  
To	  identify	  cell	  surface	  markers	  that	  may	  be	  characteristic	  for	  resistant	  disease,	  we	  interrogated	  the	  cell	  surface	  
proteomes	   of	   19	   BCP-­‐ALL	   patient	   derived	   xenografts	   (PDX)	   that	   we	   had	   previously	   defined	   using	   the	   Cell	  
Surface	  Capture	   (CSC)	   technology	   (5).	  We	  compared	   the	   leukemia	   surfaceome	  derived	   from	  8	  BCP-­‐ALL	  cases	  
with	  a	  very	  high	  risk	  of	  relapse	  based	  on	  persistence	  of	  minimal	  residual	  disease	  after	  induction	  chemotherapy	  
and	   consolidation	   therapy	   (VHR-­‐ALL,	   week	   4,	   9	   and	   22	   on	   the	   ALL-­‐BFM	   treatment	   protocol	   (3,	   6-­‐9)	   and	   11	  
patients	   with	   an	   excellent	   clinical	   outcome	   (standard	   risk,	   SR-­‐ALL).	   To	   enrich	   for	   cell	   surface	   glycoproteins,	  
selective	   chemical	   tagging	  was	  performed	  on	   living	   cells	   that	  were	   then	   subjected	   to	   a	  workflow	   to	  prepare	  
tagged	   peptides	   from	   membrane	   fractions	   (5).	   By	   liquid	   chromatography-­‐tandem	   mass	   spectrometry,	   a	  
comparable	   number	   of	   peptides	   that	   can	   be	   matched	   to	   proteins	   were	   identified	   between	   VHR	   and	   SR	  
patients,	  on	  average	  5481	  in	  SR-­‐ALL	  and	  5714	  in	  VHR-­‐ALL	  (Figure	  1A	  and	  Supplementary	  Table	  1).	  Filtering	  this	  
dataset	  for	  proteins	  that	  are	  detected	  preferentially	  in	  VHR-­‐ALL	  resulted	  in	  the	  selection	  of	  13	  proteins	  (Figure	  
1A	  and	  Supplementary	  Table	  1).	  	  Remarkably,	  we	  found	  several	  surface	  proteins	  that	  are	  normally	  involved	  in	  
cell	   adhesion	   and	   migration,	   the	   glycophosphatidylinositol	   anchored	   surface	   proteins	   vanin-­‐family	   proteins	  
VNN1	  and	  VNN2	  (GPI-­‐80),	  the	   Ig-­‐like	  CEA	  family	  member	  CEAM1,	  the	  C-­‐type	   lectin	  receptor	  CD302,	  the	  sialic	  
acid	   binding	   Ig-­‐like	   lectin	   CD33	   and	   ITGAM	   (CD11b),	   which	   is	   also	   a	   subunit	   of	   the	   complement	   receptor	   3	  
(CR3).	   	   Furthermore,	   the	   receptors	   for	   activated	   complement	   CR1	   and	   CR2	   as	   well	   as	   components	   of	   pro-­‐
survival	   signaling	   pathways	   (TNR1B,	   IGF1R)	   were	   detected	   in	   VHR-­‐ALL	   cases.	   Notably,	   in	   3	   out	   4	   patients	  
expressing	   VNN2,	   ITAM	   is	   co-­‐expressed.	   This	   co-­‐expression	   of	   VNN2	   and	   ITGAM	   has	   recently	   been	  
demonstrated	  in	  self-­‐renewing	  human	  fetal	  hematopoietic	  stem	  cells,	  whereby	  RNA	  interference	  with	  VNN2	  or	  
ITGAM	  both	  impaired	  survival	  in	  vitro	  and	  engraftment/hematopoietic	  reconstitution	  ability	  in	  xenografts	  (10).	  
Public	  available	  microarray	  data	  (11)	  show	  a	  correlation	  of	  ITGAM	  and	  VNN2	  expression	  in	  ALL	  (Supplementary	  
Figure	  1),	  suggesting	  that	  these	  phenotypes	  may	  be	  functionally	  related.	  	  
	  
To	   validate	   the	  proteomic	   data	  we	   correlated	  RNA	  expression	  by	   quantitative	   PCR	   and	  protein	   detection	  by	  
flow	   cytometry	   for	   VNN2	   on	   an	   extended	   set	   of	   34	   ALL	   PDXs	   (Figure	   1B	   and	   Supplementary	   Table	   2).	   As	  
controls,	  we	  included	  peripheral	  blood	  cells	  from	  healthy	  donors	  that	  contain	  both	  positive	  (myeloid	   lineage)	  
and	  negative	  /	  lower	  positive	  subpopulations	  (T	  and	  B	  lymphocytes)	  (Supplementary	  Figure	  2),	  and	  a	  Jurkat	  cell	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line	  that	  we	  lentivirally	  transfected	  to	  express	  VNN2	  (Supplementary	  Figures	  3A).	  We	  validated	  the	  monoclonal	  
antibody	   3H9	   (anti-­‐VNN2)	   that	   was	   generated	   with	   extracts	   from	   neutrophils	   (12)	   using	   these	   assays	   and	  
established	  the	  criteria	  to	  define	  positive	  signals	  (Supplementary	  Figure	  4).	  We	  obtained	  similar	  results	  using	  a	  
second	   anti-­‐VNN2	   monoclonal	   antibody	   that	   was	   generated	   with	   recombinant	   human	   VNN2	   (clone	   04)	  
(Supplementary	   Figures	   3B	   and	   5).	  We	   included	   patient	   derived	   Xenografts	   (PDXs)	   from	   diagnostic	   samples	  
from	  patients	  with	  high	  risk	  (HR),	   intermediate	  risk	  (IR)	  and	  standard	  (low)	  risk	  (SR)	  of	  relapse	  based	  on	  their	  
minimal	  residual	  disease	  after	   induction	  chemotherapy.	  As	  expected,	  we	  found	  that	  higher	   levels	  of	  VNN2	   in	  
this	  cohort	  were	  found	  preferentially	  in	  HR	  and	  MR	  patients.	  Higher	  levels	  of	  VNN2	  transcripts	  correlated	  with	  
detection	  by	  flow	  cytometry	  (Figure	  1B,	  r=0.7796).	  Moreover,	  most	  of	  the	  MR	  and	  HR	  samples,	  17	  out	  of	  26,	  
and	  only	  one	  SR	  out	  of	  12	  samples	  were	  positive	  for	  VNN2	  by	  flow	  cytometry.	  Interestingly	  the	  single	  SR	  patient	  
that	  was	  positive	   for	  VNN2	  at	   diagnosis	   experienced	   a	   relapse	   (Table	   3).	   Importantly,	   detection	  of	  VNN2	  on	  
primary	  material	  remained	  stably	  detectable	  even	  after	  serial	  passage	  in	  NSG	  mice,	  indicating	  that	  this	  could	  be	  
driven	  by	  a	  leukemia-­‐intrinsic	  feature	  (Supplementary	  Figure	  6)	  
	  
VNN2	  positive	  ALL	  is	  a	  rare	  subset	  that	  includes	  the	  highly	  aggressive	  TCF3-­‐HLF-­‐positive	  ALL	  subtype	  
In	   our	   surfaceome	   dataset,	   one	   case	  with	   TCF3-­‐HLF	   positive	   ALL	   (B-­‐ALL-­‐09)	   had	   the	  most	   abundant	   spectra	  
corresponding	  to	  VNN2.	  The	  translocation	  t(17;19)(q22;p13),	  which	  results	  in	  the	  fusion	  gene	  TCF3-­‐HLF,	  defines	  
a	  rare	  subtype	  of	  ALL	  (<1%	  of	  pediatric	  ALL)	  that	  is	  typically	  associated	  with	  relapse	  and	  death	  within	  two	  years	  
from	   diagnosis	   (13,	   14).	   Remarkably,	   the	   same	   segment	   of	   the	   transcription	   factor	   TCF3	   is	   involved	   in	   the	  
translocation	  t(1;19)	  (15),	  which	  occurs	  in	  about	  10%	  of	  precursor	  B	  cell	  (pre-­‐B)	  ALL	  patients	  and	  is	  associated	  
with	  a	  five-­‐year	  event-­‐free	  survival	  of	  78-­‐85%	  (16).	  	  We	  recently	  described	  the	  genomic	  landscape	  of	  TCF3-­‐HLF-­‐
positive	  ALL	  as	  part	  of	  a	  research	  consortium	  and	  could	  show	  that	  TCF3-­‐HLF-­‐positive	  PDXs	  closely	  resemble	  the	  
original	  patient	  sample	  (17).	  Here	  we	  show	  that	  in	  all	  cases	  of	  TCF3-­‐HLF-­‐	  positive	  ALL	  we	  detected	  VNN2	  at	  the	  
cell	   surface	   both	   in	   PDXs	   and	   in	   diagnostic	   samples	   (Figure	   1B	   and	   1C).	   By	   proteomics,	   besides	   VNN2,	   we	  
detected	  VNN1,	   CR1	   and	   CR2	   strongly	   in	   the	  TCF3-­‐HLF-­‐positive	  ALL	   case.	   Interestingly,	  when	   comparing	   the	  
transcriptome	   of	   TCF3-­‐HLF-­‐positive	   ALL	   and	   TCF3-­‐PBX1-­‐positive	   ALL,	   VNN2	   expression	   correlates	   best	   with	  
higher	  expression	  levels	  of	  ITGAM,	  confirming	  our	  initial	  observations	  in	  the	  surfaceome	  that	  VNN2	  and	  ITGAM	  
provide	   a	   specific	   pattern	   (Figure	   1D).	   Co-­‐expression	  of	  VNN2	  and	   ITGAM	  could	  be	   validated	   in	   2	  TCF3-­‐HLF-­‐
positive	  cases	  by	  flow	  cytometry	  (Supplementary	  Figure	  7).	  Identification	  of	  TCF3-­‐HLF-­‐positive	  ALL	  has	  been	  a	  
challenge	   in	   the	   clinic,	   because	   the	   translocation	   is	   not	   always	   found	   by	   conventional	   cytogenetics.	   Since	   in	  
some	  cases,	  hypercalcemia	  occurs	   in	   this	  subtype,	   this	  has	  served	  as	  a	  useful	   indicator	   to	  perform	  additional	  
FISH	   studies	   to	   detect	   TCF3-­‐HLF-­‐positive	   ALL.	   Thus,	   detection	   of	   VNN2	   by	   flow	   cytometry	   will	   provide	   a	  
convenient	   and	   cost	   effective	   approach	   to	   select	   ALL	   cases	   for	   specific	   genetic	   testing	   of	   the	   TCF3-­‐HLF	  
translocation.	  	  
	  
Prospective	  pilot	  evaluation	  of	  VNN2	  as	  leukemia-­‐associated	  marker	  
To	  obtain	  a	  first	  indication	  of	  the	  frequency	  of	  VNN2	  positivity	  in	  ALL,	  we	  included	  VNN2	  in	  the	  diagnostic	  flow	  
cytometry	   panel	   of	   the	   Swiss	   national	   reference	   center	   for	   the	   clinical	   study	   AEIOP-­‐ALL-­‐BFM-­‐2009	  
(NCT01117441).	   Since	  April	   2012	  we	   included	   this	  marker	   for	   158	   patients	   and	   could	   detect	   8	   (5%)	   positive	  
cases	  (Table	  1).	  We	  confirmed	  a	  TCF3-­‐HLF	  translocation	  in	  one	  case	  within	  less	  then	  48	  hours	  based	  on	  this	  new	  
workflow.	   This	   has	   clinical	   implications	   given	   the	   importance	   to	   individualize	   treatment	   upfront	   for	   this	   ALL	  
subtype	  at	  urgent	  need	  for	  new	  treatment	  options.	  	  For	  TCF3-­‐HLF	  negative	  but	  VNN2	  positive	  cases,	  no	  other	  
recurrent	  genomic	   lesion	  could	  be	   identified.	  Extensive	  genomic	   studies	  will	  be	   required	   to	   clarify	   the	  driver	  
mutations	  that	  cause	  this	  phenotype.	  
	  
Higher	  VNN2	  transcript	  levels	  and	  VNN2	  detection	  on	  ALL	  cells	  are	  associated	  with	  a	  significant	  increased	  risk	  
of	  relapse	  
Having	  established	  that	  transcript	   levels	  correlate	  with	  protein	  detection	  by	  flow	  cytometry,	  we	  performed	  a	  
retrospective	  analysis	  on	  a	   selected	   cohort	  of	  663	  pediatric	  ALL	  patients	   that	  were	   treated	  on	   the	  ALL-­‐BFM-­‐
2000	  protocol	  (3,	  9).	  Quantitative	  PCR	  could	  be	  performed	  on	  n=209	  SR-­‐ALL,	  n=345	  IR-­‐ALL	  and	  n=109	  HR-­‐ALL	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cases	  in	  this	  retrospective	  cohort	  (Figure	  2A,	  Supplementary	  Table	  3).	  A	  striking	  observation	  was	  that	  very	  high	  
levels	  of	  VNN2	  transcripts	  were	  mostly	  detected	  in	  IR	  and	  HR	  ALL.	  Moreover,	  levels	  were	  higher	  on	  average	  in	  
IR-­‐ALL	   (1,076	   +	   0.1522,	   average	   +	   standard	   deviation;	   p-­‐value	   0.0073)	   and	   HR	   (2,502	   +	   0.6765,	   average	   +	  
standard	   deviation;	   p-­‐value	   0,0001)	   patients	   compared	   to	   SR-­‐ALL	   (0,5409	   +	   0.0444,	   average	   +	   standard	  
deviation).	  To	  explore	  the	  relevance	  of	  this	  observation	  with	  respect	  to	  outcome	  we	  determined	  a	  threshold	  to	  
define	   a	   VNN2	   high	   subclass	   using	   a	   univariate	   Cox	   model.	   Using	   a	   training	   set,	   a	   threshold	   value	   was	  
determined	  for	  VNN2	  expression	  corresponding	  to	  a	  normalized	  delta	  CT	  value	  of	  1.13	  (Figure	  2A,	  dashed	  line),	  
this	  parameter	  was	  validated	  in	  the	  second	  part	  of	  the	  cohort	  (Supplementary	  Figure	  8).	  Using	  this	  threshold,	  
57%	   if	   HR-­‐ALL,	   27%	   of	   IR	   ALL	   and	   12%	   of	   SR-­‐ALL	   were	   defined	   as	   positive.	   The	  median	   event-­‐free	   survival	  
probability	   of	   VNN2-­‐high	  ALL	  was	   significantly	   lower	   than	   the	   EFS	   of	   the	   rest	   of	   this	   cohort	   (Supplementary	  
Figure	  8),	  EFS	  n=99,	  34	  event	  vs.	  n=377,	  60	  events	  respectively,	  p=	  0,0001).	  The	  strongest	  effect	  was	  seen	  in	  the	  
IR-­‐ALL	  subgroup	  (Figure	  2B,	  p=0.0089),	  and	  in	  the	  SR	  group	  p=0.0019,	  (Supplementary	  Figure	  9A).	  Interestingly	  
in	   HR-­‐ALL,	   VNN2-­‐high	   cases	   did	   not	   experience	  more	   relapse	   than	   the	   remainder	   of	   the	  HR	   patients	   in	   this	  
cohort	   (p=0.49,	   Supplementary	   Figure	   9B).	   The	   HR-­‐ALL	   group	   is	   stratified	   to	   receive	   more	   intensive	   post-­‐
induction	  chemotherapy	  on	  the	  ALL-­‐BFM-­‐2000	  protocol.	  	  Based	  on	  this	  observation	  it	  is	  possible	  that	  treatment	  
intensification	  will	  not	  be	  of	  benefit	  for	  this	  group	  of	  patients	  and	  that	  a	  better	  understanding	  of	  the	  underlying	  
biology	  will	  be	  require	  to	  inform	  clinical	  strategies.	  
	  
VNN2	   is	   expressed	   at	   different	   levels	   by	   normal	   lymphocytes	   and	   myeloid	   cells	   (Supplementary	   Figure	   2),	  
therefore	   flow	   cytometric	   analysis	   is	   required	   to	   specifically	   assess	   the	  expression	  of	  VNN2	  by	  blasts.	   In	   our	  
retrospective	  gene	  expression	  analysis,	  the	  blast	  percentage	  in	  the	  sample	  was	  not	  detected	  as	  a	  confounder	  
(Supplementary	  Table	  3).	  We	  next	  set	  out	  to	  explore	  whether	  VNN2	  detection	  by	  flow	  cytometry	  could	  provide	  
a	  more	  stringent	  identification	  of	  ALL	  cases	  at	  risk	  with	  a	  retrospective	  pilot	  experiment.	  We	  retrieved	  frozen	  
samples	  from	  42	  cases	  that	  were	  defined	  as	  positive	  based	  on	  RNA	  expression	  data	  and	  analyzed	  surface	  VNN2	  
expression	  by	  flow	  cytometry	  gating	  on	  viable	  cells	  after	  thaw.	  	  
To	   define	   positivity,	   we	   used	   the	   approach	   that	   was	   developed	   by	   an	   international	   task	   force	   for	  
immunophenotyping	  of	  ALL	  at	  diagnosis	   ((18)	   and	  Supplementary	  Figure	  4).	   Frequency	  of	   the	  VNN2	  positive	  





	   control	   can	  express	   low	   level	  of	  VNN2.	  Samples	  with	  a	   frequency	  of	  VNN2	  positive	   cells	  
higher	  than	  10%	  were	  considered	  positive.	  The	  workflow	  and	  proportion	  of	  samples	  that	  could	  be	  included	  in	  
the	  analysis	  are	  summarized	  in	  the	  Supplementary	  Figure	  10.	  From	  42	  samples	  that	  could	  be	  retrieved	  in	  this	  
approach,	  21	  were	  VNN2	  positive	  by	  flowcytometry.	  The	  event	  free	  survival	  of	  this	  group	  of	  VNN2	  positive	  ALL	  
was	  then	  compared	  to	  the	  group	  of	  patients	  in	  the	  same	  cohort	  that	  was	  defined	  as	  VNN2	  low	  based	  on	  gene	  
expression	  data	  (Figure	  2C).	  30%	  of	  the	  VNN2	  positive	  samples	  relapsed.	  Multivariable	  analysis	  of	  clinical	  and	  
other	  genetic	  markers	  confirmed	  that	  detection	  of	  VNN2	  by	   flow	  cytometry	  was	  significantly	  associated	  with	  
poor	  prognosis	  independently	  from	  other	  factors	  that	  are	  know	  to	  predict	  adverse	  outcome	  (Table	  2).	  Indeed,	  
age	  (p=0.038),	  whole	  blood	  count	  (p=0.00013),	  Central	  Nervous	  System	  (CNS)	  infiltration	  (p=0.0092),	  response	  
to	   prednisolone	   (p=0.00019)	   and	   risk	   group	   (p=0.00009)	   and	   risk	   of	   MRD	   (p=0.0008)	   were	   related	   to	   the	  
expression	  of	  VNN2.	  Importantly	  this	  effect	  was	  independent	  from	  the	  rearrangements	  of	  CRLF2	  (p=0.8),	  which	  
was	  reported	  by	  several	  groups	  to	  be	  associated	  with	  relapse,	  in	  particular	  in	  IR-­‐ALL.	  	  This	  data	  indicates	  that	  
inclusion	   of	   VNN2	   in	   diagnostic	   flow	   procedures	   should	   identify	   a	   relevant	   subgroup	   of	   patients	   for	   further	  
biological	  studies	  and	  prospective	  validation	  of	  the	  prognostic	  significance	  of	  this	  marker.	  	  
	  
VNN2	  is	  detected	  more	  frequently	  in	  relapsed	  ALL	  
To	  investigate	  whether	  VNN2	  protein	  expression	  or	   leukemic	  clones	  VNN2	  positive	  are	  preserved	  or	  enriched	  
upon	  disease	  progression,	  we	  evaluate	  by	  flow	  cytometry	  the	  expression	  of	  VNN2	  in	  xenografts	  derived	  from	  
paired	   samples	   taken	   at	   diagnosis	   and	   after	   treatment.	   Interestingly,	   VNN2	  expression	   is	   conserved	  or	   even	  
increased	  over	  disease	  progression	  (Figure	  3).	  
This	   evidence	  was	   confirmed	   analyzing	   transcript	   level	   of	   ALL	   patients	   derived	   of	   an	   independent	   cohort	   of	  
samples,	   Supplementary	   Figure	   11.	   As	   suggested	   also	   by	   the	   xenograft	   model,	   Supplementary	   Figure	   6,	   in	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which	  VNN2	  expression	   is	  conserved	  over	  serial	  transplantation,	  VNN2	  is	  an	   intrinsic	  feature	  of	  resistant	  ALL,	  
independently	  by	  the	  microenvironment	  that	  likely	  give	  a	  clonal	  advantage.	  	  
	  
VNN2	  contributes	  to	  leukemia	  trafficking	  	  
Members	  of	  the	  vanin	  family	  of	  proteins	  have	  been	   implicated	   in	   leukocyte	  trafficking	  and	   inflammation	   (12,	  
19).	   Furthermore,	   interference	   with	   VNN2	   affects	   the	   function	   of	   fetal	   hematopoietic	   stem	   cells	   (10).	   To	  
establish	   a	   possible	   role	   of	   VNN2	   in	   the	   interaction	   of	   the	   leukemia	   cells	   with	   different	   hematopoietic	  
compartments	  we	   investigated	   the	  effect	  of	  VNN2	  blockade	  with	   a	   specific	   antibody	  on	  homing	   to	  different	  
sites	  of	  leukemia	  involvement	  in	  the	  xenograft	  model.	  We	  compared	  the	  effect	  of	  a	  blockage	  using	  either	  the	  
anti-­‐VNN2	   Ab	   or	   an	   anti-­‐CD19	   Ab,	   in	   order	   to	   rule	   out	   unspecific	   effects	   due	   to	   coating	   of	   the	   cells	   with	  
immunoglobulin,	   such	   as	   more	   rapid	   clearance	   by	   phagocytic	   cells.	   The	   anti-­‐CD19	   antibody	   was	   chosen	   as	  
control	  because	  of	  its	  ability	  to	  bind	  cells	  without	  induction	  of	  apoptosis	  and	  without	  impairing	  the	  homing	  of	  
precursor-­‐B	  cell	  ALL.	  After	  incubation	  in	  vitro	  with	  antibodies,	  cells	  were	  transplanted	  by	  intravenous	  injection	  
and	   the	  animals	  were	   sacrificed	  after	  4	  hours	   for	   analysis	  of	   the	  bone	  marrow,	   spleen	  and	  peripheral	   blood	  
involvement	   by	   flow	   cytometry	   (Figure	   4	   and	   Supplementary	   Figure	   12).	   Comparable	   results	  were	   obtained	  
when	   the	   in	   vivo	   homing	  experiment	  was	  performed	  at	   two	  different	   time	  points,	   4	   and	  16	  hours	   (data	  not	  
shown),	  for	  one	  VNN2	  positive	  case.	  Because	  of	  the	  smallest	  variation	  further	  experiment	  were	  performed	  at	  4	  
hours.	   Repopulation	   of	   the	   bone	   marrow	   and	   the	   spleen	   was	   less	   effective	   for	   VNN2-­‐positive	   ALL	   after	  
incubation	  with	  anti-­‐VNN2	  antibodies	  specifically	  compared	  to	  the	  controls	   incubated	  with	  anti-­‐CD19	  treated	  
cells	  (p-­‐value	  <0.05).	  Anti-­‐VNN2	  treatment	  did	  not	  interfere	  with	  repopulation	  of	  bone	  marrow	  and	  spleen	  for	  
the	  two	  VNN2-­‐negative	  leukemias	  that	  we	  tested	  (Figure	  6	  B).	  Binding	  of	  VNN2	  by	  the	  antibody	  was	  controlled	  
using	  a	  secondary	  antibody	  after	   the	   in	  vitro	   incubation	  step	  and	  at	   the	  time	  of	  harvest	  (Supplementary	  13).	  
We	  also	  show	  that	  VNN2	  treatment	  did	  not	  result	  in	  increased	  apoptosis	  in	  these	  experiments	  (Supplementary	  
14).	   Collectively	   our	   results	   indicate	   that	  VNN2	   is	   not	   only	   a	  marker	   for	  more	  unfavorable	  disease	  but	  must	  
have	   important	   functions	   for	   the	   disease.	   Follow-­‐up	   experiments	   are	   warranted	   to	   clarify	   the	   underlying	  
genomic	  alterations	  leading	  to	  this	  phenotype	  and	  address	  the	  function	  of	  VNN2	  in	  leukemogenesis.	  The	  data	  
reported	   here	   amply	   justify	   to	   initiate	   prospective	   follow-­‐up	   clinical	   studies	   to	   confirm	   the	   prognostic	  
significance	  of	  this	  marker	  and	  to	  address	  the	  underlying	  biology.	  
	  
MATERIAL	  AND	  METHODS	  
Patient	  samples	  
All	  patients	  were	  enrolled	  in	  multicenter	  trials	  on	  treatment	  of	  pediatric	  ALL	  conducted	  by	  individual	  member	  
groups	  of	  the	  International	  BFM-­‐Study	  Group	  2000	  (I-­‐BFM-­‐SG):	  the	  AIEOP-­‐BFM	  study	  group	  (Austria,	  Germany,	  
Italy,	  Switzerland),	   the	  FRALLE	  study	  group	   (France),	  and	   the	  United	  Kingdom	  (UK)	  National	  Cancer	  Research	  
Institute	   (NCRI)	   Childhood	  Cancer	   and	   Leukaemia	  Group.	   (3,	   20)	   Relapse	   samples	  were	   included	   in	   the	   BFM	  
Study	   Group	   2002	   (ALL-­‐REZ-­‐BFM).	   For	   all	   patients	   informed	   consent	   in	   accordance	   with	   the	   Declaration	   of	  
Helsinki	  and	  ethics	  commission	  of	  the	  University	  of	  Zurich	  was	  obtained.	  Diagnostic	  samples	  were	  classified	  as	  
standard	   risk	   (SR),	   intermediate	   risk	   (IR),	   high	   risk	   (HR)	   and	   very	   high	   risk	   (VHR)	   of	   relapse	   according	   to	   the	  
clinical	   criteria	  used	   in	  ALL-­‐BFM	  2000	   (7,	  21).	  Briefly,	  SR	  patients	  are	  prednisone	  good	  responders	   (PGR)	  and	  
have	  a	  negative	  Minimal	  Residual	  Disease	  (MRD)	  at	  time	  point	  1	  (TP1,	  day	  33);	  intermediate	  risk	  are	  also	  PGR	  
and	  MRD	  low	  positive	  (<10-­‐3)	  at	  TP2	  (week	  12).	  Finally,	  the	  VHR	  patients	  are	  prednisone	  poor	  responders	  (PPR)	  
and/or	  have	  MRD	  at	  TP2	  of	  ≥10-­‐	  3	  and/or	  presence	  of	  one	  of	  the	  following	  chromosomal	  rearrangements:	  BCR-­‐
ABL	  or	  MLL-­‐AF4.	  Samples	  from	  morphological	  non-­‐responder	  patients	  (MNR)	  were	  obtained	  at	  relapse	  on	  the	  
ALL-­‐REZ-­‐BFM	  2002	  study.	  
	  
Xenograft	  model	  
Primary	  ALL	  cells	  were	  recovered	  from	  cryopreserved	  samples	  and	  transplanted	  intrafemorally	  to	  NSG	  mice	  as	  
previously	   described	   (Schmitz,	   2011).	   Leukemia	   progression	   in	   the	   peripheral	   blood	  was	  monitored	   by	   flow	  
cytometry	   with	   rat	   anti-­‐mouse	   CD45,	   mouse	   anti-­‐human	   CD45,	   and	   mouse	   anti-­‐human	   CD19.	   Animal	  
experiments	   were	   approved	   by	   the	   veterinary	   office	   of	   the	   Canton	   of	   Zurich,	   Switzerland.	   Approval	   for	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experiments	  with	  human	  samples	  in	  the	  mouse	  xenograft	  model	  was	  obtained	  from	  the	  ethics	  commission	  of	  
the	  Canton	  Zurich	  (approval	  number	  2014-­‐	  0383).	  
	  
Cell	  isolation	  and	  cryopreservation	  
Mononuclear	   cells	   (MNCs)	   were	   isolated	   by	   Ficoll-­‐Paque	   gradient	   centrifugation	   (Pharmacia,	   Freiburg,	  
Germany)	  from	  bone	  marrow	  of	  the	  patient	  and	  peripheral	  blood	  of	  healthy	  donors.	  
Xenograft	  material	  was	  harvested	  from	  the	  spleen	  of	  engrafted	  NSG	  mice	  and	  red	  blood	  cells	  were	  eliminated	  
by	   lysis.	   For	   cryopreservation,	   cells	   were	   frozen	   in	   FBS	   heat	   inactivated	   with	   10%	   dimethylsulfoxide	   and	  
subsequently	  stored	  in	  liquid	  nitrogen.	  
	  
Immunophenotyping	  
Immunophenotyping	   of	   xenograft-­‐amplified	   human	   ALL	   cells	   after	   recovery	   from	   the	   spleen	  was	   performed	  
with	   anti-­‐human	   CD10	   (APC,	   Ref	   312210,	   BioLegend),	   CD19	   (PeCy7,	   Ref	   25-­‐0198-­‐42,	   eBioscience),	   CD20	  
(APCH7,	  Ref	  641396,	  BD	  Biosciences),	  CD34	  (PerCpCy5,	  Ref	  347222,	  BD	  Bioscience),	  CD45	  (Pacific	  Orange,	  Ref	  
MHCD4530,	  Invitrogen),	  CD38	  (FITC,	  Ref	  303504,	  BioLegend),	  VNN2	  (PE,	  Ref	  D087-­‐5	  MBL)	  and	  anti	  mouse	  CD45	  
(eFluor®450,	   Ref	   48-­‐0451-­‐82,	   eBiosciences).	   	   In	   in	   vivo	   experiments	   CD19,	   CD45,	   CD10,	   VNN2	   and	   mCD45	  
markers	  were	   used	   to	   identify	   leukemia	   cells.	   Unstained	   or	   Fluorescence	  Minus	  One	   samples	   (FMO,	   sample	  
stained	  with	  all	  antibodies	  in	  the	  panel	  except	  VNN2)	  was	  included	  as	  negative	  control.	  Most	  of	  the	  xenograft	  
were	  constitute	  by	  95%	  of	  human	  	  leukemia	  cells.	  
For	  ALL	  cell	  viability	  analysis,	  7-­‐AAD	  (BD	  Pharmingen™,	  Cat	  No	  51-­‐68981E,	  BD	  Biosciences)	  and	  counting	  beads	  
(Spherotech	  Inc.,	  Cat	  No	  ACBP-­‐70-­‐10,	  SPHERO™	  Accu	  Count	  Blanc	  Particles)	  were	  used.	  
Data	  acquisition	  was	  performed	  using	  BD	  FACS	  Canto	  II	  (BD	  Biosciences)	  and	  analyzed	  using	  FACSDiva	  version	  
6.1.2	  (Becton	  Dickinson)	  or	  FlowJo	  version	  7.1.6	  (TreeStar)	  software.	  VNN2	  signal	  was	  scored	  comparing	  to	  the	  
FMO	  or	  unstained	  negative	  control	  for	  each	  sample.	  The	  frequency	  of	  VNN2	  positivity	  was	  evaluated	  based	  on	  
the	  standard	  operating	  procedure	  of	  AIEOP-­‐BFM	  ALL	  Immunophenotyping	  Consensus	  Guidelines	  version	  1.6.2	  
of	  January	  16,	  2013.	  A	  frequency	  of	  VNN2	  positive	  cells	  higher	  than	  ≥10%	  respect	  to	  the	  control	  was	  considered	  
as	  positive	  for	  VNN2.	  Positive	  samples	  are	  further	  classified	  as	  weak	  positive	  if	  the	  percentage	  of	  the	  positive	  
population	  is	  between	  10	  to	  50	  %,	  and	  strong	  positive	  if	  higher	  than	  50%.	  	  	  
	  
Cell	  culture	  
Jurkat	  cell	  were	  cultured	   in	  RPMI	  1640	  medium	  supplemented	  with	  10%	  heat-­‐inactivated	   fetal	  bovine	  serum	  




Transient	  overexpression	  of	  VNN2	   in	   Jurkat	  cells	  was	  obtained	  cloning	  VNN2	   in	   the	  p-­‐CMV-­‐VNN2-­‐CF	  plasmid	  
(Invitrogen)	  with	  and	  without	  FLAG	  and	  transfecting	   Jurkat	  cells	  by	  electrophoresis	   (Neon	  system	   Invitrogen)	  
according	  to	  the	  standard	  protocol.	  	  
	  
RNA	  extraction	  and	  Reverse	  Transcriptase	  
Total	   RNA	  was	   isolated	  with	   Trizol	   reagent	   and	   subsequently	  with	  RNeasy®	  Mini	   Kit	   (Cat	  No	  74106,	  Qiagen)	  
according	   to	   standardized	   protocols.	   The	   amount	   and	   quality	   of	   the	   extracted	   RNA	   was	   measured	   with	   a	  
Spectrophotometer	   (Nanodrop®	  ND-­‐1000).	   RT-­‐PCR	  was	  performed	  using	   10xRTbuffer	   (P/N	  4319981,	  Applied	  
Biosystems),	   25xdNTP	   (P/N	   362271,	   Applied	   Biosystems),	   10xRT	   Random	   Primer	   (P/N	   4319979,	   Applied	  
Biosystems),	  Multiscribe	  Reverse	  Trascriptase	  (P/N	  4319983,	  Applied	  Biosystems),	  Rnase	   inhibitor	  (P/N	  N808-­‐
0119,	  Applied	  Biosystems)	  and	  Rnase	  free	  H20.	  This	  mix	  with	  the	  equal	  volume	  of	  RNA	  (1000ng	  of	  RNA	  for	  each	  
PCR	   reaction)	   was	   process	   according	   tot	   he	   following	   protocol:	   Preheating:	   25°C/10min,	   Synthesis	   cDNA:	  





TaqMan	  Gene	  Expression	  Assays	  were	  used	  to	  measure	  mRNA	  abundance	  of	  VNN2,	  with	  SDHA	  as	  control	  gene.	  
The	  TaqMan®	  Gene	  Expression	  Master	  Mix	  (P/N	  4369016,	  Applied	  Biosystems,	  Foster	  City,	  USA),	  the	  assay	  on	  
demand	  (TaqMan®	  Gene	  Expression	  Assays,	  Hs01546812_m1	  VNN1,	  Hs00190581_m1	  VNN2,	  Hs00417200_m1	  
SDHA,	  Applied	  Biosystems)	  and	  water	  were	  mixed	  (5:3:2)	  are	  mixed	  and	  cDNA	  (1:3	  dilution)	  added.	  The	  same	  
was	  done	  with	  a	  Sybrgreen	  assay	  for	  VNN2	  and	  SDHA	  as	  housekeeping	  gene	  (QuantiTect	  SYBR®	  Green	  PCR	  Kit,	  
Power	   SYBR®Green	   PCR	   Master	   Mix,	   P/N	   4367659,	   Applied	   Biosystems,	   Quantitect®	   Primer	   Assay,	  
Hs_VNN2_1_SG,	  Cat	  No	  QT00034902	  and	  Hs_SDHA_1_SG,	  Cat	  No	  QT00059486,	  Qiagen).	  
For	  both	  methods,	  iScience,	  7900HT,	  Fast	  Real-­‐Time	  PCR-­‐System,	  from	  Applied	  Biosystems	  was	  used.	  Program:	  
2min	  50°C,	  10min	  95°C,	  50x(10sec	  95°C/1min	  60°C)	  Analysis	  was	  performed	  with	  SDS	  2.2	  software,	  calculating	  
the	  2
-­‐ΔCT
	  value.	  nature	  protocol	  thomas	  D	  schmittgen	  livak	  
	  
In	  vivo	  experiment	  
ALL	  cells	  were	  recovered	  from	  cryopreserved	  xenograft	  samples	  and	  incubated	  at	  37°C	  for	  20min	  Survival	  rate	  
after	   thawing	   was	   ≥60%.	   Cells	   were	   blocked	   for	   1hour	   at	   37°C	   with	   1mg/mL	   of	   either	   anti-­‐VNN2	   antibody	  
(VNN2,	   Ref	   D087-­‐3,	  MBL)	   or	   anti-­‐CD19	   antibody	   (LEAF™Purified	   anti-­‐human	   CD19,	   clone	  HIB19,	   BioLegend).	  
Blocked	  cells	  were	  transplanted	  in	  6	  mice	  each	  group.	  10,000,000	  cells	  per	  mouse	  were	  injected	  in	  the	  tail	  vein	  
of	  12	  NSG	  mice	  with	  similar	  weight	  and	  age.	  4h	  after	  transplantation,	  bone	  marrow,	  spleen	  and	  the	  peripheral	  
blood	  were	  examined	   for	   the	  presence	  of	   leukaemia	  cells	  using	   flow	  cytometry.	  A	   secondary	  antibody	   (Goat	  
F(ab’)	  2	  Anti-­‐Mouse	  Ig-­‐FITC,	  Human,	  Cat	  No	  2012-­‐02,	  Southern	  Biotech)	  was	  	  incubated	  for	  10min	  at	  4°C,	  after	  
washing	   1ug/ml	   IgG	   of	   mouse	   was	   added,	   left	   for	   5	   min	   and	   the	   samples	   stained	   with	   CD19,	   CD45,	   CD10,	  








	   leukemia	  cell	  was	  normalized	  
for	  the	  total	  number	  of	  lymphocytes	  acquired.	  	  
	  
Statistics	  
VNN2	   threshold	  based	  on	  Sybrgreen	  PCR	  values	  was	  defined	  dividing	   the	  663	  ALL	  patients	   included	   in	   the	   I-­‐
BFM	   –SG	   in	   Germany,	   in	   a	   training	   set	   (1/3	   of	   the	   patients)	   and	   a	   test	   set	   (2/3).	   Definition	   of	   the	   VNN2	  
threshold	  associated	  with	  higher	  risk	  of	  relapse	  was	  identified	  based	  on	  the	  lowest	  p-­‐value	  in	  a	  univariate	  Cox	  
model	   in	   the	   training	   set.	   This	   threshold	   was	   used	   for	   dichotomizing	   the	   patients	   in	   the	   test	   set.	   For	   the	  
definition	  of	  VNN2	  high	  and	  low	  	  cases	  in	  the	  Swiss	  and	  Austrian	  cohort	  (n=113)	  screened	  by	  TaqMan,	  average	  
+	  standard	  deviation	  of	  the	  values	  of	  the	  2
-­‐ΔCT
	  of	  the	  SR	  cases	  was	  used.	  	  ΔCt=CtVNN2-­‐CtSDHA.	  
Samples	  included	  in	  the	  I-­‐BFM	  –SG	  with	  2
-­‐ΔΔCT
>	  1.13	  (cut	  off	  VNN2	  transcript	  level	  predictive	  of	  relapse)	  and	  in	  
the	  Swiss	  –Austrian	  –SG	  with	  2
-­‐ΔCT
>	  X	  (Average	  +	  SD	  of	  2
-­‐ΔCT
	  values	  of	  SR	  cases)	  were	  Tested	  by	  flow	  cytometry	  
based	  on	  sample	  availability.	  	  
All	  statistical	  tests	  were	  performed	  using	  Graph	  Pad	  Prism	  version	  5.0	  (Graph	  Pad	  Software).	  
	  
DISCUSSION	  
To	   improve	   therapeutic	   options	   for	   patients	   with	   resistant	   disease	   additional	   biomarkers	   are	   required	   to	  
precise	   leukemia	   classification	   already	   at	   diagnosis.	   Here	   we	   report	   converging	   evidence	   that	   supports	   an	  
association	   of	   the	   glycosylphosphatidyinositol-­‐anchored	   surface	   protein	   VNN2/GPI80	  with	   ALL	   subtypes	   that	  
are	   more	   resistant	   to	   current	   chemotherapy.	   We	   identified	   VNN2	   to	   be	   preferentially	   detected	   in	   the	   cell	  
surface	  proteome	  of	  leukemia	  that	  were	  highly	  resistant	  to	  induction	  chemotherapy	  based	  on	  the	  persistence	  
of	  high	   levels	  of	  minimal	  residual	  disease.	   In	  a	  retrospective	  analysis	  of	  selected	  cohorts	  of	  ALL	  patients	  with	  
high	   risk,	   intermediate	   risk	   and	   low	   risk	  of	   relapse	  per	   current	   clinical	   stratification	  methods,	  we	  detected	  a	  
significant	   correlation	   of	   VNN2	   expression	   levels	   or	   detection	   by	   flow	   cytometry	   with	   relapse.	   Importantly,	  
VNN2	  expression	  identified	  patients	  at	  risk	  of	  relapse	  in	  the	  intermediate	  risk	  group,	  which	  still	  constitutes	  the	  
group	  with	   the	   largest	   number	   of	   relapses	   in	  ALL	   but	   for	  which	   currently	   no	   alternative	  markers	   have	   been	  
defined.	  We	  also	  found	  VNN2	  to	  be	  detected	  more	  frequently	  at	  relapse,	  which	  indicates	  that	  VNN2	  expression	  
is	  associated	  with	  more	  aggressive	  disease	  features.	  Interestingly,	  VNN2	  expression	  was	  associated	  with	  other	  
standard	  clinical	   features	  of	  high	   risk	  ALL,	   including	  high	  white	  blood	  cell	   count	   (p=0.00013),	  CNS	   infiltration	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(p=0.0092),	  poor	  response	  to	  prednisolone	  (p=0.00019),	  and	  detection	  of	  MRD	  (p=0.0008).	  Thus,	   this	  marker	  
may	  reflect	  a	  more	  general	  mechanism	  of	  resistant	  disease.	  	  
Indeed,	   VNN2	   was	   recently	   identified	   as	   a	   marker	   of	   human	   fetal	   hematopotietic	   stem	   cells	   based	   on	  
transcriptome	   analysis	   of	   sorted	   human	   fetal	   hematopoietic	   cells	   (10).	   VNN2	   detection	   by	   flow	   cytometry	  
identifies	   a	   stem	   cell	   population	   in	   different	   stages	   of	   fetal	   hematopoiesis	   (placenta,	   fetal	   liver,	   fetal	   bone	  
marrow).	   Sorting	   this	   subset	   of	   stem	   cells	   enriches	   for	   hematopoietic	   repopulation	   capacity	   in	   xenograft	  
experiments.	  RNA	  interference	  with	  VNN2	  affected	  proliferation	  of	  this	  stem	  cell	  fraction	  in	  co-­‐cultures	  in	  vitro	  
as	   well	   as	   engraftment	   in	   vivo,	   indicating	   that	   VNN2	   has	   important	   functional	   roles	   at	   these	   early	  
hematopoietic	   stages.	   VNN2	   has	   been	   implicated	   in	   leukocyte	   adhesion	   and	   migration	   (12,	   22)	   possibly	   by	  
interaction	  with	  other	  cell	   surface	  receptors	   including	   ITGAM1.	  Association	  with	   ITGAM	  was	  also	  detected	   in	  
fetal	   hematopoiesis	   and	   in	   our	   proteomic	   dataset	   in	  ALL.	   ITGAM	   (CD11b)	   has	   been	  described	   as	   a	   leukemia	  
associated	  marker	  on	  MRD	  cells	  (23).	  However	  we	  did	  not	  detect	  universal	  co-­‐expression	  of	  VNN2	  and	  ITGAM	  
by	  flow	  cytometry	  in	  VNN2	  positive	  ALL	  (data	  not	  shown),	  suggesting	  that	  underlying	  mechanism	  may	  be	  more	  
complex.	   VNN2	   expression	   was	  maintained	   in	   serial	   passages	   in	   xenograft	   experiments,	   indicating	   that	   this	  
expression	  pattern	  is	  a	  stable	  feature,	  driven	  by	  mechanisms	  that	  are	  intact	  in	  the	  xenograft	  setting.	  Anti-­‐VNN2	  
antibodies	  interfere	  with	  homing	  to	  ALL	  cells	  to	  the	  spleen	  and	  to	  the	  bone	  marrow	  in	  a	  VNN2	  specific	  manner.	  
Thus,	   VNN2	   could	   play	   an	   important	   functional	   role	   in	   ALL	   as	   well,	   possibly	   by	   affecting	   tissue	   invasion	   or	  
trafficking	  properties.	  We	  also	  detected	   the	  vanin-­‐family	  member	  VNN1	   in	   the	  surfeasome	  of	  VHR-­‐ALL	  more	  
frequently.	  Experiments	  with	  Vanin1	  deficient	  mice	  show	  that	  this	  protein	  is	  involved	  in	  inflammatory	  reaction	  
and	   stress	   response	  pathways	   (24).	   Thus	  display	  of	   vanin	   family	  members	   in	  more	   resistant	  ALL	   cases	   could	  
reflect	  the	  activation	  of	  cellular	  programs	  that	  are	  also	  required	  in	  early	  stages	  of	  hematopoiesis.	  
	  
Based	  on	  current	  evidence,	  VNN2	  may	  serve	  as	  an	  indicator	  of	  more	  aggressive	  disease.	  A	  preliminary	  analysis	  
of	   systematic	   prospective	   detection	   by	   flow	   cytometry	   in	   ALL	   indicates	   that	   VNN2	   is	   detected	   in	   about	   10	  
percent	   of	   all	   cases.	   In	   a	   smaller	   subset	   of	   these	   patients,	   VNN2	   is	   detected	   strongly	   but	   the	   value	   of	   this	  
observation	  remains	  to	  be	  evaluated	  prospectively.	  These	  included	  one	  case	  with	  TCF3-­‐HLF-­‐positive	  ALL,	  a	  rare	  
but	  mostly	  fatal	  subtype	  of	  ALL	  (our	  nature	  genetics,	  references),	  which	  fits	  to	  an	  expected	  frequency	  of	  this	  
subtype	  between	  0.5-­‐1	  %	  of	  childhood	  ALL.	  The	  translocation	  t(17;19)	  can	  be	  cryptic	  and	  difficult	  to	  detect	  by	  
routine	  cytogenetics.	  Our	  studies	  show	  consistently	  very	  high	  VNN2	  expression	   in	  TCF3-­‐HLF-­‐positive	  ALL.	  The	  
detection	  of	  VNN2	  by	  flow	  cytometry,	  helps	  preselect	  samples	  for	  specific	  diagnostic	  testing	  for	  this	  rare	  and	  
highly	  aggressive	  disease.	  	  
Given	  that	  we	  detected	  VNN2	  uniformly	   in	  a	   larger	  series	  of	  TCF3-­‐HLF-­‐positive	  ALL	  cases,	   flow	  cytometry	   for	  
VNN2	   provides	   a	   simple	   and	   economical	   way	   to	   preselect	   leukemia	   for	   further	   genetic	   assays.	   The	   correct	  
diagnosis	   of	   this	   subtype	   is	   very	   relevant	   for	   clinical	   management,	   because	   these	   patients	   are	   likely	   to	   not	  
benefit	  from	  current	  conventional	  chemotherapy	  (17)	  and	  should	  be	  offered	  alternative	  treatment	  options	  to	  
bridge	  them	  towards	  stem	  cell	  transplantation,	  including	  immunotherapy.	  We	  recently	  obtained	  full	  molecular	  
remission	   using	   blinatumomab	   in	   a	   patient	   who	   was	   refractory	   to	   the	   first	   induction	   chemotherapy	  
(unpublished	  observation).	  As	  such	  inclusion	  of	  VNN2	  in	  diagnostic	  FACS	  panel	  appears	  justified.	  	  
	  
Our	   retrospective	   analysis	   indicates	   that	   the	  more	   frequent	   non-­‐TCF3-­‐HLF	   translocated	   VNN2	   positive	   cases	  
also	  have	  a	   significant	   risk	  of	   relapse.	  A	  systematic	  prospective	  study	  has	  been	   initiated	   including	  VNN2	  as	  a	  
marker	   in	  diagnostic	   immunophenotyping	  of	  patients	  that	  are	  enrolled	  on	  the	  AEIOP-­‐BFM-­‐ALL-­‐2009	  protocol,	  
first	  in	  the	  Swiss	  national	  reference	  laboratory	  and	  more	  recently	  internationally.	  Because	  VNN2	  is	  implicated	  
at	  different	  stages	  in	  hematopoiesis,	  both	  in	  stem	  cells	  and	  fully	  differentiated	  myeloid	  cells	  (10,	  22),	  the	  best	  
approach	   will	   be	   to	   detect	   VNN2	   at	   a	   single	   cell	   level	   by	   flow	   cytometry.	   We	   validated	   two	   independent	  
monoclonal	   antibody	   clones	   and	   established	   criteria	   for	   gating	   according	   to	   standards	   of	   our	   international	  
working	  group	  ((25)	  and	  manuscript	  in	  preparation).	  To	  establish	  the	  threshold	  for	  positivity	  in	  this	  prospective	  
study	  we	  will	  compare	  to	  controls	  with	  the	  same	  backbone	  of	  antibodies	  but	  omitting	  the	  VNN2	  antibody.	   It	  
will	  be	  important	  to	  carefully	  analyze	  the	  overlap	  of	  VNN2	  surface	  expression	  with	  other	  biomarkers.	  Based	  on	  
current	   data,	   we	   did	   not	   see	   an	   association	   with	   cytogenetic	   risk	   factors	   that	   are	   routinely	   detected	   at	  
diagnosis,	   including	   MLL	   rearrangement,	   nor	   did	   we	   detect	   an	   overlap	   with	   the	   so-­‐called	   ‘switch’-­‐ALL	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phenotype	   that	   has	   been	   reported	   most	   recently	   and	   describes	   a	   subset	   in	   ALL	   with	   lineage	   switch	   to	  
myelomonocytic	  features	  and	  typical	  expression	  of	  surface	  CD2	  (26).	  The	  current	  size	  of	  our	  prospective	  data	  is	  
too	   limited	   to	  study	  association	  with	  more	  complex	  patterns	  copy	  number	  alterations,	   including	  deletions	  of	  
IKAROS,	  that	  have	  been	  demonstrated	  to	  be	  associated	  with	  an	  increased	  risk	  of	  relapse	  (27-­‐29).	  It	  will	  also	  be	  
important	  to	  evaluate	  an	  association	  with	  activation	  mutations	  in	  tyrosine	  kinases	  that	  are	  enriched	  in	  patients	  
with	  high	  risk	  ALL	  (30)	  for	  which	  retrospective	  data	  are	  currently	  not	  available.	  	  
	  
Taken	   together,	   we	   show	   here	   that	   VNN2,	   a	  marker	   of	   the	   fetal	   hematopoietic	   ‘stemness’,	   can	   be	   used	   to	  
detect	   ALL	   subtypes	   with	   an	   unfavorable	   biology	   and	   worse	   outcome	   on	   current	   therapeutic	   modalities,	  
including	   the	   deadly	   subtype	   of	   TCF3-­‐HLF-­‐positive	   ALL.	   Our	   experiments	   show	   that	   VNN2	   plays	   a	   role	   in	  
leukemia	  propagation	  by	  contributing	  to	  leukemia	  homing	  to	  different	  sites	  of	  involvement.	  Our	  data	  provide	  a	  
basis	   for	   prospective	   clinical	   studies	   as	   well	   as	   for	   the	   interrogation	   of	   underlying	   drivers	   of	   VNN2	   and	   its	  
functional	  role	  in	  leukemia.	  	  	  
	  
FIGURE	  LEGENDS	  
Figure	  1.	  	  Transcript	  levels	  of	  VNN2	  correlate	  with	  higher	  risk	  of	  relapse	  in	  B-­‐cell	  precursor	  ALL	  
A)	   Comparison	   of	   cell	   surface	   proteomes	   of	   8	   very	   high-­‐risk	   (VHR)	   and	   11	   standard-­‐risk	   (SR)	   BCP-­‐ALL.	   The	  
surfaceome	  dataset	  was	  filtered	  in	  two	  steps,	  first	  for	  peptides	  that	  match	  to	  proteins	  that	  were	  detected	  in	  at	  
least	   50%	   of	   VHR-­‐ALL	   cases	   and	   in	   less	   than	   25%	   of	   SR-­‐ALL	   cases,	   second	   by	   selecting	   peptides	   more	  
stringently	  that	  were	  present	  in	  at	  least	  75%	  of	  VHR-­‐ALL	  and	  in	  less	  than	  25%	  SR-­‐ALL	  or	  in	  60%	  VHR-­‐ALL	  and	  
less	  than	  18%	  SR-­‐ALL.	  Proteins	  are	  displayed	  based	  on	  functional	  annotation.	  B)	  Correlation	  of	  transcript	  and	  
protein	   level	   in	   patients	   derived	   xenografts	   (PDXs)	   from	   patients	   that	   were	   risk	   stratified	   according	   to	   the	  
criteria	  used	  in	  the	  ALL-­‐BFM	  2000	  protocol.	  Standard	  risk	  (SR)	  are	  indicated	  in	  green	  (n=12),	  intermediate	  risk	  
(IR)	   in	  orange	  (n=10),	  and	  high	  risk	   (HR/VHR)	   in	  turquoise	  (n=16).	  Four	  of	  the	  HR/VHR	  cases	  were	  TCF3-­‐HLF-­‐
positive	  and	  are	  depicted	  by	  a	  square.	  The	  percentage	  of	  VNN2	  positive	  cells	  by	  flow	  cytometry	  is	  plotted	  on	  
the	  Y-­‐axis	  against	  the	  mRNA	  levels	  by	  Q-­‐PCR	  as	  logarithmic	  value	  of	  2
-­‐ΔCt
	   (ΔCt=CtVNN2-­‐CtSDHA)	  on	  the	  X-­‐axis.	  C)	  
Strong	   detection	   of	   VNN2	   on	   10	   samples	   from	   TCF3-­‐HLF-­‐positive	   patients	   	   (7	   PDXs	   in	   the	   upper	   panel,	   3	  
primary	   diagnostic	   samples	   in	   the	   lower	   panel).	   The	   fluorescence	   minus	   one	   control	   is	   shown	   as	   grey	  
histogram.	  D)	  transcriptome	  data	  corresponding	  to	  the	  genes	  identified	  in	  A.	  RPKM	  values	  are	  displayed	  as	  a	  
heatmap.	  
	  
Figure	  2.	  Surface	  VNN2	  detection	  is	  associated	  with	  resistant	  disease	  in	  ALL	  
A)	  VNN2	  mRNA	  expression	  of	  663	  ALL	  patients,	  SR	  (n=209),	  IR	  (n=345),	  HR	  (n=109).	  VNN2	  mRNA	  is	  presented	  
as	   logarithmic	   value	   of	   2
-­‐ΔΔCt
	   (ΔCt=CtVNN2-­‐CtSDHA)	   normalized	   for	   a	   reference	   sample	   with	   lowest	   VNN2	  
expression.	   	   B)	   Event	   Free	   Survival	   (EFS)	   analysis	   of	   a	   retrospective	   cohort	   of	   samples	   from	   patients	   with	  
intermediate	  risk	   (IR)	  ALL.	  A	  threshold	  was	  defined	  with	  a	   test	  set	  on	  the	  entire	  cohort	  of	  663	  patients.	  The	  
probability	  of	  EFS	  is	  displayed	  for	  195	  patients	  with	  VNN2	  expression	  less	  than	  1.13	  and	  52	  patients	  more	  than	  
1.13	   normalized	   deltaCT	   value.	   Log	  Rank	   p	   0.0089.	   See	   also	   Supplementary	   Figure	   9	   for	   the	   analysis	   of	   the	  
entire	  cohort	  and	  other	  risk	  groups.	  C)	  Pilot	  evaluation	  of	  VNN2	  detection	  by	  flow	  cytometry	  based	  selection	  
of	  cryopreserved	  samples	  from	  a	  retrospective	  cohort	  including	  the	  663	  cases	  above	  and	  113	  additional	  cases	  
from	  Switzerland	  and	  Austria.	  	  The	  strategy	  for	  sample	  selection	  is	  outlined	  in	  Supplementary	  Figure	  4.	  From	  
12	   samples	   that	   were	   confirmed	   to	   be	   VNN2	   positive	   by	   flow	   cytometry	   6	   patients	   had	   an	   event.	   The	  
probability	   of	   EFS	   is	   compared	   to	   samples	  with	   VNN2	   transcript	   levels	   lower	   than	   1.13	   deltaCT	   values.	   Log	  
Rank	  p	  0.0029.	  	  
	  	  
Figure	  3.	  	  VNN2	  positive	  clones	  are	  preserved	  or	  enriched	  during	  disease	  progression	  
A)	  VNN2	  expression	  flow	  cytometry	  analysis	  of	  pair	  diagnostic	  and	  relapse	  samples	  (n=7).	  MFI	  are	  plotted.	  B)	  




Figure	  4.	  VNN2	  blockade	  reduces	  homing	  ability	  to	  bone	  marrow	  and	  spleen	  of	  VNN2	  positive	  leukemia	  
A)	   Homing	   assay	   was	   performed	   with	   patient	   derived	   xenograft	   cells	   recovered	   after	   thawing.	   Subsequent	  
blocking	  with	  anti-­‐VNN2	  and	  anti-­‐CD19	  antibody	  was	  performed	  for	  1	  hr	  at	  37°C	  5%	  CO2.	  10.000.000	  of	  cells	  
were	   intravenously	   injected	   in	  6	  NSG	  mice	  per	  condition.	  Leukemia	  cell	  number	   in	  bone	  marrow,	  spleen	  and	  
blood	   was	   measured	   after	   4	   hrs	   from	   the	   injection	   by	   flow	   cytometry.	   Dot	   plots	   represent	   the	   number	   of	  






	  and	  normalized	  for	  the	  total	  number	  of	  lymphocytes,	  distinct	  
based	  on	  FCS	  ad	   SSC.	  VNN2	  positive	   leukemia	   samples	   (B)	   and	   leukemia	   samples	  with	  undetectable	   level	  of	  
VNN2	   protein	   based	   on	   flow	   cytometry	   data	   (C)	   were	   tested.	   Error	   bars	   represent	  mean	   ±	   SEM.	   Significant	  
difference	  between	  anti-­‐VNN2	  and	  CD19	  blocking,	  p-­‐value<0.05,	  in	  VNN2	  positive	  samples.	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Supplementary Figure 2. VNN2 expression in normal hematopoetic system. a) VNN2 transcript level in 
different progenitors, DMAP (Novershtern et al, Cell 2011). b) VNN2 protein expression by cells of peripheral 










Supplementary Figure 3. Exogenous overexpression of VNN2 in cell line. (A) cDNA of VNN2 human proteins was 
cloned in the commercial plasmid pCMV with C –terminal flag. Representative FACS of VNN2 expression after 1 week from 
transfection and 3 days of G418 selection. (B) cDNA of VNN2 human protein was cloned in the commercial pInducer21, an 
inducible lentiviral plasmid. After transduction, the cells were sorted through the GFP marker and treated with 1000ng/mL of 
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Supplementary	  Figure	  4.	  Representa4ve	  FACS	  analysis	  of	  VNN2	  signal	  on	  leukemia	  cells	  
according	  to	  the	  criteria	  define	  by	  the	  AIEOP-­‐BFM	  Flow	  Network	  .	  Samples	  with	  frequency	  
of	  VNN2	  posi8ve	  cells	  lower	  than	  10%	  respect	  to	  the	  control	  are	  considered	  nega8ve	  of	  
nega8ve	  for	  the	  an8gen.	  Weak	  posi8ve	  and	  strong	  posi8ve	  is	  frequency	  of	  VNN2	  posi8ve	  




Supplementary	  Figure	  5.	  VNN2	  expression	  in	  6	  TCF3-­‐HLF	  posi?ve	  ALL	  pa?ents.	  VNN2	  
























Supplementary Figure 6. VNN2 phenotype is maintained after xenotransplantation and remains stable over several 
serial transplantations in the xenograft model . This indicates that the underlying mechanism is intrinsic to the leukemia. 






























Supplementary	  Figure	  7.	  Co-­‐expression	  of	  VNN2	  and	  ITGAM	  by	  2	  TCF3-­‐HLF	  posiEve	  ALL.	  
Bone	  marrow	  cells	  were	  analyzed	  by	  flow	  cytomery	  for	  the	  expression	  of	  VNN2	  (turquoise)	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Supplementary	  12.	  FACS	  ga4ng	  strategy	  to	  iden4fy	  leukemia	  cells	  in	  in	  vivo	  homing	  assay.	  
7AAD	  staining	   is	  used	  to	  exclude	  dead	  cells	  and	  singlets	  by	  FCS-­‐A	  and	  FSC-­‐H.	  Lymphocytes	  are	  defined	  
based	   on	   physical	   parameters	   and	   enrichment	   for	   human	   cells	   is	   obtained	   excluding	   murine	   CD45	  
posiCve	  cells.	  	  Leukemia	  cells	  are	  discriminated	  as	  CD45	  and	  CD19	  posiCve.	  At	  least	  of	  1.000.000	  of	  total	  
events	  per	  specimen	  was	  acquired.	  
Supplementary	  13.	  Valida3on	  of	  an3bodies	  binding.	  	  
Secondary	   an+-­‐mouse	   FITC	   an+body	   was	   used	   following	   in	   vitro	   blocking	   and	   in	   vivo	  
homing	  assay.	  Posi+ve	  signal	  for	  secondary	  an+body	  confirms	  the	  binding	  of	  the	  blocking	  












Anti-VNN2 Anti-CD19 Untreated 
Supplementary	   14.	   Blockade	   with	   an8-­‐VNN2	   and	   CD19	   an8bodies	   does	   not	   effect	   the	  
survival	  rates.	  Frequency	  of	  living	  cells	  was	  assessed	  excluding	  7AAD	  posi:ve	  dead	  cells	  a;er	  
in	   vitro	   blocking	   and	   a;er	   homing	   assay,	   untreated	   condi:on	  was	   included	   as	   control.	   A)	  
Representa:ve	  FACS	  analysis	  a;er	  blocking.	  B)	  Representa:ve	  analysis	  of	  the	  frequency	  of	  

























































PROPOSAL	  FOR	  PROSPECTIVE	  EVALUATION	  OF	  VNN2	  AS	  PROGNOSTIC	  MARKER	  BY	  FACS	  
FOR	  BCP-­‐ALL	  	  (18-­‐11-­‐2014)	  
	  
Rationale	  
We	   identified	  VNN-­‐2	   by	   CSC	   glycoproteomics	   as	   one	   of	   the	   cell	   surface	   proteins	   that	  was	  
almost	  uniquely	  found	  in	  high	  risk	  ALL	  compared	  to	  SR	  ALL.	  Vanin-­‐2	  (VNN2)	  is	  a	  GPI	  anchored	  
cell	   surface	   protein	   with	   potential	   function	   in	   cell	   trafficking	   and	   inflammation	   and	  most	  
recently	   functionally	   shown	   to	   be	   required	   for	   fetal	   HSC.	   VNN2	   is	   expressed	   at	   different	  
levels	  by	  normal	  hematopoietic	  cells,	   importantly	  by	  lymphocytes	  and	  myeloid	  cells	  (Figure	  
1,	   DMAP	   data	   based	   on	   RNA	   from	   sorted	   human	   populations).	   Given	   the	   correlation	   for	  	  
VNN2	   expression	   at	   RNA	   and	   protein	   level	   (Figure	   2),	   we	   assessed	   a	   cohort	   of	   663	   BFM	  
patients	  retrospectively.	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Figure	   1.	   VNN2	   expression	   in	   normal	   hematopoetic	   system.	   a)	   VNN2	   transcript	   level	   in	  
different	  progenitors,	  DIMAP,	  Novershtern,	  Cell	  2011.	  b)	  VNN2	  protein	  expression	  by	  cells	  of	  






































Figure	  2.	  Correlation	  between	  protein	  
and	  transcript	  level	  of	  VNN2.	  Y	  axis	  shows	  
the	  percentage	  of	  VNN2	  positive	  cells	  
compare	  to	  the	  staining	  control	  tube	  
(Fluorescence	  Minus	  One);	  X	  axis	  shows	  
the	  Real	  Time	  PCR	  data	  as	  delta	  Ct	  
between	  VNN2	  and	  SDHA	  house	  keeping	  
gene.	  
	  
Retrospective	  analysis	  of	  VNN2	  expression	  
Very	   high	   levels	   of	   VNN2	  were	   detected	   by	   RQ-­‐PCR	   only	   in	   HR	   and	   SR	   ALL	   patients	   from	  
selected	  cohorts	  of	  the	  ALL-­‐BFM-­‐2000-­‐Study.	  	  Moreover,	  VNN2	  expression	  was	  found	  to	  be	  
increased	   in	   paired	   relapse	   samples	   (collaboration	   with	   Truus	   teKronnie,	   AIEOP).	   Martin	  
Zimmerman	   could	   show	   that	   a	   cut	   off	   can	   be	   defined	   for	   high	   levels	   of	   VNN2	   expression	  
which	  is	  significantly	  associated	  with	  relapse	  (not	  shown).	  We	  next	  decided	  to	  evaluate	  the	  
potential	   for	  FACS	  based	  on	  this	   retrospective	  cohort.	  We	  could	  retrieve	  14	  cryopreserved	  
samples	  from	  153	  BFM	  samples	  that	  were	  above	  cut	  of	  by	  QPCR	  for	  VNN2	  high.	  By	  FACS	  7	  
samples	   were	   clearly	   VNN2	   positive,	   two	  were	   borderline.	   	   Survival	   analysis	   of	   this	   small	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  Figure	   3.	   EFS	   based	   on	   flow	   cytometry.	  
663	   ALL	   cases	   of	   the	   German	   ALL-­‐BFM-­‐
2000	  clinical	  study	  are	  screened	  by	  RT-­‐PCR	  
for	  VNN2	  expression.	  7	  out	  of	  14	  patients	  
for	   which	   cells	   were	   available	   were	  
positive	   for	   VNN2	   by	   FACS	   and	   are	  
included	  in	  the	  EFS	  analysis.	  	  
In	  this	  analysis	  samples	  with	  a	  frequency	  of	  VNN2
pos
	  cells	  higher	  than	  10%	  compared	  to	  the	  
Fluorescence	  Minus	  One	  (FMO)	  tube	  are	  considered	  positive.	  The	  FMO-­‐tube	  includes	  all	  the	  
antibodies	  used	  in	  the	  VNN2-­‐tube	  for	  the	  staining	  of	  the	  sample	  except	  VNN2	  antibody.	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A	  similar	  distribution	  was	   found	   in	  an	   independent	  retrospective	  cohort	   from	  BFM-­‐CH	  and	  
BFM-­‐A	   (not	   shown).	   In	   addition	   4/8	   cases	   in	   the	   Swiss-­‐Austrian	   cohort	   relapsed.	   Finally,	  
VNN2	  is	  also	  strongly	  positive	  in	  TCF3-­‐HLF	  ALL.	  This	  is	  added	  value	  for	  the	  VNN2	  tube,	  as	  we	  
will	  probably	  detect	  more	  cases	  with	  t(17;19)	  positive	  ALL.	  
	  
Prospective	  analysis	  on	  VNN2	  expression	  
We	   have	   included	   VNN2	   in	   PE	   in	   the	   diagnostic	   panels	   of	   BFM-­‐CH	   (Zurich)	   for	   paitents	  
enfroled	   on	   ALL-­‐BFM-­‐2009	   since	   April	   2012.	   In	   total	   160	   patients	   have	   been	   screened	   by	  
flow	  cytometry.	  This	  provides	  a	  basis	  for	  this	  proposal.	  This	  series	  included	  always	  a	  negative	  
control	   tube	   according	   to	   the	   AEIOP-­‐BFM	   FCM	   task	   force.	   We	   scored	   the	   VNN2	   signal	  




	   (normal	   NK	   and	   T	  
lymphoid	  cells).	  11	  patients	  resulted	  VNN2	  positive	  with	  a	  frequency	  of	  VNN2	  positive	  cells	  
higher	  than	  10%	  respect	  to	  the	  control	  (Table1).	  3	  out	  11	  have	  a	  percentage	  of	  VNN2
pos
	  cells	  
very	  close	  to	  the	  threshold	  (10-­‐15%),	  5	  of	  them	  are	  weak	  positive	  (15-­‐50%)	  and	  3	  of	  them	  
are	  strong	  positive	   (50-­‐10%).	  Thus	  the	  frequency	  of	  VNN2	  positivity	   in	  this	  cohort	   is	   in	  the	  




%	  VNN2	  positive	  cells	  
	  
Classification	  
(%	  of	  blasts	  VNN2
pos
)	  
CHZ	  19	   99.00	  
Strong	  positive	  (50-­‐100%)	  CHBL	  24	   67.00	  
CHBE	  19	   57.00	  
CHSG	  13	   35.20	  
Weak	  Positive	  (15-­‐50%)	  
CHZ	  3	   30.00	  
CHZ	  30	   28.60	  
CHAR	  10	   24.60	  
CHZ	  33	   18.00	  
CHSG17	   14.30	  
Borderline	  (10-­‐15%)	  CHZ	  38	   14.10	  
CHZ	  44	   12.60	  
Table	  1.	  Results	  of	  the	  Swiss	  prospective	  analysis	  (FACS).	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We	   next	   looked	   at	   the	   distribution	   of	   the	   Mean	   Fluorescence	   Intensity	   (MFI)	   of	   patient	  
samples	   that	  we	   scored	   as	  VNN2	  negative	   compared	   to	   the	  negative	   controle	   tube	   (CD45	  




population.	   Please	   note	  
that	  we	  noticed	  a	  sample	  to	  sample	  variability	  of	  VNN2	  positivity	  in	  both	  normal	  T	  cells	  and	  B	  
cells,	  which	   is	   in	   line	  with	  DMAP	  RNA	  data	   reported	  by	   the	  Broad	   Institute.	  We	   therefore	  





population	  for	  VNN2.	  Thus,	  comparision	  with	  this	   intra	   lineage	  control	  may	  
limit	   our	   resolution	   in	   the	   very	   low	   positive	   range.	   But	   we	   hypothesize	   that	   the	   most	  
relevant	   information	  will	  be	  associated	  with	   strong	  VNN2	  positivity.	   	   It	  would	  be	  useful	   to	  
obtain	  a	  larger	  series	  of	  prospective	  data	  including	  a	  negative	  tube	  (CD45	  only),	  an	  FMO	  tube	  






































Figure	  4.	  Normal	  distribution	  of	  the	  MFIs	   for	  Swiss	  ALL	  cases	   included	   in	  the	  prospective	  
analysis.	   In	  blue	  are	  depicted	   the	  MFIs	  derived	   from	  the	  blasts	  of	   the	  CD45	  single	   stained	  




	  population	  in	  the	  tube	  stained	  with	  VNN2,	  green	  and	  
orange	  represent	  the	  MFIs	  of	  the	  blasts	  of	  the	  VNN2	  negative	  and	  VNN2	  positive	  samples,	  







As	  discussed	  at	   the	  BFM	  Meeting	   in	  Zurich,	  we	  would	   like	   to	  ask	  each	  reference	  center	   to	  
include	  an	  experimental	  VNN2	  tube	  to	  the	  diagnostic	  panel	  for	  ALL.	  We	  propose	  to	  perform	  
a	  first	  series	   including	  the	  CD45	  single	  stained	  control	  tube,	  FMO-­‐control	  tube.	  Results	  can	  




population	  as	  negative	  
controls	  to	  make	  sure	  that	  we	  do	  not	  loose	  important	  information.	  	  
	  
	  
SOP	  FOR	  PROSPECTIVE	  EXPERIMENTAL	  ANALYIS	  OF	  VNN2	  SURFACE	  MARKER	  ON	  BCP-­‐ALL	  
	  
	  
Process	  the	  leukemia	  samples	  according	  to	  the	  current	  standard	  operating	  procedure:	  
FLOW-­‐Immunophenotyping	  at	  diagnosis	  AIEOP	  –	  BFM-­‐A/G/S	  –	  CPH	  –	  INS	  –	  NSW	  version	  
“International”	  1.6.2	  of	  January	  16,	  2013	  
	  
VNN2	  antibody	  reference:	  	  	  
Anti-­‐human	  GPI-­‐80/VNN2	  mAb-­‐PE,	  clone	  3H9,	  D087-­‐5,	  MBL	  International.	  
250-­‐270	  euro	  per	  antibody	  aliquot	  (50	  test)	  
	  
Procedure	  to	  obtain	  the	  antibody:	  
-­‐	  we	  propose	  that	  you	  order	  the	  antibody	  directly.	  We	  do	  not	  think	  that	  we	  can	  get	  a	  better	  
deal	  with	  a	  collective	  order	  and	  shipment	  via	  our	  center.	  We	  will	  reimburse	  your	  costs	  if	  you	  
send	  us	  an	  invoice	  from	  your	  department	  with	  both	  your	  address	  and	  our	  address	  along	  the	  
account	  detail	  for	  reimbursement:	  
	  






But	  please	  send	  the	  bill	  to	  	  
 6
Dr.	  Beat	  Bornhauser	  
Division	  of	  Oncology	  
Research	  Laboratory	  
Universitäts-­‐Kinderspital	  Zurich	  
August	  Forel	  Strasse	  1	  	  
CH	  8008	  Zürich	  
Swizerland	  	  
	  
Titer:	  the	  company	  recommends	  10-­‐20	  uL	  per	  reaction.	  Anna	  used	  down	  to	  5	  uL	  for	  500000	  




Resuspend	  500.000	  -­‐	  1.000.000	  of	  cells	  in	  100-­‐200uL	  of	  staining	  volume	  and	  add	  10-­‐20uL	  of	  
the	  PE	  labelled	  anti-­‐human	  VNN2	  monoclonal	  antibody.	  Stain	  at	  RT	  for	  at	  least	  15	  minutes	  
protect	  from	  light.	  
	  
Antibody	  panel	  to	  include	  in	  the	  VNN2-­‐tube	  















Antibody	  to	  include	  in	  the	  CD45	  single	  stained	  tube:	  
CD45	  
	  
Antibody	  panel	  to	  include	  in	  the	  FMO-­‐tube	  
All	  the	  antibodies	  included	  in	  the	  VNN2-­‐tube	  except	  VNN2	  
	  
NEGATIVE	  controls:	  
A	  negative	  region	  is	  defined	  by	  	  
1) Blasts	  in	  the	  CD45	  single	  stained	  sample	  (CD45dim)	  (Figure	  5)	  
2) Cross-­‐lineage	  population	  control	  (CD45brightCD19neg)	  in	  the	  VNN2	  tube	  (Figure	  6)	  	  




Strong	  expression	  of	  VNN2	  on	  granulocyte	  or	  monocyte	  (Figure	  8).	  
	  
Definition	  of	  antigen	  expression	  levels	  	  
A	  degree	  of	  overlap	  of	  the	  blast	  population	  with	  the	  negative	  control	  population	  is	  rated	  as	  
either	  negative	  (positivity	  in	  <10%	  of	  blasts),	  weak	  positive	  (positivity	  in	  ≥10%	  to	  <50%	  of	  
blasts),	  Figure	  9,	  or	  strong	  positive	  (positivity	  in	  ≥50%	  of	  blasts),	  Figure	  10.	  
Percentage	  of	  blasts	  VNN2	  positive	  cells	  respect	  the	  three	  controls	  and	  MFI	  of	  the	  three	  
negative	  controls	  and	  of	  the	  blasts	  in	  the	  FMO-­‐tube	  and	  VNN2-­‐tube	  should	  be	  exported	  and	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+41	  44	  266	  7304	  (mobile	  hospital)	  
+41	  79	  365	  0837	  (mobile)	  
Beat	  Bornhauser	  
beat.bornhauser@kispi.uzh.ch	  












Figure	  5.	  Gating	  strategy	  to	  define	  the	  blasts	  (CD45
dim
)	  as	  NEGATIVE	  control	  population	  in	  





































)	  in	  the	  FMO	  tube	  as	  







Figure	  8.	  Cross-­‐lineage	  POSITIVE-­‐control	  myeloid	  population	  	  
Myeloid	  population,	  depicted	  in	  purple,	  is	  identified	  based	  on	  SSC	  and	  FSC.	  Negative	  




































),	  in	  purple,	  in-­‐sample	  cross-­‐lineage	  positive	  control	  (Myeloid).	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
 
